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ABSTRACT 
In the late stage of the disease, breast cancer patients often develop bone metastases, a 
major cause of cancer-related death among women worldwide. 
The common treatment currently used clinically includes the anti-neoplastic agent 
paclitaxel combined with the bisphosphonate alendronate. 
Paclitaxel is an anti-neoplastic drug which cytotoxic effect is mainly attributed to its ability 
to promote the assembly of microtubules as well as prevent the depolymerisation of these 
microtubules. Stabilization of the microtubule networks stops mitotic functions that, in 
sequence, blocks cell division.  Paclitaxel is approved for treatment of ovarian, breast, 
and non-small cell lung cancers at late stage. However, the anti-tumour drug is highly 
hydrophobic and consequently is poorly soluble in water. Additionally, the formulation of 
paclitaxel currently used clinically, known as Taxol, contains the anti-neoplastic drug 
dissolved in a mixture of Cremophor EL and ethanol in order to increase its solubility. 
Nevertheless, administration of Cremophor EL results in serious dose-limiting toxicities 
such as hypersensitivity responses and neuropathy. Furthermore, the chemotherapeutic 
agent suffers from poor selectivity towards tumours, leading to damage of normal healthy 
cells. As a result, much effort has been made into the development of novel formulations 
of paclitaxel using biocompatible and biodegradable polymeric systems. 
Additionally, bone metastases are of considerable concern for patients with advanced 
breast cancer. Patients may tackle supplemental challenges to the cancer itself as their 
skeletal health declines and contributes to a manifest decrease in their quality of life and 
survival. Several bisphosphonates have been assessed in patients with bone metastases 
from breast primary tumour, including alendronate, in order to reduce bone resorption and 
tumour progression. 
The present project aims at developing a new nano-drug delivery system for site target, 
and controlled release of anti-tumour drug. The model developed is a polymer-drug 
conjugate where the anti-tumour drug Paclitaxel and alendronate, are attached to a 
natural polymeric carrier, Pullulan, through a spacer.  
The polymer-drug conjugate designed for controlled release under specific physiological 
conditions uses two main mechanisms for the release, including an enzymatic hydrolysis 
and non-enzymatic hydrolysis. The choice of spacers between the polymer and the drug 
was made so that the drug release only occurs once the system reaches the bone 
metastasis, using an enzymatic hydrolysis first. When polymer-drug conjugates are 
elaborated for tumour delivery, the linkage between the drug and the polymer must be 
necessarily stable under physiological conditions until the tumour target is reached. The 
drug is then cleaved rapidly to be activated.  
Abstract 
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The colloidal carrier was designed to improve the biopharmaceutical and therapeutic 
properties of the anti tumoural drug paclitaxel, increasing the paclitaxel solubility in water 
and targeting the tumour itself. The alendronate bisphosphonate was chosen as a 
targeting agent to confer a high affinity of the conjugate toward the apatite structure of 
bone metastases by exploiting the strong bone seeking properties of bisphosphonates, 
together with the micro-environment of bone metastases, in order to ensure a selective 
release and accumulation of the anti-tumour drug at the desired site of action; the bone 
metastases. 
First, preliminary studies investigated the influence of the time of oxidation of pullulan 
onto its architecture (molecular weight and polydispersivity). Pullulan was modified by 
periodate oxidation to obtain a highly reactive polysaccharide towards amines. Given the 
results of the preliminary studies, it was chosen to prepare a 30% oxidised pullulan. The 
Cathepsin K sensitive spacer Gly-Gly-Pro-Nle was then synthesised by solid phase 
peptide synthesis (SPPS) using the Fmoc strategy.   
Pactitaxel was coupled to the enzyme sensitive spacer and a self-immolative spacer via a 
six step synthesis to form a prodrug. Consecutively, the bone targeting agent alendronate 
was PEGylated via an activated carboxylic acid with N-hydroxysuccinimide.  
Finally, both “prodrugs” were successively anchored to the polysaccharide backbone 
through Schiff base formation and reductive amination. Once the polymer-drug conjugate, 
named Pull-PTX-ALN, was fully synthesised, physico-chemical characteristics of the 
colloid were investigated. 
All synthesised conjugates were characterised in terms of PTX and ALN contents, purity 
and stability under physiological conditions. These conjugates showed release of the anti-
neoplastic drug only in presence of Cathepsin K at pH 5.5, confirming that, the type of 
bond chosen allows for the drug release under precise physiological conditions, in the 
bone metastases environment only.  
The polymer-drug conjugate bearing PTX and ALN also presented a high affinity for 
hydroxyapatite in vitro, proving the potential of alendronate as targeting agent. Cytotoxic 
activity was similar to free drug or in combination with alendronate in 4T1 cells (murine 
mammary adenocarcinoma cell line), MDA-MB-231 BM (human mammary 
adenocarcinoma from Bone Metastases cell line) and SAOS-2 (osteosarcoma cell line).  
Anti-angiogenic properties of alendronate in combination with paclitaxel were also 
assessed, as well as polymer conjugates challenging the materials with HUVEC (Human 
Umbilical Vein Endothelial Cells). PTX and ALN together in their free form or conjugated 
onto Pullulan backbone presented a similar inhibition of proliferation and migration of 
HUVEC.  Additionally, a reduction of capillary-like tube formation, by approximately 40-
50%, was observed after 8hour incubation with the primary cell line. 
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RIASSUNTO 
Nell'ultima fase della malattia, i pazienti che hanno il cancro al seno spesso sviluppano 
metastasi ossee, una delle principali cause di morte legata al cancro tra le donne nel 
mondo. 
Il trattamento comune attualmente utilizzato clinicamente include l'agente anti-neoplastico 
paclitaxel (PTX) e il bisfosfonato alendronato (ALN).  
Il paclitaxel è un farmaco anti-neoplastico a quale l’effetto citotossico è attribuito 
principalmente alla sua capacità di impedire la depolimerizzazione dei microtubuli. La 
stabilizzazione dei microtubuli mitotici interrompe le funzioni che, in sequenza, blocca la 
divisione cellulare. Il paclitaxel è approvato per il trattamento del cancro dell'ovaio, della 
mammella, e del cancro ai polmoni in fase avanzata. Tuttavia, il farmaco anti-tumoure è 
altamente idrofobico e, di conseguenza, è scarsamente solubile in acqua. Inoltre, la 
formulazione di paclitaxel attualmente utilizzata in ambito clinico, nota come Taxolo, 
contiene il farmaco anti-neoplastico disciolto in una miscela di Cremophor EL ed etanolo 
per aumentarne la solubilità. Tuttavia, la somministrazione di Cremophor EL causa grave 
dose-limitante tossicità, come ipersensibilità e neuropatia. Infine, l'agente 
chemioterapeutico soffre di scarsa selettività verso i tumouri, e risulta in danneggiare le 
cellule normale e sane. Come risultato, molti sforzi sono stati compiuti per lo sviluppo di 
nuova formulazione di paclitaxel mediante polimerici biocompatibili e biodegradabili.  
Inoltre, metastasi ossee sono fonte di notevole preoccupazione per i pazienti con 
carcinoma della mammella in fase avanzata. I pazienti possono affrontare sfide 
supplementari al cancro come il declino della loro salute del squelette, e contribuisce a 
una manifesta diminuzione della qualità di vita e sopravvivenza. Alcuni bisfosfonati sono 
stati valutati in pazienti con metastasi ossee da tumoure primario della mammella, e più 
particolarmente l'alendronato, al fine di ridurre riassorbimento osseo e progressione del 
tumore. 
Il presente progetto mira allo sviluppo di un nuovo nano-sistema di veiculazione di 
farmaco al sito target, ed il rilascio controllato di farmaco anti-tumoure. Il modello 
sviluppato è un coniugato polimero-farmaco dove il farmaco anti-tumoure Paclitaxel - 
utilizzato per trattare il cancro della mammella - e l'alendronato, sono collegati ad un 
supporto polimerico naturale, il Pullulano, attraverso un  distanziatore. 
Il coniugato polimero-farmaco, progettato per il rilascio controllato in particolare 
condizione fisiologiche, utilizza due meccanismi principali per il rilascio, compreso un 
idrolisi enzimatica e un idrolisi non-enzimatica. La scelta del distanziatore tra il polimero e 
il farmaco è stato fatta in modo che il rilascio del farmaco si verifica solo una volta che il 
sistema raggiunge le metastasi ossee, rilascio utilizzando una idrolisi enzimatica prima. 
Quando i coniugati polimero-farmaco sono elaborati per tumoure, il legame tra il farmaco  
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e il polimero deve essere necessariamente stabile in condizioni fisiologiche fino a quando 
raggiunge il bersaglio tumourale. Il veicolo colloidale è stato progettato per migliorare la 
biofarmaceutica e le proprietà terapeutiche del farmaco anti-tumoure paclitaxel, 
aumentando la solubilità in acqua e l'individuazione del tumoure stesso. Il bisfosfonato 
alendronato è stato scelto come agente di mira a conferire una elevata affinità del 
coniugato verso la struttura di apatite di metastasi ossee, sfruttando la forte proprietà di 
grande affinità per l'osso dei bisfosfonati, insieme con il micro-ambiente di metastasi 
ossee, al fine di garantire un rilascio selettivo e l'accumulo dei farmaci anti-tumouri nel 
punto di azione desiderato; le metastasi ossee. 
Primo, gli studi preliminari sono state eseguiti  studiando l'influenza del tempo di 
ossidazione del Pullulano sulla sua architettura (peso molecolare e polydispersivity). Il 
Pullulano è stato modificato per ossidazione con periodato in vista di ottenere un 
polisaccaride altamente reattivo verso le ammine. Dagli risultati di studi preliminari, si è 
scelto di preparare un Pullulano ossidato a 30%. Il distanziatore GlyGlyProNle sensibile 
alla Catepsina K è stato poi sintetizzato mediante il metodo sintesi di peptidi in fase solida 
(SPPS) usando la strategia Fmoc.  
Pactitaxel è stato accoppiato con il distanziatore sensibile all'enzima, ed con un 
distanziatore auto-immolative tramite una sintesi in sei passi, per formare un profarmaco. 
Consecutivamente, il targeting delle ossa  è stato eseguito con l’alendronato, PEGilato 
tramite un acido carbossilico attivato con N-idrossisuccinimide. 
Infine, i due "profarmaci" sono stati successivamente ancorati al backbone del 
polisaccaride via formazione di base di Schiff e amminazione riduttiva. Una volta che il 
coniugato polimero-farmaco, chiamato Pull-PTX-ALN, è stato completamente 
sintetizzato, caratteristiche chimico-fisiche del colloide sono state investigate. 
Tutti gli coniugati sintetizzati sono stati caratterizzati in termine di contenuto in PTX e 
ALN, purezza e stabilità in condizioni fisiologiche. Questi coniugati hanno mostrato il 
rilascio del farmaco anti-neoplastici solo in presenza di catepsina K a pH 5,5 , 
confermando che il tipo di legame scelto consente il rilascio del farmaco sotto precise 
condizioni fisiologiche, solo nel ambiente delle metastasi ossee. 
Il coniugato polimero-farmaco, veiculando PTX e ALN, anche presenta un'alta affinità per 
l’idrossiapatite in vitro, dimostrando il potenziale del alendronato come agente di mira. 
L’attività citotossica era simile al farmaco libero o in combinazione con alendronato in 
linea cellululare 4T1 (linea cellulare adenocarcinoma mammario in murine), MDA-MB-231 
BM (linea cellulare del adenocarcinoma mammario umano da metastasi ossee) e  SAOS-
2 (linea cellulare di osteosarcoma). 
Le proprietà anti-angiogeniche dell'alendronato in combinazione con paclitaxel sono state 
valutate con HUVEC (cellule umane endoteliali di vena ombelicale), anche per i coniugati 
polimero-farmaco. Il PTX e ALN insieme, nella loro forma libera, e coniugati al Pullulano, 
hanno presentato un'inibizione notevole della proliferazione e della migrazione delle 
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cellule HUVEC. Inoltre, una riduzione della formazione di tubi capillari di circa 40-50 %, è 
stata osservata dopo 8 ore di incubazione con la linea cellulare. 
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1. Introduction 
 
1.1 Anti-tumour therapy - state of the art 
 
Tumours result from the uncontrolled proliferation of cells as a result of mutations of many 
genes, called oncogenes, which control the cell growth (growth factors genes and their 
receptors, intracellular transducers for nuclear transcription factors). The extra 
proliferation of tumour cells result in the formation of an extra cellular matrix, connective 
tissue, which provides structural support. The extra cellular matrix can be divided into two 
parts; the basement membrane which anchors the cells, and the interstitial matrix which 
forms the bulk. When mutations become more significant, the cells may take the ability to 
degrade the basal lamina, to escape the surveillance of the immune system and start to 
make contact with cells of different tissue types. The tumour then becomes invasive and 
can spread throughout the lymphatic system and circulatory system, also away from the 
first site of incidence. This process is formerly defined as tumour metastasis and defines 
the malignancy of the tumour. 
After cardiovascular diseases, cancer is the second leading cause of death in 
industrialised countries. Consequently, many efforts are made in the search for the 
development of effective anticancer therapies. 
 
Paul Ehrlich created the term chemotherapy in 1914 while searching for a substance to 
cure syphilis with his collaborator Sahachiro Hata
2
. 
Contemporary chemotherapy finds its roots in the battlefields during the First World War 
when military doctors noted that after exposure to the chemical agent called mustard gas, 
soldiers died due to their bone marrow destruction, the marrow became abnormal and the 
cells in charge of producing blood cells greatly decreases  (bone marrow aplasia). 
After these recurrent events, specialists began to investigate what was the cause of bone 
marrow destruction and found out that Nitrogen mustard works by physically modifying 
the DNA in cells. In 1942, the substance was used in USA hospitals to treat lymphoma 
patients with success. 
 
Nowadays, chemotherapy is used in treating half the patients who develop cancer. Most 
chemotherapy drugs kill cancer cells completely, or stop their duplication and spread, by 
inhibiting metabolic functions of the cancer cell. 
Most chemotherapeutic agents discovered during the first twenty years of research are 
highly cytotoxic. Their objective is targeted to damage DNA or to inhibit the cell 
replication, causing the non-selective death both of tumour cells and normal cells in 
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phase of replication. The lack of specificity of action of chemotherapeutic drugs is at the 
origin of their considerable toxicity that limits their use in anti-tumour therapy. 
Only in recent years, research started to have a basic understanding of oncogenes, gene 
suppressors. The identification of new targets for chemotherapy such as the mechanism 
of apoptosis, the signals of transduction, and the tumour vascularization and 
angiogenesis led to the development of new diagnosis, prognosis and, above all, new 
kinds of cancer therapies for targeted treatment of neoplasms. The modern therapeutic 
approach uses different mechanism/methods under development including: 
 
 The destruction of the cells by radiation; 
 The use of cytotoxic substances, often in association with one another; 
 Potentiation of the patient immune defences (adjuvant therapy), 
 Surgical removal of the cancerous tissue; 
 Gene therapy which is designed to induce the patient's own immune system to 
fight the tumour; 
 Pharmacological prevention of metastasis of the primary tumour (anti 
angiogenetic); 
 Hormone therapy which can be provided or blocked for inhibiting the growth of 
some cancers. 
 
Radiotherapy is beneficial to treat localised tumours and its effectiveness can be 
increased by combining it with radio sensitizer drugs. Chemotherapy, due to its systemic 
action, is more indicated for tumours at a metastatic stage.  
Different methods can be combined with each other, therefore evolving various 
therapeutic strategies such as: 
 
 Adjuvant therapy (post-operative treatment) used when solid tumours are localised. 
It generally proceeds in two steps, first a surgical excision of the tumour mass is 
performed, followed by chemotherapy treatment and radiotherapy, to eliminate any 
micro metastases and therefore to prevent relapses; 
 Neo-adjuvant therapy (pre-surgery treatment) is practiced to decrease the tumour 
volume, to support subsequent interventions by radiotherapy or surgery, that are 
typically needed for solid tumours, as chemotherapeutic agents often fail to reach 
the tumour heart. 
 
The aim of chemotherapy is either to target the complete healing of patients or to prolong 
their life or alleviate the symptoms. The advancement in anti-tumour therapy research 
over the last forty years has progressed rapidly, passing by alkylating agents, 
antimetabolites to natural products, and more recently interests in gene therapies, 
vaccines and other drugs that act on the immune system have increased. This has led to 
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considerable development, especially in the treatment of malignant and fatal neoplasms 
as the testicular carcinoma, lymphoma, and in particular the Hodgkin's lymphoma, and 
leukaemia. However, the tumour remission remains often difficult to achieve, especially in 
the case of solid tumours such as those of colon, prostate, breast and lung, which are 
today, the most widespread. The development of new therapeutic systems is divided into 
four main directions: 
 
 The combinatorial chemistry and screening of substances to develop low molecular 
weight natural or semi-natural molecules with anti-proliferative activity
3
; 
 The use of biochemistry and molecular biology methods to identify new target sites 
for chemotherapy, such as receptors, antigens, angiogenic factors and chemical 
mediators
4
; 
 Development of gene therapies and antisense nucleotides5; 
 Investigation of systems directing and releasing the drug to make the therapy more 
selective towards tumours. 
 
The groups of chemotherapeutic agents currently on the market or in development 
include inhibitors of cell replication and DNA synthesis (cross-linking agents, alkylating 
agents, DNA-intercalating antimetabolites, and precursors), topoisomerase inhibitors and 
antibiotics-anti-tumour substances, substances stabilizing or destabilizing microtubules, 
enzyme inhibitors receptor antagonists.  
Some new drugs do not interfere directly with DNA; among these agents, there are 
monoclonal antibodies and inhibitors of the tyrosine kinase (Gleevec), which aim to hit 
specific targets present on some types of tumour cells. Other drugs modulate the 
characteristics of tumour cells without binding to them, within this category of adjuvants, 
fall hormones. 
With the discovery of new anticancer agents, the chances of a cure have already 
increased. However, due to their low selectivity for cancer cells, there are still major 
issues encountered and to be resolved. These drugs are often very powerful; 
nonetheless, most of anticancer drugs enter non-specifically into all types of cells, both 
healthy and sick, causing serious side effects that often cause a drastic worsening in the 
patient's life and in the most severe cases even death. 
In addition, the reduced specificity infers the use of these drugs in high doses, with 
consequent impact including serious toxic effects. A further limitation of chemotherapy 
treatments is the occurrence of resistance to the drug due to significant heterogeneity of 
neoplastic cells and selective pressure. Furthermore, sometimes resistance is seen 
towards other anti-tumour drugs, thus negating the possibility of intervention. Finally the 
same chemotherapeutic agents can become in their turn mutagenic and carcinogenic, 
due to modifications that are within the body. Initially, the patient may responds well to a 
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treatment, but at times, as a result of a recurrence of the tumour, the same drug or even 
other with different structure can be becomes inefficient. 
Many experts believe that a sufficient number of anticancer agents are known, but an 
effective cancer therapy can be only reached by obtaining suitable drug delivery systems, 
able to act solely into target site. Finding a molecule that is selectively toxic to tumour 
cells is much difficult, because these cells have essentially the same biological events as 
healthy cells and the differences in biochemical and molecular mechanisms are minimal
6
. 
Consequently, the diffusion of the drug in various organs can cause cellular and tissue 
damage. 
The normal cells most affected by anticancer drugs are those with a rapid proliferation, 
such as those of hair bulbs, red blood cells, white blood cells and the cells of the intestinal 
epithelium. The side effects that occur most often are linked to the cytostatic action on the 
bone marrow cells and include myeloid suppression, leukopenia, neutropenia, 
thrombocytopenia, anaemia and damage to the immune system, involving the patient's 
exposure to pathologies induced by microorganisms. Other issues might be ulcerations of 
mouth and intestine mucous membranes with predisposition to bacterial sepsis of the 
intestinal tract (in case of immunosuppression); pulmonary fibrosis; venous occlusion of 
the liver; neurotoxicity and ototoxicity, alopecia, nausea, vomiting, diarrhoea or 
constipation; cardio toxicity, hepatotoxicity and nephrotoxicity. Other side effects may 
include erythema, loss of appetite with consequent malnutrition and weight loss. In some 
cases, memory loss and dizziness, dehydration or water retention, xerostomia and 
haemorrhage are observed. 
Support therapy is often use to address these problems and may provide transfusion of 
platelets, or whole blood, or even bone marrow transplantation, administration of 
allopurinol in order to prevent the hyperuricemia, growth factors, hematopoietic to 
counteract the loss of red blood cells and neutrophils, broad spectrum antibiotics to 
prevent bacterial infections, and powerful antiemetics
7
 as antagonists 5-HT3 inhibitors
8
 or 
substance P
9
 as aprepitant as well as derivatives of THC (tetrahydrocannabinol), as the 
Marinol
10
. 
Another limitation of chemotherapy is that every treatment allows to remove only a 
fraction of cells (fractional kill), for which continual administrations and numerous 
chemotherapy cycles are necessary to prevent the tumour regrowth and continues 
reduction of its size. The development of effective therapeutic procedures is, however, 
complicated by the tumour physico-pathological trends and the diverse evolution trends, 
by the different pathological severity and by individual variability. 
The main challenges in the research for new cancer therapies are to reduce the systemic 
toxicity, increase the selectivity, improve compliance, reduce the frequency of 
administration, decrease the dose and increase the absorption; these are the primary 
objectives in the development of efficient anticancer systems. 
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1.2 The tumour microenvironment 
 
Currently, the identification of tumours genetic constitution, enzymatic activity and growth 
is better known; yet, no actual treatment is able to exploit these characteristics. 
Nonetheless, tumour tissues are a lot different from the healthy tissues and these 
distinctions could be advantageous for target therapy thus, an understanding of the 
pathophysiology of cancer is required to target drug in the systemic circulation. 
1.2.1 Tumour vascular architecture 
 
Tumours develop from a single neoplastic cell. The uncontrolled proliferation of the cells 
produce a mass of about 150-200 nm. At the beginning, the tumour cells beneficiates of 
the blood supply from the vasculature of healthy tissues. As it increases in size, the cell 
mass needs another supply for supply of oxygen, nutrients and metabolites to ensure its 
growth. The cell mass then starts to produce its own vascular system, producing new 
blood vessels through the mechanism of angiogenesis.  
Angiogenesis in tumour tissue is particularly active and extended
11
; the production of a 
new vascular system is disordered in all possible directions, at all junctures. The central 
part of the tumour remains in hypoxia, devoid of nutrients, which lead to poor penetration 
of blood supply inside the solid tumour.  
As a result, a dense network of vascularization jars with incomplete endothelium, and with 
ample fenestrations is formed, thus, the tumour tissues are particularly permeable, 
causing intra-tumour dissimilarities.  
Healthy tumour cells have a regular lining of endothelial cells which form tight junction 
with neighbouring endothelial cells, from 2 to 6nm. 
Tumour vasculature is significantly different from those present in healthy tissues in terms 
of cellular composition of the endothelial wall, basement membrane shape and of 
dimensions of the fenestrations, which may reach 100-780nm wide due to the 
discontinuous endothelial lining. New vessel walls are devoid of pericytes, which are the 
regulators of maturation and differentiation of capillaries. The blood vessel permeability is 
extremely high, not only due to the increased width of intercellular junctions and the 
incompleteness of the basal membrane, but also for the presence of numerous factors of 
permeabilisation such as an elevated level of growth factors (VEGF, bFGF, bradykinin 
and nitric oxide) leading to vasodilatation, extravasation of large molecule and retention in 
tumours. 
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1.2.2 Lack of lymphatic drainage 
 
Lymphatic vessels are formed as termination capillaries delimited by a single layer of 
endothelium. The lymph fluid is drained by a series of lymphatic vessels and lymph nodes 
and flocked in the venous circulation Their greater permeability than blood vessel allows 
them to transport macromolecules in normal tissues such as proteins from the interstitial 
spaces back into the blood circulation.  
Solid tumours are exempted of effective lymphatic drainage system. Fluid is not seeped 
efficiently, resulting in a backpressure increase and thus, restricts the blood escape from 
vessels. The higher backpressure encourages outward flow of fluid from the tumour 
tissue, therefore limiting the convective extravasation of macromolecules, despite leaky 
vasculature. 
This can lead to the collapse of the capillaries in the cancerous tissue with the formation 
of hypoxic and anoxic regions and the consequent start of necrotic foci within the 
neoplastic tissue itself.  
1.2.3 pH decrease 
 
Tumour uses preferentially glycolysis as route of energy, producing lactate. The poor 
vasculature and the lack of lymphatic drainage in solid tumour increase the concentration 
of metabolites by-products including lactic acid and carbonic acid in the tumour 
interstices, inducing a decrease of pH. 
Healthy tissues and tumour having different pH, it can be exploited to design site-specific 
cancer drugs. Tumour acidity influences drug uptake into tumour cells. For example, a 
weak acid drug can be dissociated; therefore it becomes relatively lipophilic at an acid pH 
at the tumour site and can easily cross the cell membrane
12
.  
1.2.4 Tumour hypoxia 
 
The high density of tumour cells deprives certain region of oxygen, phenomenon known 
as hypoxia. Malignant progression is often connected to hypoxia, increased tumour 
invasion, angiogenesis and an increased risk of metastasis formation. Hypoxia might 
also induce increased resistance to apoptosis and as a result, indirectly contributes to 
treatment resistance.  
Hypoxia is an issue in radiotherapy as oxygen radicals are produced following radiation 
under well-oxygenated conditions, contributing to DNA damage
1, 13
.  
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Effects of chemotherapy may also be inhibited through the same mechanism. In the 
presence of oxygen, some drugs, doxorubicin for example, can produce reactive oxygen 
species such as super-oxides that can damage DNA
12b
.  
1.3 Breast cancer and bone metastasis 
 
Cellular movement is a key component in tumour progression. Neovascularisation and 
angiogenesis are the results of endothelial cell movement; it also is the factor contributing 
to tumour cell movement, leading to cancer progression and metastasis. 
Metastasis is defined as the delocalisation and propagation of tumour cells from primary 
site to distant tissues or organs. Metastases are directly connected to breast cancer-
related mortality and occur in 25 to 50% of patient diagnosed with the disease. Only 25% 
of patients reached the average of 5 year survival rate. 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1-2 Tumour metastases
14
 
 
 
Figure 1-1 Tumour hypoxia – The unique physiology of solid tumours
1
 
 
Normal Tumour 
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The metastasis process is understood as an inefficient process, a cascade progression 
consisting of multiple barriers to cancer cell propagation, for instance:  
 
 The invasion through the extracellular matrix and stromal cells in the local tumour 
microenvironment; 
 The intravasation into the lamina of blood vessels; 
 The survival and persistence into circulation; 
 The extravasation into the parenchyma of a distant tissue; 
 The survival and proliferation in a foreign microenvironment. 
 
The most common site for breast cancer dissemination is the bone, with 65 to 80% of 
patients in late stage disease diagnosed with skeletal metastasis. 
Breast tumour progression to bone is often related to oestrogen receptors in the primary 
mass, in contrast with tumours which metastases develop in visceral organs and brain.  
The dissemination into bone is generally a sign of an irredeemable disease and the 
median survival is between 2 to 3 years. 
Bone metastatic lesions are seldom a direct cause of death in cancer patients; however 
they contribute to a noteworthy degree of morbidity. 
Complications include chronic bone pain, pathological fractures, hypercalcaemia, and 
spinal cord or nerve root compression. 
The initial significant event in breast cancer bone metastasis is the tumour cell seeding 
within the bone. 
The process thought to be involved in seeding is the adhesion of breast cancer cells to 
the bone marrow endothelium, mechanism similar to the physiological mechanism used 
by hematopoietic cells (HSCs) migrating to bone. In recent years, there has been an 
increase interest in defining which disseminated tumour cells first self-establish once they 
reach the bone marrow. 
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 Figure 1-3 Breast tumour metastases to bone 
 
Bone is a multifunctional organ which micro-environment consists of a mineralised 
organic matrix and a variety of bone resident cells namely chondrocytes, osteoblasts, 
osteocytes, osteoclasts, endothelial cells, monocytes, macrophages, lymphocytes and 
haemopoietic cells. The cell environment produces a range of biological regulators which 
control the local bone metabolism. 
The entrance of tumour cells within the bone internal environment disturbs the finely 
organised homeostasis, releasing tumour derived growth factors and cytokine. 
Mineralisation of the bone matrix is achieved through the activity of osteoblasts while 
osteoclasts are responsible for bone resorption. Sustain of bone architecture and mass 
are accountable to these two major cells in the bone micro-environment. 
 
The bone-forming cells osteoblasts originate from mesenchymal stem cells and are 
recruited to bone formation sites where they actively synthesise and secrete an organic 
bone matrix called osteoid. This matrix is essentially composed of type I collagen and 
other protein of non-collagenous origins. Once the matrix formed, osteoid undergoes fast 
mineralisation with hydroxyapatite. Osteoblasts not only synthesise bone matrix but they 
also have a role of producing many regulatory elements such as prostaglandins, 
cytokines and growth factors, and maintaining a high alkaline phosphatase activity. These 
elements are thought to stimulate both bone formation and resorption. 
In contrast, osteoclasts are large specialised multinucleated cells of hematopoietic origin 
that adhere to the bone surface and actively demineralise and degrade the bone matrix. 
They are formed from the fusion of mononuclear progenitor cells that arrive via 
vasculature. Following the production and release by osteoclasts of lysosomal enzymes, 
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hydrogen protons and free radical into a restricted space next to the bone (resorptive 
compartment), the bone matrix mineral dissolves and degrades.  
Distinctive resorptive cavities called Howship’s lacunae are produced by osteoclasts in 
contact with mineralised surfaces. Bone modelling and remodelling process is therefore 
influenced by the regulatory control of systemic and local factors in bone cells. 
 
A significant signalling system effective both in bone and immune cell communication is 
the RANKL-RANK-OPG association (Figure 1-4). 
 
 
 Figure 1-4 Factors that promote differentiation and function of osteoclasts and 
osteoblasts
15
 
 
 
RANKL protein is secreted or expressed on  osteoblast surfaces and activates T cells. 
RANKL is a member of the tumour necrosis factor (TNF) cytokine family and is ligand 
or osteoprotegerin (OPG). It plays a key role in giving the necessary signal to pre-
osteoclast to differentiate and activate. OPG is produced by dendritic cells and is a 
soluble decoy receptor for RANKL that competitively inhibits RANKL binding to RANK. On 
the other hand, RANK is expressed on osteoclasts or pre-osteoclasts, and dendritic cells, 
both resulting from myeloid stem cells.  
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1.4 Polymer therapeutics 
 
In recent years, the field of polymer therapeutics represents a sphere of major interest in 
drug formulation and is main subject of research in private and public institutions. They 
allow controlled release and drug delivery to a target site. They include covalently 
attached drug onto a polymer backbone and self-assembled polymer or polymer 
complexes. 
Conventional drugs are often of micro molecular size and consequently free and easily 
diffused throughout the biological system. Many substances are potentially active and 
efficient as drugs but suffer from the serious drawbacks of being two rapidly excreted or 
metabolised or having grave side effects
2
. Additionally, drug release relies on the 
physico-chemical properties of the drug itself, targeting an organ or a tissue can then turn 
out to be difficult. On the other hand, polymer therapeutics diffuses slowly and the 
attachment of pharmaceutical moieties leads to polymer-drug with specific 
pharmaceutical properties and behaviour
3
. They are very attractive as they possess a 
prolonged drug activity, and improve drug release and latency.   
1.4.1 Models of polymer bioconjugates 
 
The area of polymer therapeutics can be mainly divided in five categories. The first 
category includes polymer as drugs where the polymer is not a carrier but is a drug itself. 
The four next categories are all macromolecular carriers which can themselves be divided 
into two subtypes: the drug can be either entrapped into a polymer matrix through 
physical bond (an example would be Van-der-Waals bonds) or through chemical covalent 
bonds. Polymer-drug conjugate and polymer-protein conjugates, polyplexes and finally 
self-assembled polymeric micelles are the four other categories of polymer therapeutics. 
 
Figure 1-5 Tumour-targeted nanomedicines: principles and practice
13
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In the case of macromolecular carriers, the polymer plays a protective role of the drug to 
avoid its rapid elimination or metabolism. Generally temporarily lost when onto its 
macromolecular carrier, the activity of the drug can be restored by cleavage from the 
polymer. The latter can be achieved via hydrolysis or enzymatic degradation of a 
cleavable bond such as an ester, anhydride, orthoester or acetal. In most cases, the drug 
is attached away from the main polymer chain and pendant groups, using a spacer 
moiety which allows better hydrolysis or the use of specific enzymes. 
The control of the polymer molecular weight allows to decide the mode of excretion 
(kidney or liver), whether it should pass the blood stream barrier or whether it should 
accumulate in a particular site (type I : tissue or organ, type II : certain cells or type III : 
intracellular compartments) and implicate the notion of target. 
1.4.2 Characteristics of polymeric carriers 
 
Polymers used as drug carriers must be eliminated from the body. They should be either 
degraded in the case of biodegradable polymers or excreted in the case of non-
degradable polymers.  
Polymeric carriers can be natural polymers, sometimes partially chemically modified, and 
synthetic polymers. 
 
 Biodegradable polymeric carriers are macromolecules which bonds in the 
backbone can undergo hydrolytic or enzymatic cleavage. Degradations products 
such as saccharides and amino acids are then formed and may be eliminated 
following the biological pathway in the body; this is the case of the natural 
polymers collagen and hyaluronic acid for example. Some acetylated residues 
may also be obtained by lysosome degradation of the polysaccharide chitosan. 
Another example is dextran which is degraded in presence of dextranase. 
Synthetic polymers may degrade in a similar fashion, namely poly(L-glutamic 
acid) and poly(aspartic acid). These two polymers are extremely prone to be 
degraded by lysosomal enzymes, generating amino acids as products of 
degradation. 
 Semi-degradable polymers are macromolecules which chain backbone is attached 
to a degradable linker. At the target site, the active drug is release by cleavage of 
the degradable linker, simultaneously degrading the polymer backbone into some 
blocks able to be excreted by the kidney. Monomer units may be bound to acid 
labile linkers such as ketal or acetal bonds followed by polymerisation. In such way, 
the polymer is able to degrade under acidic conditions in the intracellular 
environment. 
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 Non-degradable polymers can be used in drug delivery, for example polyethylene 
glycol (PEG) and poly(hydroxpropylmethacrylate) copolymer (HPMA). However, 
their elimination might be hampered if their molecular weight is higher than the 
kidney threshold. The poor lymphatic drainage in tumour already leads to slow 
elimination. A high molecular weight increases the accumulation of the polymer in 
the tumour upon repeated administration and might cause adverse clinical effects. 
Sometimes, accumulation might be observed also in clearance organs such as 
kidney, liver, or spleen resulting in iatrogenic illnesses. 
 
The most popular polymers used as carrier in polymer therapeutics are synthetic or 
natural or semi-synthetic, namely PEG, PGA, HPMA copolymer, Dextran and Chitosan 
respectively: 
 
 PEG, widespread in the market, stands for linear polyethylene glycol and can bear 
one or two functional groups at its ends, useful for the attachment with drugs or 
other functional groups. PEG was the first polymer used as a carrier as it has the 
advantage of being biocompatible. It is also soluble either in water or organic 
solvents. These features make it a good candidate for PEG-protein conjugation as 
well as carrier, or spacer. It will be discussed later in the section 1.8.2. 
 PGA or poly(glutamic acid) contains glutamic acid monomer units and can be 
easily degraded in the physiological environment, thanks to cysteine proteases 
which encourage its lysosomal degradation. As well as being water-soluble, non-
toxic and biodegradable, PGA is a versatile polymer thank to its 9 carboxylic 
groups present on the backbone on which multiple drug attachment can be done. 
PGA is an attractive carrier for polymer therapeutic and the actual most advanced 
polymer-drug conjugate in the channel for market approval (Phase III trials) derived 
from PGA, namely OPAXIO, which is a PGA conjugated to the anti-tumour drug 
Paclitaxel against ovarian cancer and non-small lung cancer (Figure 1-6). 
 
Figure 1-6 OPAXIO 
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 HPMA copolymer or poly(hydroxpropylmethacrylate) copolymer have been of 
major interest in the last thirty years, often investigated for the development of new 
polymer-drug conjugate for cancer therapy, often modified for target specific drug 
delivery of anti tumoural drugs. The key event which led to this amplified interest 
has been the clinical trial performed in 1994 on PK1 and PK2,  HPMA copolymers 
carrying doxorubicin (DOX) on their backbone, linked through a degradable 
peptidyl linker (Figure 1-7). HPMA has the advantage of being non-immunogenic, 
neutral and bio-compatible. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-7 PK1and PK2 HPMA copolymers for drug delivery 
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 Dextran belongs to the family of polysaccharides. From bacterial origins, it contains 
glucose monomer units bound via α-1,6 linkages. The presence of several primary 
alcohol groups on its backbone allows direct conjugation of drugs, spacers, or 
proteins. The natural polymer is able to dissolve in water and organic solvents and 
is biocompatible and biodegradable in the gastro-intestinal tract and blood. The 
polysaccharide has been clinically approved as blood expander. 
 
 Chitosan also belongs to the polysaccharide family, derivatised from deacetylation 
of chitin. The poly(-D-glucosamine) contains numerous amines, available for 
chemical conjugation. The polymer is biodegradable and biocompatible. Polymer-
drug conjugates based on chitosan and camptothecin have already been tested 
clinically
16
. Chitosan can also be used for oral delivery of drugs due to its strong 
muco-adhesive property and for gene therapy. 
 
1.4.3 Examples of molecular models clinically used 
 
Abraxane, which is an albumin-bound paclitaxel, was the first passively tumour targeting 
polymer therapeutic approved by Food and Drug Administration (FDA) in 1995. 
 
 
 
 
 
 
 
Cremophor-formulated version of paclitaxel has gone through a large phase III trial in 
which over 400 women with metastatic breast had an improved response and less side 
effects than standard free drug, 
Besides these paclitaxel based drugs, a variety of polymer therapeutics has been 
assessed clinically. Oncaspar, for example, is a PEG polymer conjugated to the protein L-
asparaginase in order to decrease allergic reactions and frequency of administration and 
has been used for treating patients with acute lymphoblastic leukaemia for over 10 years. 
 
Doxil is a PEGylated (polyethylene glycol coated) liposome-encapsulated form of 
doxorubicin (Figure 1-9), ordinarily used in the treatment of an extensive range 
of cancers, including haematological malignancies, various types of carcinoma, and soft 
tissue sarcomas. Doxil was the first FDA-approved nano-drug (1995).  The free drug 
doxorubicin is very potent but severe side effects, such as cardiotoxicity and myelo-
Albumin shell 
Paclitaxel 
Figure 1-8 Abraxane model 
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suppression, have restricted its use. Doxil has shown considerably enhanced safety and 
efficiency, compared with conventional doxorubicin 
 
 
 
 
 
 
 
 
Another example of drug delivery system, not yet approved by FDA but promising in 
clinical trials is Aurimune. Aurimune (CYT-6091) entails a recombinant human tumour 
necrosis factor alpha (TNF), a known tumour-killing agent, bound to the surface of 
PEGylated colloidal gold nanoparticles.  The gold PEGylated surface prevents the 
therapeutic payload from immune detection and allows its safe travel through the 
bloodstream. Patients taking an intravenous injection of Aurimune have been able to 
tolerate 20 times higher dose than the usual dose of conventional TNF-α. 
The following table summarizes the current clinical trials investigating nano-medicines 
(Table 1-1). 
 
Table 1-1 Current clinical trial on .nano-systems for drug delivery
17
 
Nano-systems 
Commercial 
Name 
Cancer type 
Clinical 
Phase 
Liposomal doxorubicin 
Myocet,  
Caelyx (Doxil) 
Breast, ovarian, 
KS 
Approved 
Liposomal daunorubicin Daunoxome Kaposi sarcoma Approved 
Liposomal vincristine Onco-TCS 
Non-hodgkin 
lymphoma 
Approved 
Liposomal cisplatin SPI-77 Lung Phase II 
Liposomal lurtotecan OSI-221 Ovarian Phase II 
Cationic liposomal c-Raf 
AON 
LErafAON Various Phase I/II 
Cationic liposomal E1A 
pDNA 
PLD-E1A Breast, ovarian Phase I/II 
Thermosensitive liposomal 
doxorubicin 
ThermoDox Breast, liver Phase I 
Albumin-paclitaxel Abraxane Breast Approved 
Albumin-methotrexate MTX-HSA Kidney Phase II 
Dextran-doxorubicin DOX-OXD Various Phase I 
PEG-L-asparaginase Oncaspar Leukaemia Approved 
PEG-IFN 2a/-IFN 2b 
PegAsys/ 
PegIntron 
Melanoma,  
leukaemia 
Phase I/II 
PHPMA-doxorubicin PK1 Breast, lung, colon Phase II 
Lipid bilayer 
Entrapped Doxorubicin 
Liposomal Doxorubicin Entrapment 
Figure 1-9 Doxil model 
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Table 1-  (continued) Commercial Name 
Cancer 
type 
Clinical 
Phase 
    
Galactosamine-targeted 
PK1 
PK2 Liver Phase I/II 
PGA-paclitaxel Xyotax Lung, ovarian Phase III 
Paclitaxel-containing 
polymeric micelles 
Genexol-PM Breast, lung Phase II 
Cisplatin-containing 
polymeric micelles 
Nanoplatin Various Phase I 
Doxorubicin-containing 
polymeric micelles 
NK911 Various Phase I 
SN38-containing polymeric 
micelles 
LE-SN38 Colon, colorectal Phase I 
90
Yttrium-Ibritumomab 
tiuxetan ( -CD20) 
Zevalin 
Non-hodgkin 
lymphoma 
Approved 
DTA-IL2 fusion protein 
( -CD25) 
Ontak T-cell lymphoma Approved 
Ozogamycin-gemtuzumab  
( -CD33) 
Mylotarg Leukaemia Approved 
Doxorubicin-cBR96  
( -CD174) 
SGN-15 
Lung, prostate, 
breast 
Phase II 
 
1.5 Passive and active tumour targeting 
 
One of the major causes for the toxicity of antineoplastic chemotherapeutic agents is their 
poor selectivity for tumours cells. Their low molecular weight contributes to the large 
distribution volume. Low molecular weight drugs enter the cells mainly by a diffusion 
mechanism. By acting without distinction even on healthy cells, it gives rise to a whole 
series of side effects. Creating a drug which is able to act only on the tumour is today’s 
challenge. The conjugation of low molecular weight drugs to high molecular weight carrier 
substantially influences the mechanism of entry into the cell.  The drug can be brought to 
the tumour by two main mechanisms, the EPR effect also known as passive and the 
active targeting
18
.  
More efficient targeting may be obtained by conjugation of polymer-dugs with specific 
target molecules, characteristic of tumours of specific to an organ or tissue.  
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1.5.1 Passive targeting 
 
Substances of low molecular weight generally diffuse in healthy and diseased tissues 
without distinction. On the contrary, macromolecular drugs like albumin accumulate 
passively in the tumour mass. This phenomenon was observed for the first time by H. 
Maeda in 1986. Their studies demonstrated that solid tumours produce a large amount of 
various vascular permeability factors, resulting from the faulty architecture of their blood 
vessels. This amplified permeability ensures sufficient supply of nutrients and oxygen for 
the tumour to grow rapidly. The reduced drainage of the lymphatic system associated 
with the high interstitial fluid pressure in the tumour tissues (enhanced retention) reduces 
the clearance of the macromolecule and therefore increases passively its accumulation in 
tumour tissues. This phenomenon results in a greater extravasation of a drug in the 
tumour tissues and permanence in the site of action. The distinctive pathophysiological 
feature of tumour vasculature, easing the transport of molecules in the tumour tissue, was 
then namely introduced as the Enhanced Permeability and Retention (EPR) effect
18
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-10 The EPR effect – inspired from Eldon et. al Oct 2007
19
 
 
The EPR effect depends on molecular size. Molecules should be larger than 40kDa, 
value of renal threshold for polymers to ensure a slower clearance, hence a prolonged 
circulation time
20
. Molecules can then gradually permeate the tumour and stay for a 
reasonably long time in the tumour. 
Not only molecular size is important but also surface charge. Positive charge polymer-
drug conjugate might bind rapidly to vascular endothelial luminal cell surface which is 
known to carry a negative charge. The plasma half-life decreases and consequently the 
tumour drug accumulation decreases too. Weakly negative or near-neutral particles are 
therefore more likely to have longer plasma half-life.  
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Finally, a third aspect that might be taken into account for the EPR effect, is the 
hydrophobicity. A highly hydrophobic molecule has a greater affinity for cell membranes 
and a much faster endocytosis up-take. However, attention should be paid as highly 
hydrophobic polymers might cause haemolysis of red blood cells. 
1.5.2 Active targeting 
 
The active targeting of drugs represents one of the most interesting approaches to obtain 
effective therapeutic systems.  Targeting is obtained by insertion onto the 
macromolecular structure, of molecules able to recognise antigen or specific cell 
population receptor. 
Antibodies and antibody fragments, vitamins, peptides, folate and transferrin are some 
targeting ligands which have been evaluated in cancer therapy. 
The targeting ligand must be subtly chosen according to its specificity, stability, 
availability and to the selective display of its corresponding pair on the target cells. 
Other factors should also be considered such as conjugation chemistry, density and 
accessibility of the ligand in order to design an efficient targeting vector. 
Active targeting complements passive accumulation into tumours and therefore offers an 
improved result due to specific interactions with target cells 
Many studies have been focusing on folic acid, galactose
21
 and small peptides for active 
targeting. The high affinity of these ligands for biological receptors, mainly the membrane, 
allows a selective bio-distribution of the macromolecular system and in some cases 
promotes the cell internalisation.   
 
Attractive results have been obtained, employing ligands that are internalised through the 
endocytosis pathway after recognition with the actual membrane receptor, such as the 
folic acid
17c, 22
. Folate receptor is a well-known tumour marker. It binds to the folic acid 
vitamin and folate-drug conjugate. This high affinity allows the transport of these bound 
molecules into the cells via receptor-mediated endocytosis. This way the entire 
supramolecular drug penetrates in the cell, carrying a drug.  Such systems, besides 
favouring the localised drug build-up in the target tissue and reducing the distribution and 
systemic toxicity, also often consent to escape the intrinsic resistance acquired or 
multidrug-resistance.   
Another receptor highly present in cancer cells is the transferrin receptor. Transferrin is a 
serum glycoprotein which transports iron through the blood and into cells by binding to 
transferrin receptor
23
. 
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1.5.3 Intracellular trafficking 
 
As soon as the drug delivery carrier has reached tumour tissues, successive drug release 
may occur in the extracellular space, or following internalisation of the carrier. Some 
drugs with intracellular action are unable to cross cell membranes and necessitate to be 
assisted in getting to their target. Mechanisms or combination of mechanisms involved in 
cellular uptake diverge accordingly with the cell type (phagocytic or non-phagocytic cells), 
the physicochemical properties of the internalised entity and the mode of activation 
(receptor mediated endocytosis).  
Non-targeted polymer-drug conjugates reach the tumour tissue target passively through 
the EPR effect. Subsequently, they release the drug in the vicinity of the cell or in contact 
with the cell membrane.  
Furthermore, intracellular targeting is feasible through the use of ligands. Ligand targeted 
polymer therapeutics may bind to epitopes on cell surface, endocytosis may occur 
following binding to receptors which stimulate internalisation, or it may not be specific 
(Figure 1-11). Once internalised, the colloid either escapes into the cytoplasm or 
discharges the drug in vesicular organelles in response to environmental stimuli such as 
enzymes, pH, temperature or reductive conditions. 
 
 
Figure 1-11 Passive and active targeting approaches of nanomedicines in 
cancer therapy
24
  
 
 
Desired subcellular localisation has already been achieved successfully by the use of 
lysosome degradable linkers, nuclear localisation and acid or reduction responsive 
polymer-drug conjugates, exploiting the endosome maturation. 
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1.5.4 Targeting to bone 
 
One of the main bone features which differs the most from other tissues is the presence 
of bone calcium/phosphate-based mineral, hydroxyapatite (HAp) Ca10(PO4)6(OH)2, which 
introduces other ions and salts in its structure.  The mineral component is the main 
constituent of bone (per mass basis) and is the essential element responsible for the 
mechanical support function. As osseous tissues mainly consist of this mineral, they also 
have a very low blood flow rate. 
In order to get bone targeting systems, drugs or drug conjugates must be designed so 
that they have a very strong affinity for hydroxyapatite. Thus, after systemic 
administration, the drug conjugate accumulates in bones.  
A number of elements rule the binding effectiveness to the apatite surface, including the 
blood supply, the molecular structure of the apatite surface, the effective binding surface 
area and the local extravasation rate of the compound into the interstitial fluid where the 
bone surface is exposed. 
To achieve this objective, a number of molecules and moieties can be used as selective 
bone-targeting ligands. A bone-targeting moiety should preferably have a strong affinity 
for hydroxyapatite, be chemically modifiable to allow its conjugation to carriers or other 
molecules used to build the drug delivery system. The introduction of bone-targeting 
ligands must not affect the drug delivery system in terms of toxicity but also in terms of 
overall biological activity. A variety of bone targeting agent owning these characteristics 
are recognised and described briefly in the subsequent sections. 
1.5.4.1 Tetracyclines  
 
Tetracycline was discovered in the late 1940s by the American botanist Benjamin Duggar 
from soil near cemeteries (Figure 1-12). The yellow crystalline substance, derived from 
the metabolites of the Streptomyces rimosus bacteria, is an amphoteric substance which 
inhibits aminoacyltRNA from entering into bacterial ribosomes and thus inhibits the 
protein elongation; it affects the general bacterial metabolism.  
 
 
 
 
 
 
 
 
 
 
Figure 1-12 Tetracycline 
Introduction 
 
  
Page 40 
 
  
Tetracycline was first used as an antibiotic in 1947 for a wide range of bacteria. Soon 
after its clinical use, it was noticed a considerable deposition into hard tissues including 
teeth enamel and bones, leading to the interruption of the prescription of the medicine to 
young children as the strong affinity to hard tissues caused the staining of children’s teeth 
to a yellow colour. However, its use as bone targeting ligand as persevered for its 
interesting properties. Tetracycline belongs to a family of polycyclic naphthalene 
carboxamides. The atoms involved in the hydroxyapatite binding are the oxygen atoms in 
C2, C10 and C12, therefore allowing modifications around the C5, C6 and C7 carbon atoms 
without altering the binding and biological activity. The tetracycline binding properties to 
hard tissue were first attributed to the interaction of the molecule with organic 
compounds. Later, it was recognised that tetracycline have distinct metal complexing 
abilities and one explanation for their binding to bone apatite was their capacity to chelate 
with hydroxyapatite surface calcium ions
25,26
 
1.5.4.2 Acidic oligopeptides. 
 
Bone hydroxyapatite mineral is amphoteric and presents a complex variety of charges 
due to Ca
2+
, PO4
3-
, OH
-
 and other substituents under physiological environments. Such 
ionic species provide plenty of sites for the binding of proteins via electrostatic 
interactions. 
In the last few years, new bone targeting drug delivery systems based on oligopeptides 
are evolving. Non-collagenous proteins based on the repetitive sequence of acidic amino 
acids (L-aspartic acid of L-glutamic acid) are well known for binding to hydroxyapaptite 
after addition to osteoblastic cell culture; for example bone sialoproteins which are highly 
modified anionic phosphoproteins exclusively expressed in mineralized connective 
tissues and osteopontins which are multifunctional proteins containing various structural 
areas such as an integrin binding (RGD) adhesive area and aspartic acid rich calcium-
binding area. 
A minimum number of 6 amino acids in the sequence should be maintained to obtain high 
binding capacity to hydroxyapatite. Ionic interactions between the negatively charged acid 
groups of these proteins and the positively charged calcium ions within the mineral 
constituent of bone, explain the affinity of acidic oligopeptides to hydroxyapatite at 
physiological pH.  
 
1.5.4.3 Bisphosphonates 
 
Bisphosphonates are synthetic equivalents of a naturally occurring polyphosphate 
present in serum and urine, the inorganic pyrophosphate. They are able to stop bone 
calcification by binding to newly produced hydroxyapatite crystals. Bisphosphonates are 
composed of two phosphonate groups linked to a central (geminal) carbon atom by 
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phosphor-ether bonds. Effective bone targeting drug-delivery systems based on 
bisphosphonate as for site-specific delivery of other drugs to the osseous tissues have 
already been developed, fructifying the adsorption of the prodrug to the mineral 
component of the bone
27
.  
The present thesis project uses this strategy; the role of bisphosphonate will be 
developed further in the next sections. 
 
1.5.4.4 Other targeting agents 
 
The increased knowledge of the bone metastasis mechanism has led to the development 
of novel bone-targeting agents including RANK ligand (RANKL) inhibitors (for example, 
denosumab), Src inhibitors (for example, deastinib, bosutinib and saracatinib), Cathepsin 
K, chemokine receptor type 4 and GPNMB inhibitors. These models are currently 
investigated in different phases of preclinical trials (Phase I–III), RANKL inhibitor 
denosumab being one of the most studied at present. 
1.6 Drug release from polymer-drug conjugates 
 
The attachment of a drug to a polymeric carrier leads to a polymer-drug conjugate. The 
type of binding between the drug and the polymer defines the stability of the conjugate, 
influencing the rate of drug release. Polymer-drug conjugates designed for controlled 
release under specific physiological conditions uses two main mechanisms for the 
release, including an enzymatic hydrolysis or non-enzymatic hydrolysis. The hydrolysis 
rate constant depends on the chemical nature of the linkage, the structure of the polymer 
and the environmental parameters. Other factors may influence the cleavage rate, such 
as the distance between the polymer and the drug, in addition to steric hindrance and the 
hydrophilicity of vicinal groups. The choice of the bond type between the polymer and the 
drug is often restricted by the functional groups present on the drug and on the polymer. 
The introduction of a spacer may overcome this limitation. When polymer-drug 
conjugates are elaborated for tumour delivery, the linkage between the drug and the 
polymer must be necessarily stable under physiological conditions until the tumour target 
is reached. The drug should then be cleaved rapidly to be activated.  
1.6.1 Carboxylic esters 
 
Carboxylic esters have the ability to hydrolyse more easily than carbonates, carbamates 
and amides at physiological pH.  Polymer-drug conjugates, hydrogels or micelles have 
been developed using the characteristic of carboxylic ester for drug delivery. The 
hydrolysis in these systems is primarily aqueous. 
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Factors influencing rates of hydrolysis of carboxylic esters include the steric hindrance 
and the distribution of the drug along the backbone. The more the distribution is 
homogeneous, the quicker the release might be
27-28
.  
1.6.2 Carbonate esters 
 
Carbonates hydrolyse nearly 3 times slower than esters of analogous architecture; they 
are generally tough to non-enzymatic hydrolysis at physiological pH. However, in vivo, 
carbonate may hydrolyse in presence of enzymes
27-28
.  
1.6.3 Carbamate esters 
 
As for carbonates, carbamates are not sensitive to enzymatic hydrolysis at physiological 
pH. However, their strong bonds become weaker at extreme pH, either basic or acid. This 
property has been used by Yoo et al. to free doxorubicin from a PGLA-doxorubicin 
conjugate connected through carbamate bonding
2a
. 
Carbamates are generally less sensible to esterases than carbonates. However, N-
substituted or mono-substituted carbamates derived from phenolic compounds show a 
greater lability than aliphatic hydroxyl carbamates which are very stable, and therefore, 
phenolic carbamates are favourable to enzymatic hydrolysis. 
1.6.4 Hydrazones 
 
Hydrazones are widely used for targeted delivery. Their attractiveness is attributable to 
their property of hydrolysis in function of the environmental pH; hydrazones are stable at 
7.4, physiological pH, but hydrolyse at pH 5.0. This characteristic has particularly been 
exploited in the design of polymer-drug conjugates for tumour or lysosome targeting
28b
.  
1.6.5 Amide 
 
Amides are generally very stable entities. They are not affected neither by aqueous nor 
by enzymatic hydrolysis and are particularly adapted for systems which need a 
permanent polymer-drug linkage. 
1.6.6 Peptidyl spacers 
 
Peptidyl spacers are usually used as enzyme substrates. In the case of cancer, proteases 
are very much involved in the development of tumours and can be used as triggers. 
Proteolysis is an irrevocable regulatory mechanism in which enzymes selectively cleave 
specific substrates based on amino acids. The bond rupture occurs at the amide bond 
between the C-terminal of the peptide and the amine group of the drug.  
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Proteases are an essential factor in numerous biological and pathological developments 
by the proteolysis regulatory mechanism; they are present in a large amount in normal 
lysosomes as well as in metastatic cancer. In neoplastic diseases, unusual proteolytic 
activity results either from greater protease expression, reduced levels of proteinase-
inhibitors, altered subcellular distribution patterns or a combination of them. Proteases 
themselves originate not only from tumour cells but also from the various cell types 
present in the tumour microenvironment, where stromal cells such as fibroblasts, 
inflammatory cells such as macrophages, mast cells and neutrophils, and blood vessel 
cells such as endothelial cells interrelate in a complex network 
 
Alterations in protease expression and substrate proteolysis are important elements in the 
pathogenesis of many diseases. Deregulated, excessive or incorrect proteolysis are 
characteristic features of neoplastic as well as inflammatory, cardiovascular, 
neurodegenerative, bacterial, viral and parasitic diseases.  
In the case of tumour-specific targeting, the enzyme exploited for drug release and 
activation should be exclusively present in the tumour cell.  
Perhaps the most direct way to design protease-sensitive prodrugs is to attach a cytotoxic 
agent covalently to a peptide substrate of the enzyme to be targeted. Ever since the early 
reports by Carl et al., several variants of this concept have been explored using different 
peptide substrates and chemotherapeutics.  
Acetylation of the terminal amine function of the peptide is a frequent way to synthesise 
peptide-based prodrugs. 
Designing a polymer-drug conjugate bound together via a peptidyl spacer has been 
investigated by several groups as exampled in section 1.6.  
 
1.7 Examples of drug release triggered by small proteases 
 
A commonly acknowledged approach to improve efficiency of chemotherapeutics is to 
direct anti-tumour drugs to their target site. The release of these drugs can be achieved 
by insertion of a spacer that is receptive to a disease-specific trigger. Methods using 
protease-sensitive spacers have attracted wide interests among researchers and more 
particularly polymer-drug conjugates involving activation by cleavage of small protease-
sensitive peptide spacers. 
A first example is the use of the Cathepsin-B sensitive spacer Gly-Phe-Leu-Gly in the 
synthesis of several N-(2-hydroxypropyl)-methacrylamide-copolymer (HPMA)-based drug 
conjugates in order to achieve lysosomal drug release.  
N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates with anti-tumour 
agents have been most extensively studied. Generally, the drugs are bound to the 
polymer backbone using peptidyl spacers designed for cleavage by lysosomal The most 
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promising conjugate of this type is PK1; the polymer-drug conjugate went through to 
Phase I and Phase II clinical trials. 
The first synthetic polymer-drug conjugate is a HPMA copolymer doxorubicin (PK 1), in 
which the anti-tumour agent doxorubicin is bound to the polymer backbone by a Gly-Phe-
Leu-Gly peptidyl side chain. The conjugate displays anti-tumour activity and is five to ten 
times less toxic than free doxorubicin and shows evidence of tumour selective targeting.   
Studies demonstrated that an increase of lysosomal Cathepsin B activity was associated 
with a higher amount of free doxorubicin in the tumour tissue. Clinical trials established 
that the maximal tolerated dose (MDT) was found to be approximately 5 times higher 
compared to free doxorubicin and no cardiac failure were reported.  
Other drugs using were covalently attached to HPMA via the Gly-Phe-Leu-Gly spacer, 
including Adriamycin, daunomycin, 5-fluorouracil or Pt(II)complexes.  
Using the same peptide linker, but using alendronate as a therapeutic agent, HPMA-
copolymer conjugates were developed by Satchi fainaro et al. These studies confirmed a 
strong affinity for bone tissues of the conjugate. 
Gly-Gly-Pro-Nle is another linker which has been employed to connect HPMA copolymer 
to prostaglandin E1for bone targeting. The Cathepsin K sensitive spacer was intended to 
achieve site- release with potential applications in osteoporosis or other bone diseases.  
In vitro studies validated that the osteoclasts activated efficiently the prodrug.  
Another example uses a MMP-2/-9 sensitive dextran-methotrexate conjugate. The 
polymer, developed by Chau et al., contained a Pro-Val-Gly-Leu-Ile-Gly peptide linker. In 
vitro experiments showed release of 89% and 61% of the methotrexate after incubation 
with MMP-2 and MMP-9, respectively, for 24 hours. Moreover, it was shown that the 
liberated methotrexate-Pro-Val-Gly digestion product had cytotoxic effects in cell culture, 
although with a lower potency than free methotrexate.  
In opposition to free methotrexate, the MMP-sensitive conjugate demonstrated 
acceptable in vivo side effects and successful inhibition of tumour growth by 83% in two 
independent MMP-overexpressing tumour models. MMP-insensitive conjugates, though 
able to inhibit tumour growth, caused toxicity in the small intestine and bone marrow.  
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1.8 Material involved in the project – Design of Pullulan-paclitaxel 
alendronate with Cathepsin K sensitive spacer  
 
The concept of macromolecular carrier had already been defined at the beginning of the 
last century, when in 1906 Ehrlich created the term "magic bullet" to indicate the transport 
of drugs with a high molecular weight.  
In the seventies, Helmut Ringsdorf proposed the first model of polymer therapeutics, in 
which the cytotoxic agent could be conjugated to different polymeric backbone
29
.  
 
The model proposed by Ringsdorf consisted of an inert water soluble polymeric carrier on 
which different components were attached
29
: 
 
 A biodegradable spacer interposed between the polymer backbone and the drug, 
allowing a sensitive chemical or enzymatic hydrolysis only at the site of action, 
releasing the active drug (intracellularly cleavable linker). 
 A drug covalently linked to the spacer. 
 Optionally, a targeting agent bound to the polymer structure can be added, 
promoting the guiding and the uptake to specific targeted cells, while minimising 
the non-specific interactions.  
 Another optional element is the addition of solubilisers able to modulate the 
solubility of the polymer-drug conjugate. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Bio-conjugation is a strategy particularly encouraging for increasing the efficiency of 
injectable drugs since it allows to obtain new chemical entities with special chemical-
physical and biological characteristics that positively influence the pharmacokinetics and 
pharmacodynamics of the drug itself
30
. 
Figure 1-13 Model of polymeric carrier 
 
 
 
Drug molecule 
Cleavable Spacer 
Targeting agent 
Solubilising agent  
Polymeric Carrier 
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However, there are still many hurdles to overcome before succeeding in finding the ideal 
ligand for the polymer-drug conjugate. 
One of the objectives to be attained is the improvement of the chemical bond so that the 
activation and coupling does not affect the properties of the polymer, and that the active 
site of the drug remains available.  
A further challenge is to obtain well characterised polymers with low polydispersity. 
Finally, there is a need to develop appropriate analytical methods for the characterisation 
of the conjugate and its components. 
 
Although bio-conjugation is challenging, it is still considered as a key method with 
numerous benefits, among which: 
 
 The disguise of the antigenic sites of the drug resulting in a reduced uptake by the 
immune system; especially in case protein drugs, 
 The greater plasma half-life and the reduction of the renal excretion due to the high 
hydrodynamic volume; 
 The greater solubility of drugs in water normally poorly soluble if used alone. 
 The specific targeting of the drug in the tumour tissue due to the presence of 
targeting agents. 
 The accumulation of the drug in the tumour tissue by passive targeting.  
 The likelihood of less frequent administrations, and at lower doses reducing 
systemic toxicity. 
 
The main advantage is still the ability to direct and release the drug only to the target site, 
exploiting the characteristics of the tumour tissue and the polymer-drug linkage or spacer. 
 
Many polymer-drug conjugates are currently in clinical trial at various phases. As 
mentioned earlier, PK1 was among the first to be tested on humans, where HPMA is 
used as a carrier for the anti-tumour drug doxorubicin. Studies showed that the bio-
conjugation permitted an increase of up to five times the maximum tolerated dose of 
doxorubicin alone, without presenting phenomena of cardiotoxicity, which appears to be 
the most harmful side effect of this drug
31
.  
The same polymer was further modified with the introduction of galactosamine, a 
selective ligand for the hepatic asialoglycoprotein, in order to obtain a liver targeting. The 
polymer obtained named PK2 also entered clinical trials. It confirmed an accumulation 
capacity in the hepatic tumour cells, up to 50 times greater than that of the free drug
32
. 
However, it was evidenced that the bio-conjugate ligand was not selective for cancer cells 
but amassed equally in healthy hepatocytes. Other bio-conjugate were synthesised to 
increase the solubility of poorly soluble drugs such as paclitaxel and camptothecin. The 
derivatives of these drugs conjugated to HPMA have revealed issues related to the 
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stability of the spacer between the polymer and the drug, As a result, the polymer 
released the drug into the bloodstream, result of a too fast kinetic of hydrolysis of the 
ester bond, causing record phenomena of neurotoxicity, attributable to the circulation of 
the paclitaxel but not the conjugate
33
.  
 
In a similar fashion, following Ringsdorf’s model, the present project investigates the 
engineering and design of a new polymer-drug conjugate, involving a natural polymer, the 
Pullulan polysaccharide, a Cathepsin K sensitive spacer, an anti-tumour drug, Paclitaxel 
and a targeting agent, Alendronate. 
1.8.1 Pullulan 
 
Pullulan was first discovered by Bauer in 1938
34
. It is a neutral water-soluble 
polysaccharide, a random coil glucan, aerobically grown and produced extracellularly by 
some strains of the polymorphic yeast-like fungus Aureobasidium pullulans which is found 
commonly in the environment such as soil, wood or decaying leaf. 
The biopolymer is composed of the trisaccharide maltotriose G3 -(14)Glup--
(14)Glup--(16)Glup- and a small percentage of tetramer maltotetraose -
(14)Glup--(14)Glup--(14)Glup--(1 6)Glup- (maximum 7%). Therefore, 
pullulan possesses a molecular structure between amylose and dextran as the single 
polymer holds both types of glycosidic bonds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pullulan is soluble in water which gives stable low viscosity solutions, in respect to other 
polysaccharides. It decomposes at high temperature (250°C-280°C). It is only soluble in 
the two organic solvents dimethylformamide and dimethylsulfoxide. 
Figure 1- 1 Pullulan 
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Pullulan number-average molecular weight (Mn) is about 100-200kDa and the weight –
average (Mw) between 362-480kDa. The polydispersity (Mw/Mn) is frequently reported as 
being between 2.1 and 4.1, significantly lower than other common hexo-polysaccharides 
such as amylase and dextran. 
The polysaccharide chain contains hydroxyl groups in position 2,3 and 4 which all 
possess a different chemical reactivity. Its non-toxic, non-immunogenic, non-mutagenic 
and non-carcinogenic properties make it an ideal candidate for numerous medical or 
biomedical applications including polymer therapeutics, gene delivery and tissue 
engineering
35
.  
The biocompatibility of the polymer was confirmed by some studies on human fibroblast.  
After prolonged incubation periods with high concentrations of pullulan nanoparticles, no 
significant decline of the cellular vitality or morphological variations nor interferences with 
cell adhesion could be observed
36
. The adhesion is mediated by the interactions between 
surface proteins such as integrin, and proteins of the extracellular matrix (or the ones 
present on the surface of other cells or particles).  The test of cell adhesion is of crucial 
importance in the growth, migration, differentiation, survival and organisation of tissues, 
thus, it is fundamental to make sure that the carrier is not responsible of such 
interferences or of other kinds of inflammatory phenomena. 
As for many other polysaccharides, after intravenous administration pullulan is 
disseminated mainly to liver.  Biodistribution studies in rats showed that the 
asialoglycoprotein receptor (ASGPR) contributes in a crucial way to the liver distribution.  
The inhibition of such receptor reduces the connection and the internalisation of the 
polymer at the level of the liver parenchyma.  On the base of such observations, it can be 
thought of the use of pullulan as a potential passive carrier or active one via indirect 
endocytosis via receptors for the delivery to the liver.  However, pullulan uptake is 
achieved via a specific path of recognition resulting in a high sensitivity towards the 
stereo chemical configuration of the molecule and to the position of the hydroxyl groups in 
the pyranose unit. Consequently, structural alterations can alter significantly the 
behaviour of the polymer. 
 
Kaneo et al. proved that pullulan strongly binds to the asialoglycoprotein receptors 
expressed on the sinusoidal surface of hepatocytes
37
. 
Pullulan accumulates in the liver in a higher amount than other water soluble polymers 
and is widely used for targeting gene/drug in the liver. In the treatment of hepatic C virus 
induced liver disease, interferons (IFN) are commonly used, however, they are clinically 
insufficient. Suginoshita et al developed a method to target IFN to liver by complexation 
with modified pullulan DTPA12. They noticed an enhanced activity of the IFN from IFN-
DTPA-pullulan conjugate in respect to the free IFN
38
. 
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In recent years, polysaccharides play an important role in the development of drug 
delivery systems for tumour targeting. Researchers have shown an increased interest in 
using pullulan for this application. A few examples include the self-assembly of 
hydrophobised pullulan, pH sensitive modified pullulan nanoparticles or else, anionic or 
amphiphilic microparticles. 
Nogusa H et al. showed that the carboxymethylation of pullulan introduces negative 
charges onto the polysaccharide, leaving a derivative with low affinity for asiaglycoprotein 
unlike the native pullulan. Consequently, the liver uptake of pullulan decreased by more 
than a hundred fold. This property was exploited in the field of chemotherapy; for 
example, the anti-tumour agent Doxorubicin has been conjugated to the modified pullulan 
via a peptide linker. The authors found the conjugated drug was more efficient on solid 
tumours that the free drug
39
. 
Other research focuses on the modification of pullulan to render it hydrophobic. The new 
material can then self assembles to form nanoparticles. 
 
1.8.2 Polyethylene glycol 
 
Polyethylene glycol (PEG) is the product of polymerisation of ethylene oxide by ring 
opening polymerisation. The polymer is ordinarily prepared by anionic polymerisation,   
The polymerisation occurs in three steps including an initiation steps which involves a 
nucleophilic attack of a hydroxide ion on the epoxide ring, a propagation step by epoxide 
addition and a termination step. 
 
 
 
Figure 1-14 Synthesis of polyethylene glycol. 
 
PEGs are often functionalised in order to increase their reactivity towards biomolecules. 
For example, the conjugation with amino acids will use a PEG-epoxide, PEG aldehyde, or 
PEG succimidyl. Molecules bearing hydroxyl groups will react with PEG-NHS or PEG 
nitrophenyl chloroformate. 
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A large number of derivatives of PEG have been developed to give chemical groups with 
different reactivity. PEGs have several applications in drug development, they are used 
for enhancing the load of low-molecular weight drugs with reduced biological activity or 
increase the solubility of a drug in the physiological environment as it has got unique 
solvatation properties. PEG conveys properties to conjugates such as biocompability, 
anti-immunogenicity, and antigenicity. 
The alcohol function of PEG is poorly reactive under the conditions needed for 
bioconjugation. Consequently, the polymer must be functionalised to increase its 
reactivity, introducing epoxide, aldehyde, thiol or succinimidyl functions for the 
conjugation of amino groups or N-hydroxysuccinimide and p-nitrophenyl chloroformate for 
the coupling with hydroxyl groups for example. 
Bifunctional PEG can also contain protective groups such as t-Boc and Fmoc to prevent 
the reaction between the active ester and the amino group present onto the same PEG 
chain but also to ensure selective modifications of PEG. Bifunctional PEGs can also be 
used for crosslinking reactions. t-Boc and Fmoc are easily removed with trifluoroacetic 
acid and the mild base piperidine respectively. 
Polyethylene glycol is widely used for pharmaceutical applications to obtain bioconjugates 
with new chemical and physical characteristics, and the enhancement of pharmacokinetic 
and pharmacodynamics of drugs without drastically altering the biological activity. Active 
PEGylated molecules gain new properties such as the increase of plasma half-life, the 
reduction of renal excretion and biodistribution for the increase of the molecular weight, 
the reduction of the hydrolytic and enzymatic degradation, the reduction of uptake into the 
reticulo-endothelial system, the increased solubility in water and the reduction of 
immunogenicity and antigenicity. 
The PEGylation was initially used to conjugate peptides and proteins, but issues of 
stability occurred. Mild chemistry is needed so not to disable or denature the protein
40
.  
Several conjugates in both clinical trials and market are currently available including: 
- ADAGEN: PEG and bovine conjugate adenosine deaminase is promoted by Enzon, 
Inc., for the treatment of combined immunodeficiency syndrome 
- PEG-INTRON: PEG 12000 Da and ,2b-interferon conjugate (-IFN) to treat hepatitis 
C. 
More recently PEG was conjugated with insulin, superoxide dismutase, interleukin- 2, 
haemoglobin. 
PEGylation has also been widely used in cancer therapy in order to target the drug 
specifically to tumour tissue, preventing the distribution to other areas and normal tissues, 
avoiding side effects. ONCOSPAR ® conjugate between PEG and L-asparaginase is an 
example, used in the treatment of cancer Acute lymphocytic leukemia;  
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Other examples of PEG conjugated with anticancer drugs include camptothecin, an anti-
tumour alkaloid whose solubility is increased by binding to the polymer
41
, or doxorubicin, 
which substantially reduced the cardio toxic effects. 
AraC, methotrexate and taxanes PEG conjugates are currently being developed in order 
to target the antineoplastic agent in the tumour tissue, consequently reducing systemic 
toxicity and improving the pharmacodynamic and pharmacokinetic profiles. 
PEGylation of antiviral, antimalarial and anti-AIDS drugs are also being studied to 
improve their pharmacological properties. 
PEG is also used for other applications than pharmacological ones. Its very flexibility, its 
strong ability to coordinate water molecules and its high hydrodynamic volume is 
exploited in the "two phases partitioning" purification technique. 
Furthermore, PEG is used for protein or nucleic acid precipitation and for peptide and 
oligonucleide synthesis in liquid or solid phase. The polymer is also very present in the 
field of cosmetics. 
In recent years, it has been widely used in the pharmaceutical industry for the preparation 
of drug delivery systems such as liposomes, nanoparticles, nano-and microspheres, 
dendrimers and hydrogels and for the preparation of prodrugs by bioconjugation with 
peptides, proteins or low molecular weight drugs. 
The delivery of biologically active molecules using various types of polymer systems has 
many advantages including a less frequent dosing, lower doses necessary, and being 
below the minimum toxic concentration. Using PEG allows the protection of the drug from 
inactivation resulting in prolonged half-life. 
1.8.3 Paclitaxel 
 
Paclitaxel, also known as Taxol, is extracted from the bark of the Pacific Yew tree (Taxus 
brevifolia), and is one of the main effective anti tumoural drug used to treat various solid 
tumours such as in head and neck human carcinomas, AIDS-related Kaposi’s carcinoma 
as well as lung, metastatic breast  and advanced ovarian cancers.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1-15 Paclitaxel 
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The paclitaxel structure is composed of a tetracyclic core, an eight-membered ring, a 
four-membered ring and two six membered rings Several functional groups are attached 
to this skeleton, including a benzoyl group, particularly essential for maintaining the 
molecule’s bioactivity Other functional groups, present on paclitaxel’s side chain are also 
crucial for its anti-tumour activity and particularly an amide-acyl group at the end of the 
chain Due to this structure, paclitaxel is a particularly hydrophobic molecule (solubility in 
water 1g.ml
-1
).  
Paclitaxel is a known cytotoxic agent used in anti-tumour therapy, alone or in association 
with cis-platinum, in affected patients from ovarian carcinoma, or like medicine of second 
choice in the breast cancer when not responding to other treatments.  It is also indicated 
treatment for pulmonary carcinoma and sarcoma of Kaposi AIDS-correlated. 
The biological activity of taxols is attributable to the specific and stoichiometric connection 
to tubules, constituent protein of the microtubule skeleton.  Microtubules are cellular 
components involved in the correct separation of the chromosomes during cellular 
division.   
When paclitaxel binds with tubulin, it encourages the polymerisation and stabilises the 
micro tubular structure, modifying a normal equilibrium.  A stabilised cell with microtubule 
undergoes a programmed process of cellular death or apoptosis.   
An albumin bound paclitaxel (named Abraxane®), is actually used clinically This 
alternative formulation where paclitaxel is bound to albumin nano-particles is formulated 
with Cremophor EL which leads to numerous side effects of the drug including reactions 
of hypersensitivity, neurotoxicity and nephrotoxicity. These effects are sometimes very 
serious and in some cases, a preventive medication with corticosteroids and 
antihistaminic is necessary.   
In order to overcome these side effects, researchers concentrate on developing new drug 
delivery systems which would increase the solubility of paclitaxel and even target the drug 
to the tumour tissues.  
The intravenous administration of the medicine requires long times and slow flow. Recent 
studies seem to confirm a reduction of the efficiency of the anti-tumour drug due to the 
presence of the Cremophor EL.  For these reasons, a special attention is drawn to the 
development of alternative drug delivery systems, Cremophor-free. Among these, can be 
included the use of liposomes, cyclodestrin, micro emulsions, microspheres or polymeric 
nanoparticles. 
Such systems are used not only to increase the solubility of the medicine, but also to 
target the drug to the tumour. Restricted delivery of paclitaxel would give sustained drug 
exposure to tumour cells and enhance the tumour penetration of cytotoxic agents and 
decrease the rate of replication of tumour cells.  
Targeting chemotherapeutics delivery to the tumour site is also thought to enhance the 
chemo responsiveness by exposing tumours and adjacent metastases to high drug 
concentrations at the same time as reducing its systemic exposures. 
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Encouraging results were obtained for chemically modified paclitaxel (prodrugs) 
incorporated into lipidic systems using acid folic as targeting agent. Liposomes have been 
also synthesised using folic acid, offering a greater half-life with respect to the traditional 
carriers. The cytotoxicity was four times superior with respect to the same liposomes 
without folic acid. 
Other polymeric micelles having an average diameter of 130 nm have been achieved 
using the copolymer (NIPAAm-co-DMAAm)-b-PLGA, in which a large amount of 
paclitaxel was physically loaded, ensuring the same sustained release
42
.  Similar features 
were observed for micellar aggregates based on triblock copolymer-PLA-PEG-PLA 
synthesised by ring opening polymerisation at different molar ratios of ethylene 
glycol/lactic acid
43
. Other micellar systems based on low molecular weight diblock 
copolymer mPEG-block-poly(D,L-lactide) maintained a comparable cytotoxicity to the free 
drug on a MCF-7 cell line However, in vivo bio distribution assays showed greater drug 
levels, from 2 to 3 times higher in the liver, kidney, spleen, lung and tumour tissue
44
. 
A micellar type system was also developed by preparing immune-micelle of PEG-
phospholipids, chemically modified by covalent binding with specific monoclonal 
antibodies capable of recognising a wide range of tumour cells and showed that these 
systems increase the cytotoxicity
45
 . 
Among the drug delivery systems for paclitaxel based on polysaccharides, the most 
encouraging ones were obtained by using  amphiphilic derivatives of chitosan such as the 
conjugate N-octyl-O-sulfate chitosan micellar system, ,able to solubilise up to 25% by 
weight of paclitaxel
46
, the derivative N-mPEG-N-octyl-O-sulfate-chitosan which reached 
40% loading by weight and the N-lauryl-carboxymethyl chitosan conjugate, which led to a 
1000 fold increase solubility in an aqueous environment, ensuring the in vitro cytotoxic 
activity
47
. 
Hydrophobised glycol-chitosan with 5β-cholanic acid has also been developed to produce 
nanoparticles of 400 nm in diameter, able to upload up to 10% by weight of paclitaxel. 
The nanoparticles were stable in PBS for up to 10 days. It was determined that 50% of 
the drug was released in the first 24 h, and stabilised progressively up to 80% over the 
next 10 days. However in vitro cytotoxicity studies show a lower efficiency of the micellar 
systems with respect to commercial preparation with Cremophor
48
. 
1.8.4 Bisphosphonates and Alendronate 
 
The “seed and soil” Paget’s theory of bone metastases describes the travel of metastatic 
cells in all body once entered in the bloodstream and  their attachment only in favourable 
environments, bone marrow being one of those. Once in the bone, bone anabolism and 
catabolism causes patients severe bone pain and increases mortality.  
Small drug molecules are often used as osteoclast target for the treatment of these 
metastases such as Cat K inhibitors, Reveromycin or bisphosphonates (BPs). 
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As bone metastases progress, hydroxyapatite (HAp) is exposed to blood and constitutes 
a target for BP attachment. This characteristic can also be utilised to deliver high drug 
loads specifically to disease tissue. Macromolecular therapeutics are able to travel into 
the tissue due to vascular pressure and be retained into the tumour tissue due to the poor 
tumour vasculature.  
Alendronate belongs to the family of bisphosphonates which constitutes the most 
important category of anti-resorptive agents.  
 
 
 
 
 
 
 
 
 
 
This class of drug is characterised by a high affinity for bone and hydroxyapatite.  
In the 1960s, original investigations revealed that inorganic pyrophosphates (IPP) were 
capable of inhibiting calcification by binding to hydroxyapatite crystals, suggesting that 
regulation of IPP levels could be the mechanism by which bone mineralization is 
regulated. 
Bisphosphonates are analogous to inorganic pyrophosphate in which the hydrolysable 
oxygen bridge between the two phosphate atoms has been replaced by a more stable 
carbon with various side chains to give a high affinity to bone and retain much of the 
binding affinity after conjugation to other molecules and carriers.  
 
 
 
 
 
 
 
 
 
 
 
 
Bisphosphonates are preferably assimilated into sites of active bone remodelling, as it 
normally takes place in disorders characterized by accelerated skeletal turnover. The free 
Figure 1-16 Sodium alendronate 
Figure 1-17 Comparison inorganic pyrophosphate and bisphosphonate 
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bisphosphonate, not retained by the skeleton, is rapidly cleared from the circulation by 
renal excretion. Moreover, bisphosphonates inhibit hydroxyapatite breakdown and 
efficiently prevent bone from resorption
49
. 
 
Bisphosphonates increase the calcium balance and the mineral density of bones. They 
are used in the treatment of metabolic bone diseases, including tumour-associated 
osteolysis, hypercalcemia, Paget’s disease and osteoporosis. The potency of inhibiting 
bone resorption is very variable between different bisphosphonates and can increase up 
to 10 000 fold. 
They are resistant to enzymatic hydrolysis due to the carbon atom in their structure. The 
composition of their derivatives induces diverse cellular and molecular mechanisms; their 
activity varies from one another depending on the length and substitution of the aliphatic 
carbon atom. Modifications of the R2 side chain demonstrates that the presence of a 
nitrogen atom onto the alkyl chain, as in alendronate, ibandronate or pamidronate, 
increases the anti-resorptive potency of the drug (10 to 1000 fold) in respect to the earlier 
generation of bisphosphonates such as etidronate (Figure 1-18
50
).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-18 Bisphosphonate structures and approximate relative potencies for 
osteoclast inhibition.  
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The more the nitrogen atom on the R2 chain is distant from the P-C-P group, the greater 
is the potency of the bisphosphonate (Figure 1-19).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If an OH group in R1 is replaced by a methyl group, the bone activity is noticeably 
reduced as well as the anti-resorpsive activity. 
The increasing antiresorpsive activity of common bisphosphonate is as follow: 
etidronate<clodronate<pamidronate<alendronate<risedronate 
 
In recent years, the amino bisphosphonate alendronate (ALN) has arisen as an efficient 
therapeutic method for the prevention of skeletal troubles produced by bone metastases. 
Similar to all bisphosphonates (BPs), it exhibits a remarkably high affinity to the bone-
mineral hydroxyapatite (HAp). ALN is approved by the FDA for the treatment of bone 
related diseases and cancer connected hypercalcaemia. 
Considerable efforts have been made to conjugate BPs with non-specific bone 
therapeutic agents in order to obtain osteotropicity because of their high bone affinity. 
ALN was successfully conjugated with polymer-drug delivery systems. 
Recent works have shown that both low doses ALN and PTX may selectively inhibit 
endothelial functions important to angiogenesis, phenomenon now recognized as an 
important mechanism in tumour progression and metastasis formation. 
This high affinity for bone mineral allows bisphosphonates to reach a high local 
concentration throughout the entire skeleton. Consequently, bisphosphonates have come 
to be the primary therapy for skeletal disorders characterised by extreme or imbalanced 
skeletal remodelling, in which osteoclast and osteoblast activities are not strongly united, 
leading to excessive osteoclast-mediated bone resorption. 
 
 
 
Figure 1-19 General features of bisphosphonates 
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1.8.5 Cathepsin K 
 
Cathepsins, found in various types of cells, break apart other proteins by hydrolysis of 
amide bonds and belong to papain-like cysteine proteases. The twelve constituents of 
this enzyme family are distinguished by their structure, catalytic mechanism and which 
molecule they cleave, i.e. by their substrate specificities. They include plant enzymes 
(papain and bromelain), paisite proteases (cruzain and falcipain) and human cysteine 
Cathepsins (B, H, L, S, C, K, O, F, and V, X, W)
51
. 
Most of human Cathepsins are activated in lysosomes where pH is low. Their main 
localisation in the endosomal/lysosomal compartment affords cysteine Cathepsins with 
optimum conditions for substrate cleavage. Together with their physiological functions, 
they are significantly involved in several pathological disorders. This often implicates 
relocalisation from their usually lysosomal compartment to extracellular sites. Amplified 
expression of cysteine Cathepsin arises often in premalignant or early lesions.  For 
example Cathepsin B is over-expressed in Barrett’s oesophagus and stage I 
oesophageal tumours or Cathepsin H in lymph node-negative lung tumours. Bio-
responsive release is achieved by insertion of a spacer that is responsive to a disease-
specific trigger. Therefore, a substantial and homogeneous expression at the diseased 
site is required, with low or no activity in normal tissues or serum. 
In the case of breast cancer bone metastasis, an over-expressed enzyme is Cathepsin K, 
highly present at osteolytic lesions and site of active bone resorption. 
Cathepsin K works extracellulary subsequent to the secretion of osteoclasts, leading to 
destruction of bone matrix through type I collagen degradation, a known substrate of 
Cathepsin K containing multiple glycine-proline sequences
52
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-20 Osteoclast morphology 
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The highly overly expressed Cathepsin K in osteoclasts has also been found in the serum 
of Gaucher patients, in lung epithelial cells, in cancer prostate cells and in macrophages. 
Beside their physiological function by protein degradation/turnover in 
endosomal/lysosomal system, they also are involved in pathological processes such 
Alzheimer's disease, tumour invasion, muscular dystrophy, osteoporosis or rheumatoid 
arthritis.  
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2. Materials and methods 
 
1.9 Reagents 
 
 Fmoc-proline, Fmoc-glycine, Fmoc-Norceuline-Wang resin (Fmoc-Nle-Wang-R) 
were procured by Bachem (Bubendorf, Switzerland) 
 HOBt and HBTU were acquired from ABI S.r.l (Milano, Italy) 
 Reactors for solid phase peptide synthesis (SPPS) were purchased from Grace 
Davison Discovery Sciences (Columbia, USA) 
 Cathepsin K was obtained from Calbochem, (Darmstadt, Germany) 
 Alendronate was acquired from LTBio (Shanghai, China) and alendronic acid 
from Surfactis Technologies (Angers, France) 
 Paclitaxel was obtained from LC Laboratories (Woburn, USA) 
 Pullulan and all other chemical reagents, including salts, silica gel, trifluoro 
acetic acid, coupling agents and solvents, were purchased from Sigma-Aldrich 
(Saint Louis, USA).  
 Alpha-t-Butyloxycarbonylamino-omega-carboxy succinimidyl ester poly(ethylene 
glycol) (tBoc-NH-PEG3000-NHS, 3000Da) was purchased from Iris biotech 
(Marktredwitz, Germany) or from JenKem Technology USA (Allen, USA) 
 Deuterated solvents used for NMR spectroscopy analysis,  incuding chloroform, 
water and dimethylsufoxide, were obtained from Sigma Aldrich (Saint Louis, 
USA)  
 All solvents of appropriate purity (HPLC or higher degree of purity) were 
obtained from Sigma Aldrich (Saint Louis, USA), VWR (Milan, Italy) or Carlo 
Erba (Milano, Italy). 
 All reactions requiring anhydrous conditions were performed under N2 
atmosphere.  
 Chemicals and solvents were analytical grade reagents and anhydrous solvents 
were obtained by distillation and conservation on molecular sieves. 
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1.10 Cell culture 
 
 Dubelcco’s modified Eagle’s medium (DMEM), RPMI 1640, Fetal Bovone Serum 
(FBS), Peniccilin, Streptomycin, Nystatin, L-Glutamine, Hepes buffer, Sodium 
pyruvate, and fibronectin were procured by Biological Industries Ltd (Kibbutz Beit 
Haemek, Israel). growth factor reduced medium EBM-2, and EGM-2 medium was 
purchased from Cambrex (Walkersville, MD, USA). Matrigel was from BD 
Biosciences (USA).  
 
 MTT was purchased from Sigma Aldrich (aint Louis, USA) 
 MDA-MB231 human mammary adenocarcinoma, SAOS-2 osteosarcoma and 4T1 
murine adenocarcinoma cell lines were purchased from American Type Culture 
Collection (ATCC). Human Umbilical Vein endothelial cells (HUVEC) were obtained 
from Cambrex (Walkersville, USA). 
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1.11 Instruments 
 
 Ultraviolet-Visible Spectrophotometry measurements were performed using a UV-
Vis 25 Perkin Elmer (Norworlk, CT, USA) apparatus. 
 
 Spectrofluorimetric analyses were performed using a FP 6500 Jasco 
Spectrofluorimeter (Tokyo, Japan). 
 
 A plate reader was used for 96 well plates using the Microplate Autoreader (mod. 
EL311SK) from Biotek instrument Inc. (Highland, Vermont, USA) 
 
 A Fourier Transform Infrared spectroscopy instrument FT/IR-6000 series from 
Jasco (Tokyo, Japan) was used. Samples were dispersed in KBr pellets and 
recorded with an instrumental resolution of 2 cm
-1
 and an average of 256 scans on 
the FTIR spectrometer, with a resolution of 3 cm
-1
. 
 
 A Jasco HPLC equipped with two P1580 pumps, a UV-1575 detector, a Hercule 
Lite fornito recorder from JMBS, and a RP Phenomenex Luna C18 250x4.60 mm 
column. 
 
 Solid Phase Peptide Synthesis (SPPS) was performed using a PS3 peptide 
synthesiser from Protein Technologies Inc. (Tucson, USA) 
 
 Freeze drying was performed on a Hetossic HETO Lab Equipment freeze drier or 
Speed Vac, Vacuum Centrifuge HETO Lab Equipment apparatus (Birkerod, 
Denmark) 
 
 Solvents were removed using a R114 BÜCHI Labortechnik AG rotavapor 
(Postfach, Switzerland) 
 
 pH of solutions were measured using a Seven Easy S20-K Mettler Toledo pHmeter 
with Mettler Toledo Inlab 413 electrode (Schwerzenbach, Switzerland) 
 
 Aldehyde titrations were performed using a Fisherbrand Hydrus600 pHmeter 
(Illkirch, France) 
 
 Centrifugation was achieved using a CENTRIKON T-42K Kontron Instruments, 
Z300 Hemle (Eching , Germany) and with a ALC micro centrifuge 4214 from ALC 
international (Cologno Monzese, Italy) 
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 The NMR spectroscopy analyses were performed using a Spectrospin AMX 300 
MHz Bruker NMR instrument (Billerica, MA, USA). 
 
 The ESI-MS measurements were achieved using an Applied Biosystem Mariner 
ESI-TOF ESI-TOF mass spectrometer (Monza, MI, Italy). 
 
 Ultra-filtrations were carried out using an Amicon system (Denver, MA, USA) 
equipped with an YM1 membrane (cut-off 10.000 Da) and an Amicon ultraFree-MC 
Millipore with a 1kDa or 30kDa cut-off. 
 
 Buffer solutions were filtered using a Millipore (Bendford, MA, USA) fritted 
glassware with a 0.22 m filter 
 
 An ultrasonic bath from Branson Ultrasonics (Danbury, USA) was used to sonicate 
buffers and eluents prior to chromatographic analysis. 
 
 The size of polymeric nanoparticles was estimated by Dynamic Light Scattering 
using a Zetasizer NanoZS instrument (Malvern Instruments Ltd, UK). 
 
 TLC plates used were covered with silica gel (60ALUGRAM SIL/UV254, Sigma 
Aldrich, Saint Louis, USA) and were eluted using the solvents mixtures indicated. 
Products were detected using a UV lamp at 254nm. 
 
 Dialysis tubes used for drug release studies and purifications were made of 
regenerated cellulose (Visking, cut-off 3.5kDa and 14kDa) and supplied by 
Delchimica Scientific Glassware (Naples, Italy).  
 
 Endothelial cells and 4T1 cells were counted using Coulter Counter Cell and 
Particle Counters, Coulter Z series from Beckman Coulter Inc. (Highland, Vermont, 
USA). 
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1.12 Methods 
1.12.1 Analytical methods  
1.12.1.1 Determination of aldehyde groups 
 
Aldehyde groups react instantaneously with hydroxyl amine to form an oxime and free a 
molecule of hydrochloric acid. This later can be titrated using sodium hydroxide (NaOH, 
0.1mol.l-1) and the quantity of aldehyde groups can be deduced from the titration 
(Scheme 2-1). 
 
 
 
 
 
 
 
Protonation induces an increase of electrophilicity of the carbon-oxygen double bond of 
the carbonyl, which encourages the nucleophilic attack of the hydroxylamine with release 
of water from a tetrahedral intermediate to form an oxime. 
In the case of using hydroxylamine chloride, hydrochloric acid is released and can easily 
be titrated using a standard solution of sodium hydroxide or other alkali standards to 
quantify the number of carbonyl groups in the compound. The reaction of oximation is 
equilibrium and it must be remembered that the reaction does not go to completion for all 
carbonyl groups so that a fraction of the compound remains in carbonyl form. The 
presence of an excess of hydroxylammonium hydrochloride, which is also an acid, could 
cause a lack of precision in the determination point. For this reason, a potentiometric 
titration is more suitable to obtain an accurate result. 
1.12.1.2 Determination of primary amine content by Snyder test  
 
The quantification of primary amino groups was determined using the 
trinitrobenzenesulfonic acid (TNBS) also referred as Snyder test. 
 
 
Scheme 2-1 Titration of aldehydes by hydroxylamine 
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Scheme 2-2 Titration of primary amine group containing compounds by Snyder 
colorimetric assay 
 
TNBS reaction with amine is preferred over its reaction with hydroxyl groups if under low 
ionic strength and temperature conditions and a pH value, 0.5 unit below the pKa amine 
value. Therefore, the spectrophotometric quantification of amino groups can be realised 
in aqueous solution due to the slow rate of reaction of TNBS with hydroxide ions in 
comparison with amino groups (two to three times more rapid than with hydroxide ions).  
A calibration curve using the simplest of dipeptides glycyl-glycine (H2Ngly-glyOH) was 
first plotted as reference to deduce the amount of primary amines in primary amine 
containing compounds. A gly-gly solution (0.4mmol.l
-1
) was prepared in milliQ water.  
Briefly, to some vials, were added NH2gly-glyOH various quantities ranging from 0 to 
250µl. Subsequently, a borate buffer solution at pH 9.3 (acid boric, 0.1mol.l
-1
) was added 
to obtain a volume of 970µl. Finally 30µl TNBS solution in water (1%w/w, freshly prepared 
to avoid hydrolysis) was added to make a total volume of 1000µl. A blank sample - not 
containing NH2gly-glyOH - was prepared as reference for spectrophotometric 
measurements.  
All mixtures were left at room temperature for 30min to allow the reaction of TNBS with 
NH2gly-glyOH primary amino group. The calibration curve was drawn as a linear 
regression between absorbance and primary amine concentration. 
 
 
Graph 2-1Primary amine calibration curve by Snyder test – Reference compound: 
NH2gly-glyOH 
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1.12.1.3 Determination of alendronate content by spectrophotometry 
 
The formation of a complex between alendronate and ferric ions (Fe(III)) in perchloric acid 
solution (HClO4, 2mol.l
-1
) allowed the determination of alendronate content in all 
derivatives prepared with the bisphosphonate. 
A calibration curve was obtained by using a series of alendronate solution at 
concentration varying from 0 to 3mol.l
-1
.  
A ferric standard solution was made by dissolution of ferric chloride hexahydrate into an 
HClO4 solution (2mol.l
-1
). A stock solution of alendronate (5mmol.l
-1
) in perchloric acid 
(2mol.l
-1
) was prepared and conserved at a temperature below 6C.  
Standard solutions of alendronate were freshly prepared from the stock solution by 
suitable dilution into perchloric acid solution (2mol.l
-1
). 
 
 
 
Graph 2-2 Alendronate calibration curve by spectrophotometry 
 
Alendronate content in conjugates was determined as follow: 
Succinctly, the conjugate (0.1ml, 2-10mg.ml
-1
) was added to FeCl3 (0.1ml, 4mol.l
-1
) in 
HClO4 (0.8ml, 0.2mol.l
-1
) at room temperature to instantaneously form a complex. 
Absorbance was immediately read against blank, at a wavelength =of 280nm. 
1.12.1.4 Determination of paclitaxel content by Reverse Phase High Performance 
Liquid Chromatography (RP-HPLC) 
 
Standard solutions ranging from 2g.ml
-1
 to 100g.ml
-1
 were prepared in acetonitrile.  All 
solutions were centrifuged for 5min at 6000rpm prior to RP-HPLC analysis.  
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Samples were eluted in isocratic mode, using a C18 type column at room temperature and 
a UV detector. The acetonitrile/water (55/45 vol/vol, 0.05%TFA) eluent was ran at 1ml.ml
-1
 
and paclitaxel absorbance was read at =227nm to give the following calibration graph. 
 
 
Graph 2-3 Paclitaxel calibration curve by HPLC 
 
1.12.1.5 Determination of pullulan Molecular Weight (Mw) 
 
Molecular weight (Mw) of native, oxidised pullulan and pullulan conjugates were 
determined by SEC-HPLC using two columns TSK G3000SWXL and TSK G4000SWXL 
(7,8 X 300 mm, Tosoh) in series. The samples were eluted in isocratic mode at room 
temperature using a Refractive Index (RI) detector. MilliQ water was used as eluent and 
ran at 0.6ml.ml
-1
  
 A calibration curve was obtained employing pullulan standards of known molecular 
weights (270 kDa, 150 kDa, 80 kDa, 50kDa, 25 kDa, 12kDa). 
The pullulan standards Mw were expressed in logarithmic scale (log(Mw)) and plotted 
against time retentions (tR) to give a linear calibration curve. 
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Molecular weights of final polymer conjugates were determined by comparing the elution 
times of samples with the linear calibration curve.  
1.12.1.6 Determination of molecular size 
 
Size distributions of the polymer conjugates were determined using Dynamic Light 
Scattering (DLS), allowing the determination of hydrodynamic radius. Polymers were 
dissolved in water or acetate buffer (pH5.5) or phosphate buffer (PBS, pH7.4) at a 
concentration of 1mg.ml
-1
. 
1.12.2 Synthesis 
1.12.2.1 Kinetic of oxidation of pullulan 
 
Sodium periodate is used in the oxidation of polysaccharides by converting the free 
vicinal hydroxyl groups of the polymer units into aldehyde functions. The resulting 
modified polysaccharide becomes highly reactive towards amine
12
. 
To a solution of native pullulan (Mw~100 kDa, 100mg, 617µmol glucosidic monomer units) 
in ultrapure water (8.15ml), was added sodium periodate (4.3mg, 20.4µmol).  The final 
solution obtained was maintained in the dark at room temperature under stirring.  
Sampling (500µl) was performed after 30min, 1h, 2h, 3h, 4h, 6h, 20h and mannitol 
(10mg, 50µmol) was added.  After 1 hour, the solution was ultra-filtered using a with 10 
kDa cut-off  
membrane. The determination of aldehyde content on the polysaccharide backbone was 
then performed using the method described previously. 
y = -0.0964x + 7.4697 
R² = 0.9998 
2.00
2.50
3.00
3.50
4.00
4.50
5.00
5.50
6.00
10.00 15.00 20.00 25.00 30.00 35.00 40.00
lo
g(
M
w
) 
tR (min) 
Graph 2-4 Pullulan calibration curve by GPC 
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1.12.2.2 Synthesis of 30 % oxidised pullulan (Pullox30) 
  
Pullulan (500mg, 3.09mmol glucosidic monomer unit) was dissolved in milliQ water 
(50ml). The mixture was heated at 40°C under stirring to ease the dissolution. After 
cooling, sodium periodate (21.7mg, 0.102mmol) was added to the pullulan solution under 
stirring and left to react overnight protected from the light.  
After 16h, the oxidation of the polymer was stopped using mannitol (27.7mg, 0.154mmol). 
Past 2h, the excess mannitol was removed from the reaction mixture by ultra-filtration 
using an Amicon system equipped with a 10 kDa cut-off membrane. 
Once ultra-filtered, the oxidised polysaccharide was lyophilised to give a light white 
cotton-like solid.  
For the synthesis of 95% oxidised pullulan, a ratio Pullulan glucosidic monomer:sodium 
Periodate of 1:0.95 was used. The procedure of synthesis remained the same. 
The quantification of aldehyde groups on the oxidised pullulan chain was performed by 
titration as reported in the 2.3.1.1.  
1.12.2.3 Synthesis of Fmoc-Gly-Gly-Pro-Nle-OH by solid phase peptide synthesis 
(SPPS) 
 
The peptide synthesis was performed on a 0.5 mmol scale, using a synthesiser after 
setting up the reaction conditions beforehand, by manual peptide synthesis. 
Wang-Nle-Fmoc resin was chosen as a solid phase matrix. It was approximately 65%n/w 
Nle activated. Therefore, 770mg of resin were used for the synthesis of the four amino 
acid oligopeptide. 
Each amino acid was placed into an assigned vial, together with the HBTU and HOBt 
activators. 
To a first vial, was added Fmoc-Proline (674.8mg, 2mmol), O-Benzotriazole-N,N,N’,N’-
tetramethyl-uronium-hexafluoro-phosphate (HBTU – 758.6mg, 2mmol) and N-
Hydroxybenzotriazole (HOBt – 234.25mg, 2mmol) coupling agents. 
To a second vial, was added Fmoc-Proline (674.8mg, 2mmol), O-Benzotriazole-
N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate (HBTU – 758.6mg, 2mmol) and N-
Hydroxybenzotriazole (HOBt – 234.25mg, 2mmol) coupling agents. Proline was more 
difficult to couple so it was chosen to perform a double coupling without deprotection in 
order to ensure maximum yield. 
To a third vial, was added Fmoc-Glycine (594.6, 2mmol), O-Benzotriazole-N,N,N’,N’-
tetramethyl-uronium-hexafluoro-phosphate (HBTU – 758.6mg, 2mmol) and N-
Hydroxybenzotriazole (HOBt – 234.25mg, 2mmol) coupling agents.  
To a fourth vial, was added Fmoc-Glycine (594.6, 2mmol), O-Benzotriazole-N,N,N’,N’-
tetramethyl-uronium-hexafluoro-phosphate (HBTU – 758.6mg, 2mmol) and N-
Hydroxybenzotriazole (HOBt – 234.25mg, 2mmol) coupling agents.  
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A deprotection cocktail was prepared, adding a 20%mol pyridine solution in 1-methyl-2-
pyrrolidone (NMP (17.2g, 0.21mol) and NMP (82.4g, 0.83) into the appropriate 
synthesiser bottle. Finally, a coupling cocktail containing 5%mol N,N-Diisopropylethylamine 
(DIPEA – 4.52g, 5mol) in dimethylformaldehyde (DMF- 89.3g, 95mol) was added into a 
second synthesiser bottle.  
The synthesiser was programmed so that it started with the deprotection of the Fmoc-
Norleucine Wang resin (Fmoc-Nle-Wang) in order to free the amino acid primary amine, 
followed by the coupling of Fmoc-Pro. A second batch of Fmoc-Pro was added to 
optimise the coupling yield without preliminary deprotection of the first Fmoc-Pro batch. 
Successively, a Fmoc-deprotection was performed on Fmoc-Pro and the coupling of 
Fmoc-Gly was performed. Finally, Fmoc-Gly was deprotected and a second Fmoc-Gly, 
the ultimate amino acid in the sequence, was added to yield Wang-Nle-Pro-Gly-Gly-Fmoc 
modified resin. 
 
Isolation of the peptide from Wang resin –Analytical cleavage 
 
After completion of the synthesis, a small aliquot of the reaction mixture was taken from 
the reaction vessel and the peptide was cleaved from the resin. Before cleavage, the 
aliquot was washed three times with NMP, three times with DCM and three times with 
methanol (MeOH), corresponding to an increasing solvent hydrophobicity. Between each 
wash, the resin was vacuum dried. After the final wash, the resin was carefully air dried. 
The cleavage procedure was then performed. The Wang-NleProGlyGlyFmoc solid was 
left to react for 30min in the dark with a 95/5 %vol solution of trifluoroacetic acid (TFA) in 
water. After the peptide was extracted by filtration; the solid phase corresponding to the 
resin was discarded and the liquid phase containing the peptide was kept, diluted 10 
times in water. After centrifugation and lyophilisation, a white/off white powder was 
obtained. The product was analysed by mass spectrometry (ESI-TOF, Positive mode). 
 
1.12.2.4 Synthesis of FmocGGPNlePTX  
 
Multiple approaches were considered for the synthesis of peptylpaclitaxel including, the 
two step synthesis using first N,N'-dicyclohexylcarbodiimide (DCC) coupling in presence 
of 4-(dimethylamino)pyridine (DMAP) catalyst, and 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide  (EDC) coupling in presence of DMAP. These techniques led to very poor 
yield and a new approach was used to include a phenyl ring between the tetrapeptide 
and paclitaxel. Only this new approach is reported in this chapter in the following 
sections. 
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1.12.2.5 Synthesis of FmocGGPNleOH 
 
To a solution at -18°C (freezer) of Fmoc-Gly-Gly-Pro-Nle (100mg, 177mol) in a 
dioxane/THF solvent mixture (20/80%v/v, 4ml) under stirring, was added N-
methylmorpholine at once (NMP, 19l, 177mol) and isobutylchloroformate (28l, 
212mol). The reaction was left under stirring for 20min and 4-aminobenzyl alcohol (4-
ABA, 32.7mg, 265mol) was then added. The reaction was left in freezer and stirring was 
performed manually every 20min for 16h. Upon this time, the prodrug was filtered and the 
filtrate concentrated by roto evaporation to give a yellow viscous substance. 
FmocTOH was purified by two silica column chromatographies using ethylacetate 
(100%) first and ethylacetate/acetone solvent mixture (20/80%v/v) then. Fractions were 
analysed by TLC and mass spectrometry (ESI-TOF, positive mode, 
acetonitrile:H20:Formic acid 49:50:1) to collect the ones containing FmocTOH. After 
elimination of the solvents under vacuum, FmocTNO2 was recovered as a white powder. 
1.12.2.6 Synthesis of FmocGGPNleNO2 
 
To a solution at 0°C (ice bath) of Fmoc-Gly-Gly-Pro-NleOH (113mg, 168µmol) in 
anhydrous THF (4ml) under stirring, was added diisopropylethylamine at once (DIPEA, 
117µl, 674µmol), p-nitrophenyl chloroformate (102mg, 506µmol) and a catalytic amount 
of pyridine. The reaction was left under stirring at 0°C for 16h. Upon this time, the 
reaction mixture was concentrated under vacuum and dissolved in ethylacetate (5ml).  
The organic phase washed three times with ammonium chloride (saturated solution, 
3x5ml), dried over sodium sulphate and finally filtered off. The filtrate was concentrated 
by rotoevaporation.   
1.12.2.7 Synthesis of FmocGGPNlePTX 
 
To a solution at room temperature of Fmoc-Gly-Gly-Pro-NleNO2 (59mg, 71µmol) in 
anhydrous THF (4ml) under stirring, was added paclitaxel at once (PTX, 72mg, 85µmol), 
and dimethylaminopyridine (DMAP, 13mg,  106µmol). The reaction was left under stirring 
at room temperature for 8h.  
The reaction mixture was then concentrated under vacuum using a roto evaporator. The 
residue was then purified by two silica column chromatographies using ethylacetate 
(100%) first and ethyl acetate/acetone solvent mixture (20/80%v/v) consecutively. 
Fractions were analysed by TLC and mass spectrometry (ESI-TOF, 
positive mode, acetonitrile:H2O:Formic acid 49:50:1) to collect the ones containing Fmoc-
Gly-Gly-Pro-NleNO2. After elimination of the solvents under vacuum, Fmoc-Gly-Gly-Pro-
NlePTX was recovered as a white powder. 
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1.12.2.8 Synthesis of NH2GGPNlePTX – Deprotection of FmocGGPNlePTX 
 
To a solution of FmocTPTX (93mg, 90µmol) in dichloromethane (DCM, 4ml), was added 
DMAP (11mg, 77.4µmol) at once. The reaction mixture was left under stirring at room 
temperature for 48h and monitored by mass spectrometry ESI-TOF, positive mode, 
acetonitrile:H20:Formic acid 49:50:1). 
NH2TPTX was recovered by precipitation of reaction mixture into cold diethyl ether three 
times, collection of the precipitate and evaporation of solvents to yield a white powder. 
1.12.2.9 Synthesis of Fmoc-GGPNle-Alendronate 
 
Multiple tactics were considered for the synthesis of peptylalendronate including, N,N'-
dicyclohexylcarbodiimide (DCC) coupling in presence of 4-(dimethylamino)pyridine 
(DMAP) catalyst, and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide  (EDC) coupling in 
presence of DMAP,  solution phase O-Benzotriazole-N,N,N’,N’-tetramethyl-uronium-
hexafluoro-phosphate / Hydroxybenzotriazole  (HBTU/HOBt) coupling, EDC in presence 
of N-hydroxysuccinimide (NHS) coupling, 4,5-dihydrothiazole-2-thiol (TT) in presence of 
DCC coupling, pH were varied from 7 to above 11.  These synthesis trials are not 
described in details here as the synthesis were not successful and did not lead to the 
desired product. Possible reasons will be discussed in the result and discussion 
paragraph.  
A new approach was thought, which would include a relatively low molecular weight 
poly(ethylene glycol) (PEG) in the alendronate derivative. By attaching the PEG in its 
form tBoc-NH-PEG-NHS to alendronate first, tBoc-NH-PEG-alendronate would be 
produced and facilitate the attachment of this first compound to the pullulan aldehyde 
groups after tBoc deprotection. 
1.12.2.10 Synthesis of tBoc-NH-PEG-Alendronate 
 
To a stirred solution of alendronate (50mg, 153.84mol) in borate buffer (0.1mol.l
-1
, pH 8, 
5ml), tBoc-NH-PEG3000-NHS (3000Da, 165mg, 55mol) was added at once. The reaction 
mixture was stirred for 5h at room temperature, under atmospheric pressure. 
Upon this time, the pH was adjusted at 4.5 using a hydrochloric acid solution (0.2mol.l
-1
).  
tBoc-NH-PEG-Alendronate was extracted in dichloromethane (6x5ml), the organic phase 
dried over sodium sulphate and lastly, precipitated into diethyl ether after filtration. 
Determination of free alendronate was made by measuring free primary amino groups by 
Snyder test and showed the absence of free amine in the white powder product. 
Alendronate content was assessed by spectrophotometric method, showing 24%mol 
alendronate 
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1.12.2.11 Synthesis of NH2-PEG-Alendronate 
 
A solution of trifluoroacetic acid/dichloromethane (TFA/DCM, 50/50%v/v, 1ml) was added 
to tBoc-PEG-alendronate (60mg, 20mol) at once. The reaction mixture was left at room 
temperature under stirring for 30min.  
Upon this time, DCM and TFA were removed under vacuum and NH2-PEG-ALN 
recovered by precipitation into diethyl ether to obtain a white powder.  
1.12.2.12 Synthesis of Pull-PTX 
 
To a solution of 30% oxidised pullulan (Pullox30, 15mg, 185mol eq aldehyde) in DMSO 
(2ml), was added NH2-GGPNlePTX (60mg, 45mol) at once. The reaction mixture was 
left at room temperature under stirring for 12h. Upon this time, sodium borohydride 
(NaBH4, 7mg, 155µmol) was added at once. The reaction mixture was left for 24h under 
stirring at room temperature. 
1.12.2.13 Synthesis of Pull-PEG-ALN 
 
To a solution of 30% oxidised pullulan (Pullox30, 15mg, 185mol eq aldehyde) in milliQ 
water (2ml), was added NH2-PEG-Alendronate (60mg, 30mol) at once. The reaction 
mixture was left at room temperature under stirring for 4h. Upon this time, sodium 
borohydride (NaBH4, 7mg, 155µmol was added and the reaction mixture was left for 72h 
under stirring at room temperature. 
The conjugate was then dialysed against water for 48h using a 3500Da cut-off dialyse 
membrane in order to remove salts and excess NH2-PEG-alendronate. The product was 
lyophilised to yield a white brittle powder. 
1.12.2.14 Synthesis of Pull-PTX-ALN 
 
To a solution of oxidised pullulan (24%mol oxidation, 100mg, 296µmol aldehyde eq) in 
dimethylsulfoxide (DMSO, 8ml) was added a solution of NH2GGPNlePTX 
(124mg,93µmol) in DMSO (2ml). After 12 h, was added sodium triacetoxyborohydride 
(20mg, 93µmol).  
The reaction mixture was left under stirring for 6 hours. Upon this time, NH2PEGALN 
(170mg,56µmol) dissolved in DMSO (1ml) as added to the pullulan solution. The reaction 
was maintained overnight at room temperature under stirring.  
Subsequently, sodium borohydride (NaBH4, 11mg, 296µmol) was added at once. The 
reaction mixture was left at room temperature, under stirring overnight. 
Purification was conducted by dialysis against water for two days (release medium 
renewed 4 times a day). The product was then freeze-dried,. followed by washes with 
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methanol (5 times 5ml) to ensure the full removal of unreacted NH2GGPNlePTX. 
Solvents were evaporated under vacuum to yield a white/off-white brittle powder.  
 
1.12.2.15 Determination of total paclitaxel content in the conjugates    
 
All solutions were prepared in sodium acetate buffer at pH5.5 (50mM, 100mM NaCl). 
 
To a L-cysteine solution (303μl, 2.5mM), was added a solution of 
Ethylenediaminetetraacetic acid (EDTA,146μl, 5mM) and DL-Dithiothreitol (DTT, 84μl, 
5mM). The solution was warmed up at 37°C for 5min. Cathepsin K (162μl, 150nM) was 
then added to the mixture. 
Finally, a Pull-PTX-ALN solution (305μl, 75μM PTXeq), was added to the Cathepsin K 
containing reaction mixture. 
The mixture was incubated at 37 °C. After 480min, the drug was extracted by 
dichloromethane. The organic phase was evaporated and the residue was solubilised in 
acetonitrile. 
The amount of free paclitaxel in the conjugates was evaluated by reverse phase HPLC 
using a C18 (4.6 × 250 mm; 5 μm) column, with the UV detector set at 227 nm. MilliQ H2O 
(0.05% TFA) and acetonitrile (0.05% TFA) were used as eluent A and B respectively. 
Elution was performed in isocratic mode at a flow rate of 0.7ml.min
-1
,
 
using a 45/55%v:v 
H2O/acetonitrile ratio. 
The total drug content was evaluated by RP-HPLC following the release of PTX from the 
conjugates.  
 
As second check, the total drug content of the polymer-drug conjugates was also 
analysed by UV spectrophotometry at λ=234nm and results were confronted with the 
ones obtained by RP-HPLC. 
 
1.12.2.16 Determination of alendronate bound to PEG 
 
The formation of a chromophoric complex between alendronate and Fe(III) ions in 
perchloric acid solution (HClO4, 0.2mol.l
-1
) was used to determine spectrophotometrically 
the quantity of alendronate bound to PEG.  
Conjugates (2.5, 5 and 10 mg) were dissolved in a mixture of 100µl Fe(III)Cl (4mmol.l
-1
) 
solution in HClO4 and 900µl of HClO4 solution. The alendronate content in the conjugates 
was determined against a calibration graph of serial dilutions of alendronate solution from 
0 to 3mmol.l
-1
  
Sample absorbance was measured by UV spectrophotometry at a wavelength of 300nm. 
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1.12.2.17 Determination of Critical Micelle Concentration (CMC) 
 
The critical micelle concentration (CMC)of the modified pullulan Pull-PTX-ALN was 
determined by a fluorescence spectroscopy method, using pyrene monomer fluorescence 
as a hydrophobic probe. 
Briefly, the polymer conjugate was dissolved in 750µl Phosphate Buffer Saline (PBS, 
20mmol.l
-1
) containing sodium chloride (NaCl, 0.15mol.l
-1
) at pH7.4. Polymer 
concentrations ranged from 0.2 to 100.0µg.ml
-1
. To 750µl of polymer solution, was added 
a pyrene solution in acetone (5µl, 0.18mmol.l
-1
).  
Samples were incubated under gentle shaking at room temperature and were left 
overnight and protected from the light to allow equilibration. 
Prior to measurements, polymer solutions were incubated at 37°C for 15min. 
Fluorescence excitation spectra were recorded using a Jasco FP-6500 
Spectrofluorometer. 
The emission wavelength (em) was set at 390nm and excitation spectra were recorded in 
the 300 to 360nm wavelength range. The excitation and emission band slits were set at 4 
and 2nm respectively. 
The I(ex 339nm)/I(ex 334nm) intensity ratios were plotted as a function of the logarithm of the 
polymer conjugate concentration (logC). 
The CMC was determined from the intersection point at low polymer concentration. 
 
1.12.2.18 Determination of particle size and charge in solution 
 
The particle size, polydispersity and zeta potential were measured by Dynamic Light 
Scattering (DLS) using a Malvern Instrument Ltd Zetasizer Nano ZS (Malvern, UK). 
Polymer conjugate samples were analysed at a concentration of 1mg.ml
-1
, in sodium 
acetate buffer at pH5.5 (20mmol.l
-1
) and PBS at pH7.4(20mmol.l
-1
, NaCl 0.15mol.l
-1
), and 
milliQ water. 
 
1.12.2.19 Stability assay  
 
The drug release assay was carried out in in sodium acetate buffer at pH5.5 (20mmol.l
-1
) 
and PBS at pH7.4 (20mmol.l
-1
, NaCl 0.15mol.l
-1
), Polymer solutions (3mg.l
-1
, 3ml) were 
placed into a dialysis bag (regenerated cellulose, 3.5kDa cut-off). Then, the dialysis bag 
was quickly immersed in the appropriate release medium (50ml, pH=pH inside bag) kept 
under controlled temperature at 37°C and under continuous stirring. At given time 
intervals, 600µl sample was withdrawn from the dialysis bag and the equal volume of 
fresh medium was refilled. The sample was divided into two equivalent volumes, one 
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designated for the determination of released alendronate by spectrophotometry after 
complexation with Fe(III) irons and the other one for the determination of paclitaxel 
release by UV spectrophotometry and RP-HPLC as reported previously. 
1.12.2.20 In vitro-drug release assay in presence of Cathepsin K 
 
All solutions were prepared in sodium acetate buffer at pH5.5 (50mM, 100mM NaCl). 
 
To a L-cysteine solution (303μl, 2.5mM), was added a solution of 
Ethylenediaminetetraacetic acid (EDTA,146μl, 5mM) and DL-Dithiothreitol (DTT, 84μl, 
5mM). The solution was warmed up at 37°C for 5min. Cathepsin K (162μl, 150nM) was 
then added to the mixture. 
Finally, a Pull-PTX-ALN solution (305μl, 75μM PTXeq), was added to the Cathepsin K 
containing reaction mixture. 
The mixture was incubated at 37 °C and aliquots (75μΙ) were taken after 0 min, 15 min, 
30 min, 45, 60 min 120, 240, 480 and 1220 min and analysed by HPLC.  
The assay was produced in triplicate. 
1.12.2.21 Hydroxyapatite binding assay 
 
In order to assess the affinity between the bisphosphonate containing polymer conjugates 
and the bone mineral hydroxyapatite, a hydroxyapatite binding assay was designed. 
Polymer conjugates solutions (3mg.ml
-1
) were prepared in acetate buffer at pH5.5 
(20mmol.l
-1
) and PBS at pH 7.4 (20mmol.l
-1
, NaCl 0.15mol.l
-1
). Solutions were incubated 
under stirring at 37°C. After equilibration, hydroxyapatite (30eq) was added at once to the 
polymeric solutions. 
Hydroxyapatite binding was monitored spectrophotometrically by determination of the 
decrease over time, of the polymer conjugate concentration in the supernatant, 
measuring the quantity of paclitaxel and alendronate by UV spectrophotometry. 
The percentage of binding to hydroxyapatite was calculated as follow:  
 
 
Equation 2-1Equation used for the calculation of the %binding onto hydroxyapatite  
 
%binding 
[(                                                                                  )]
[                                          ]
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1.12.3 Cell culture 
 
MDA-MB-231 human mammary adenocarcinoma, SAOS-2 osteosarcoma and 4T1 
murine mammary adenocarcinoma cell lines were provided by American Type Culture 
Collection (ATCC).  
MDA-MB231 cells were cultured in DMEM supplemented with 10% FBS, 
100µg/mlPenicillin, 100U/ml Streptomycin, 12.5U/ml Nystatin and 2mM L-Glutamine. 
SAOS-2 cells were cultured in DMEM supplemented with 10% FBS, 100µg/mlPenicillin, 
100U/ml Streptomycin, 12.5U/ml Nystatin, 2mM L-Glutamine and 1mM sodium pyruvate. 
4T1 cells were cutured in RPMI 1640 supplemented with 10% FBS, 100µg/mlPenicillin, 
100U/ml Streptomycin, 12.5U/ml Nystatin, 2mM L-Glutamine, 10mM Hepes buffer, and 
1mM sodium pyruvate. 
Human UmbilicalVein Endothelial Cells (HUVEC) were obtained from Cambrex 
(Walkersville, USA) and grown according to manufacturer’s protocol in EGM-2 medium 
(Cambrex). All cells were grown at 37°C, 5% CO2. 
1.12.3.1 MTT assay 
 
A solution of 1-(4,5-Dimethylthiazol-2-yl)-3,5-diphenylformazan, Thiazolyl blue formazan 
(MTT, 5mg/ml) was prepared in sterile PBS at 37°C. After centrifugation, 20µl of MTT 
solution was added into each well of a 96-well plate. After incubation at 37°C, 5%CO2, 
the mixture of medium and MTT was removed by vacuum and replaced by 200µl 
dimethylsufoxide. After dissolution of the crystals, the 96-well plate was read by UV 
spectrophotometry at =565nm. 
1.12.3.2 Cell proliferation assays 
 
MDA-MB231 cells were plated onto a 96-well plate (5.10
3
cells/well) in DMEM 
supplemented with 5% FBS and incubated for 24h (37ºC, 5% CO2). Following 24h 
incubation, the 5%FBS supplemented DMEM medium was replaced by a 10%FBS 
supplemented DMEM medium. Cells were challenged with free paclitaxel and free 
alendronate, unmodified native pullulan, Pull-PTX, Pull-ALN and Pull-PTX-ALN at  
serial concentrations for 72h. Following incubation,   MDA-MB231 cells viability was 
measured by MTT assay. 
SAOS-2 cells were plated onto a 96-well plate (2.10
3
cells/well) in DMEM supplemented 
with 5% FBS and incubated for 24h (37ºC, 5% CO2). Following 24h incubation, the 
5%FBS supplemented DMEM medium was replaced by a 10%FBS supplemented DMEM 
medium. Cells were challenged with free paclitaxel and free alendronate, unmodified 
native pullulan, Pull-PTX, Pull-ALN and Pull-PTX-ALN at serial concentrations for 72h. 
Following incubation,   MDA-MB231 cells viability was measured by MTT assay. 
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4T1 cells were plated onto a 24-well plate (4.10
3
cells/well) in RPMI supplemented with 
5% FBS and incubated for 24h (37ºC, 5% CO2). Following 24h incubation, the 5%FBS 
supplemented RPMI medium was replaced by a 10%FBS supplemented RPMI medium. 
Cells were challenged with free paclitaxel and free alendronate, unmodified native 
pullulan, Pull-PTX, Pull-ALN and Pull-PTX-ALN at serial concentrations for 72h. 
Following incubation, 4T1 cells viability was measured Coulter Counter. 
HUVEC cells were plated onto a 24-well plate (1.5.10
3
cells/well) in growth factor reduced 
media EBM-2 supplemented with 5% FBS and incubated for 24h (37ºC, 5% CO2). 
Following 24h incubation, the 5%FBS supplemented EBM-2 medium was replaced by 
EGM-2. Cells were challenged with free paclitaxel and free alendronate, unmodified 
native pullulan, Pull-PTX, Pull-ALN and Pull-PTX-ALN at serial concentrations for 72h. 
Following incubation, HUVEC cells viability was measured Coulter Counter 
 
1.12.3.3 In Vitro Tube Formation assay  
 
Matrigel (50 μl) was carefully added in a thin layer into each well of a 24-well plate and 
allowed to solidify at 37°C for 30 min. After the solidification of the Matrigel, HUVEC 
(3.10
4
cells/well) were added in 500 μl of EGM-2 medium. Cells were incubated for 24 h at 
37°C in a humidified incubator (95% air/5% CO2).  
HUVEC were challenged with free PTX (10nM), a combination of free PTX and ALN 
(23nM), free ALN, Pull-ALN, Pull-PTX, Pull-PTX-ALN at equivalent concentrations, and 
were seeded on the coated plates in the presence of complete EGM-2 medium. After 8 h 
of incubation (37°C; 5% CO2), wells were imaged using Nikon TE2000E inverted 
microscope integrated with Nikon DS5 cooled CCD camera by 4X objective, bright field 
technique. The tube networks were quantified by image analysis using ImageJ. 
1.12.3.4 Wound healing assay 
 
MDA-MB231 cells were plated onto a 6 well plate (4.10
5
cells/well) 24h prior performing 
the scratch wound assay. The confluent monolayer was scratched by a pipette tip, rinsed 
with PBS to remove detached cells and fresh medium was added.  
Digital images of cells were taken immediately after scratching (t = 0). Cells were 
challenged with free paclitaxel and free alendronate, unmodified native pullulan, Pull-
PTX, Pull-ALN and Pull-PTX-ALN for 24h, at a concentration just below the IC50 of PTX. 
After 24h incubation, the distance between cells in the scratched area was evalated 
using ImageJ. Results were normalized to untreated control cells. 
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1.12.3.5 Red Blood Cells Lysis assay 
 
Rat Blood Cells were obtained from whole rat blood. Blood was first diluted in PBS at pH 
7.4 (20mmol.l-1, NaCl 0.15mol.l
-1
). 
After mixing for 10 s and incubating for 2 min at room temperature, the mixture was 
centrifuged at 1000rpm for 5 min at 4°C using a refrigerated centrifuge. The supernatant 
was discarded and the packed cells washed again, repeating the procedure twice more, 
using PBS at pH 7.4 (20mmol.l-1, NaCl 0.15mol.l
-1
). 
Rat RBC solution (2%w/w) was incubated for 1h at 37°C, with serial dilutions in PBS (pH 
7.4, 20mmol.l
-1
, NaCl 0.15mol.l
-1
) of free paclitaxel and free alendronate, unmodified 
native pullulan, Pull-PTX, Pull-ALN and Pull-PTX-ALN at equivalent concentration of PTX 
and ALN. 
Negative controls were PBS (pH 7.4, 20mmol.l
-1
, NaCl 0.15mol.l
-1
) and Dextran (MW 
70kDa) whereas positive controls were Triton X100 (1%w/v) and poly(ethylenimine). 
Following centrifugation (7min, 3000rpm), the supernatant was drawn off and its 
absorbance measured at 550nm using a micro-plate reader. The results were expressed 
as percent of haemoglobin released relative to the positive control (Triton X100). 
1.12.3.6 Statistical methods 
 
In vitro data are expressed as mean ± s.d. Statistical significance was determined using 
an unpaired t-test. P < 0.05 was considered statistically significant. All statistical tests 
were two-sided. 
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3. Results 
 
1.13 Synthesis of Pullulan-Paclitaxel-Alendronate – Pull-PTX-ALN 
 
The following sections describe the different stages in the creation of the polymer-drug 
conjugate Pullulan-Paclitaxel-Alendronate (Pull-PTX-ALN), main compound in this 
project. 
1.13.1 Carrier function: Periodate oxidation of pullulan 
 
Preliminary studies in agreement with Brunel
53
, allowed to assess the conditions of 
activation of pullulan by sodium periodate and showed that the oxidation of vicinal diols 
was a rapid process. The oxidation reached 24% and 60% after 30min for 30% and 100 
% oxidation targets, to reach a plateau after 6h (Figure 3-1).   
 
The use of  periodate ions enabled the selective oxidation of the vicinal diols to form 
aldehydes, with simultaneous disruption of the connection C2-C3 and consequent 
opening of the glucopyrannose polysaccharide ring as shown in Scheme 3-1. 
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Figure 3-1 Kinetics of oxidation of pullulan by periodate oxidation – 30% target ( ) 
and 100% target ( ) 
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Scheme 3-1 Periodate oxidation of pullulan 
 
The target oxidation for the matter of this project was 30%, leading to the oxidised 
pullulan Pullox30.  The success of the reaction was determined by qualitative and 
quantitative analysis.  
‘H NMR spectroscopy  
‘H NMR spectroscopy performed in deuterated water D2O allowed to confirm the 
presence of aldehyde groups on pullulan backbone after oxidation, as revealed by the 
appearance of a peak at =9.26ppm as shown in Figure 3-2 
1
H NMR Spectra in D2O of 
native Pullulan- Top () and  Pullox30.-Bottom ().  This peak corresponded to the aldehyde 
formyl hydrogen which was strongly deshielded: aldehyde compounds have a distinctive 
chemical shift which appears to be between 9-10 ppm, Aldehyde hydrogens are also 
slightly deshielded because of the electron withdrawing from the oxygen from the 
carbonyl group. The peak at 2.21ppm represents the acetone solvent, commonly used in 
laboratories. 
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Fourier Transform Infrared Spectroscopy (FT-IR)  
Oxidised pullulan (Pullox30) was also analysed by Fourier Transformed InfraRed 
Spectroscopy (FT-IR) as presented in Figure 3-3. Native pullulan and oxidised pullulan 
differed from each other in the region of 600-800cm
-1
. Indeed, after oxidation, the 
formation of aldehyde on the polysaccharide’s chain could be observed by the apparition 
of two peaks in this region, typical from C-O stretching from carbonyl groups. However, 
regions were stretching vibrations (CO) C-O-C of the glycosidic bridge in 
oligosaccharides were observed for both modified and non-modified polysaccharides, in 
the range of 1100-970 cm
-1
 as expected.  
 
 
 
 
 
 
 
Figure 3-2 
1
H NMR Spectra in D2O of native Pullulan- Top () and  Pullox30.-Bottom () 
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Potentiometric titration of aldehydes 
In addition to qualitative analysis, Pullox30 was analysed quantitatively, the amount of 
aldehyde generated in the oxidised polysaccharide was estimated by the hydroxylamine 
hydrochloride reaction. This reagent is involved in a nucleophilic attack of one aldehyde 
that leads to formation of an oxime and stoichiometric release of hydrochloric acid (HCl).  
HCl can then be potentiometrically titrated with sodium hydroxide (NaOH) (Scheme 3-2). 
 
 
 
This analytical method allowed the determination of the amount of aldehydes produced 
after pullulan oxidation. The oxidation degree obtained was of 23%mol of glucopyranose 
units by using a periodate : maltotriose molar ratio of 0.3:1. This result matched with 
literature (Bruneel D., 1993) where it was reported that only 2/3 of all aldehydes formed 
could be detected.  
Indeed, this quantification method uses a nucleophilic attack of the reagent onto the 
carbonyl carbon, but not all aldehydes are accessible.  A possible explanation of such 
phenomenon is the spontaneous formation of a hemiacetal (with recyclisation) in α-1,4 of 
the glycosidic residue as illustrated in Scheme 3-3. 
R H
O
+ NH2 OH*HCl
R
HC N
OH
+ HCl
Scheme 3-2 Titration of aldehyde groups in oxidised pullulan 
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Figure 3-3 FT-IR spectra on KBr plate of native Pullulan (A) and Pullox30 (B) 
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Consequently, this could be translated as a protection (and consequent loss of reactivity) 
of 2 of 6 aldehydes obtained in the completely oxidised maltotriose unit. 
Gel Permeation Chromatography (GPC) 
 
 
 
 
 
 
 
 
 
 
The periodate oxidation caused a reduction of the polysaccharide molecular weight from 
~110kDa to ~93769kDa and a PDI decrease from 2.35 to 1.90.  
1.13.2 Enzyme triggered release function: Synthesis of the 
FmocGlyGlyProNle peptide 
 
The method chosen for the synthesis of the Cathepsin K sensitive spacer Gly-Gly-Pro-Nle 
was the widely used solid phase peptide synthesis (SPPS) in which chemical 
transformations are performed onto a solid support. This concept was first introduced by 
Bruce Merrifield to synthesise polypeptides and earned him the Nobel Prize in1984. 
Wang resin was selected as support matrix, a 4-Benzyloxybenzyl alcohol, polymer-bound 
Figure 3-4 GPC chromatogram of aldehyde pullulan Pullox30 
Scheme 3-3 Spontaneous hemiacetal formation occuring in a maltotriose unit. 
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resin which allows the peptide to remain covalently bond to the insoluble, yet porous 
bead until cleavage. This is advantageous as the immobilised peptide could be retained 
during filtration process while liquid reagents and by products could be flushed away. The 
resin was provided with the first protected amino acid Norleucine already anchored.  
As 99% of coupling sites are located inside the resin beads and not at their surface, the 
resin must be prepared before synthesis. It was swollen using 1-methyl-2-pyrrolidone 
(NMP) for 30min in order to ensure an optimal permeation of the N-protected amino- 
acids in the polymer matrix. 
The succession of coupling and deprotection cycles permitted the growth of the 
tetrapeptide in a linear fashion using a C-N strategy, from C-terminus to N-terminus. N-
protected C-terminal amino acid residues were anchored via their carboxyl group to the 
amino group ending resin to yield an amide linked peptide (Scheme 3-4).  
 
Scheme 3-4 Solid Phase Peptide Synthesis general principle 
 
Amino acids were added in large excess to ensure complete coupling for each step. Two 
N-terminal protecting groups are much used namely tBoc and Fmoc. Such groups protect 
the amine by carbamate formation which lability allows the release of CO2 during the 
deprotection process. The base labile Fmoc protecting group was selected for the 
Cycles 
of deprotection 
and 
acylation
Deprotection
Acylation
Resin
Resin
Resin
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protection of the amine group of the amino acids as it allows the use of mild conditions for 
deprotection and for the cleavage of the peptide from the resin, 
The removal of the Fmoc protecting group from the N-terminus of the resin-peptyl was 
achieved by treating the beads with a 20%v/v of piperidine in 1-methyl-2-pyrrolidone for 
20min to ensure a complete deprotection. The deprotection results in the formation of a 
dibenzofulvene-piperidine adduct as shown in Scheme 3-5.  
 
 
 
 
 
 
 
 
 
 
 
Soluble side products and the excess of reactants were removed by washing steps during 
coupling and deprotection steps. 
Concentrated trifluoroacetic acid solution in ultrapure water (95/5%v/v) was used for the 
cleavage of the peptide from the resin after several wash of the resin –peptyl with a series 
of solvents in order of increasing hydrophilicity  NMP<dichloromethane<methanol. 
After extraction of the tetrapeptide FmocGlyGlyProNle into iced cold water, the white 
product was analysed by mass spectrometry (positive mode, ESI-TOF) as exposed in 
Figure 3-5. 
 
 
 
 
Scheme 3-5 Mechanism of Fmoc protected amine deprotection by piperidine 
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Mass Spectrometry  
 
 
 
 
 
 
 
 
 
Figure 3-5 Mass spectrum (ESI-TOF, positive mode)of  tetrapeptide 
FmocGlyGlyProNle  
 
The analysis by mass spectrometry showed a peak at m/z= 565.3051 corresponding to 
the protonated tetrapeptide Fmoc GGPNleOH [M+H]
+
. 
At m/z=1129.6279, was observed the aggregate of two tetrapeptides and at 
m/z=1695.8540, the aggregate of 3 tetrapeptides a common artefact of mass 
spectrometry. 
All the peptide was then cleaved from the resin as mass spectrometry analysis showed 
the success of the synthesis. 
‘H NMR spectroscopy  
The chemical composition of the final product was also checked by 
1
H NMR performed in 
deuterated dimethylsufoxide (DMSO-d6) spectroscopy. The spectrum of Figure 3-6 
reports the characteristic signals of the tetrapeptide. 
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Figure 3-6 
1
H NMR spectrum in DMSO-d6 of FmocGlyGlyProNle 
 
The methyl protons (a) at δ=0.84ppm  were set as reference and were attributed to 3H 
from the CH3 of the norleucine amino acid since the protons were the most shielded in 
the tetrapeptide molecule. Integrations of all peaks allowed the determination of all 
protons present in the molecule. The amide protons were detected at δ=8.38ppm 
(1H,NH) and 8.05 ppm (1H,NH). Fmoc protecting group was present in the range 
between δ=7.36 and 7.88ppm, typical from cyclic molecules where protons are highly 
deshielded.  More particularly, Fmoc protecting group was found at δ=7.36ppm (m, 
4H,CH, Fmoc),  δ=7.70ppm (m, 1H+1H,CH, Fmoc) and δ=7.88ppm (m, 2H,CH, Fmoc). 
Norleucine methylene protons (b,c,d) could be identified at δ=1.27ppm (m, 4H, CH2-CH2) 
and δ=2.11ppm (m, 2H, CH2). In the table hereafter, are recognised all protons from 
FmocGlyGlyProNle, integrations corresponded to the theoretical values (Table 3-1). 
 
 
 
 
Table 3-1 
1
HNMR chemical shifts () and proton number for FmocGlyGlyProNle 
 
ppm () 
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Mass spectrometry and 
1
H NMR spectroscopy showed the successful synthesis of the 
tetrapeptide sensitive spacer FmocGmyGlyProNle. 
 
1.13.3 Anti-tumour function: Synthesis of NH2TPTX paclitaxel prodrug 
 
Multiple approaches were considered for the attachment of the N-terminus of the 
tetrapeptide spacer (S1) Gly-Gly-Pro-Nle to the hydroxyl group of paclitaxel (Figure 3-7-
A) including common techniques also used in protein coupling such as the N,N'-
dicyclohexylcarbodiimide (DCC) coupling in presence of 4-(dimethylamino)pyridine 
(DMAP) catalyst or the  1-ethyl-3-(3-dimethylaminopropyl) carbodiimide  (EDC) coupling 
in presence of DMAP. These techniques were worked on different conditions 
(temperature, atmosphere, solvents) but none of them led to successful synthesis or the 
yield was unreasonably poor.  
To overcome these issues, it was decided to insert a 1,6-elimination spacer based on 4-
aminobenzyl alcohol (Figure 3-7-B). The latter was used to link the N-terminus of the 
peptide to the OH-group of the paclitaxel. The insertion of this second spacer (S2) would 
not modify the aim of the project, which was to use the enzymatic environment in bones 
Proton δ(ppm) Theoretical number 
Experimental 
number 
a 0.84 3 3.00 
b 1.27 2 
4.09 
c 1.27 2 
d 1.86 2 2.11 
e 3.93 1 
e,f,i,j7.70 
f 3.93 1 
g 3.47 2 2.63 
h 3.65 2 2.48 
i 3.93 2 
e,f,i,j7.70 
j 3.93 2 
k 4.38 2 
K,l,m5 l 4.38 2 
m 4.45 1 
n 7.70 2 1.74 
o 7.36 2 
4.01 
p 7.36 2 
q 7.88 2 2.61 
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to cleave the tetrapeptide spacer and release paclitaxel. It was also reported in literature 
by Greenwald and co-workers
54
 that the strong electronic-donating amine group of the 
1,6- elimination spacer would is exposed upon enzymatic cleavage of the peptide spacer 
and consequently, a n-electronic cascade commences, that leads to the cleavage of the 
ester bond and release paclitaxel. 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the following section, (T) will be used for the tetrapeptide GlyGlyProNle part of the 
prodrug and () for the phenyl carbonate self immolative spacer The detailed synthesis is 
described in Scheme 3-6 
Figure 3-7 Molecules designed for the synthesis of a Cathepsin K sensitive PTX 
prodrug. First design S1-PTX or NH2TPTX (A), second design S1-S2-PTX or 
NH2TPTX (B) 
A B 
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The previously synthesised (1.13.2) N-Protected tetrapeptide (T) FmocGlyGlyProNle (1) 
was mixed with isobutyl chloroformate in presence N-methylmorpholine. The carboxyl 
group was activated by the isobutylchloroformate to form a mixed carboxylic-carbonic 
anhydride intermediate. The intermediate was then reacted with 4-aminobenzyl alcohol to 
yield FmocTOH (2). The choice of solvent mixture tetrahydofuran/dioxane was made in 
order to maximise the solubility of the tetrapeptide and ensure a successful coupling; 
traditional solvents such as chloroform, dichloromethane, tetrahydrofuran alone, and 
toluene were not able to dissolve to dissolve the tetrapeptide. The reaction temperature 
was lowered at -18C in order to avoid the degradation of the tetrapeptide as observed at 
higher temperatures. Two column chromatography purifications allowed the separation of 
by-products from final products and starting materials. The first column chromatography 
using the highly hydrophobic hexane allowed the elimination of NMP originated by-
products, while the second column chromatography used a mixture of acetone and 
ethylacetate (80/20%v/v) in order to separate the eventual non-reacted tetrapeptide from 
the product (2). The yield of the reaction was of 99%mol. Mass spectrometry (Figure 3-8) 
allowed to check the purity of FmocTOH and pursue to the next step.  
 
Mass spectrometry  
 
 
 
 
 
 
 
 
 
 
 
The analysis by mass spectrometry (Positive mode, ESI-TOF) showed a peak at m/z= 
670,3291 corresponding to the protonated modified tetrapeptide FmocTOH [M+H]
+
. At 
Figure 3-8 Mass spectrometry (ESI-TOF, positive mode) of FmocTOH 
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m/z=652.3257 was observed the dehydrated form [M-H2O]
+
 of FmocTOH, and finally, at 
m/z=1340.6746 was observed the aggregate of two modified tetrapeptides. 
These results were considered satisfying to pursue to the next step as high purity was 
obtained, shown by the absence of starting material. 
In a second step, the resulting benzylic alcohol FmocTOH (2) was activated with 4-
nitrophenyl chloroformate in presence of pyridine and diisopropylethylamine to yield to 
yield the corresponding p-nitrophenyl carbonate FmocTNO2 (3). The reaction was 
performed at 0C under anhydrous conditions. In order to favour the formation of 
FmocTNO2, a large excess of p-nitrophenyl chloroformate was necessary. The reaction 
did not always reach completion. A probable explanation is the fast degradation of p-
nitrophenyl chloroformate. The chloroformate was highly unstable in ambient 
environment; even if carefully conserved under nitrogen at 6°C, it degraded in 3 main 
products (a, b, c)  as presented in Figure 3-9. 
 
 
 
 
 
 
 
The best yield (44%mol) was obtained by double coupling; more specifically, a first 
coupling of FmocTOH with p-nitrophenyl chloroformate was performed followed by full 
purification (extraction and two silica gel chromatographies) and then a second coupling 
was performed in the same manner followed by full purification (extraction and two silica 
gel chromatographies).  
The separation of FmocTOH and FmocTNO2 was achieved by extraction in 
ethylacetate from a saturated solution of ammonium chloride after filtration, in order to 
remove pyridine and derivative by products soluble in water. The purification was then 
followed by two column chromatographies. The two compounds FmocTOH and 
FmocTNO2 are very similar in term of polarity and it was always found some residual 
FmocTOH after purification as shown by the mass spectrometry in Figure 3-10 
(positive mode, ESI-TOF). 
 
Figure 3-9 Products of degradation of p-nitrophenyl-chloroformate (a, b, c) 
M(g.mol
-1
)           304.03        139.11                     181.15  
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The analysis by mass spectrometry (Positive mode, ESI-TOF) showed a peak at m/z= 
852.3674 corresponding to the protonated modified tetrapeptide FmocTNO2 [M+H]
+
. At 
m/z=652.3431, was observed the dehydrated form [M-H2O]
+
 of FmocTOH,  
Mass spectrometry is not quantitative; consequently, it was not possible to determine 
the purity of FmocTNO2. 
1
H NMR spectroscopy of FmocTNO2 and FmocTOH were 
too similar to be able to distinguish characteristic peaks for (2) and (3) and quantify their 
ratio. 
The presence of FmocTOH was not considered as an issue as it was hypothesised it 
should not react in the following step. Therefore, it was decided to move onto the next 
step where FmocTNO2 was attached to paclitaxel (4) in presence of DMAP catalyst at 
room temperature. Paclitaxel was used in excess in order to optimise the yield of 
reaction and obtain FmocTPTX (5). 
The crude product was purified by column chromatography using hexane first, to 
remove PTX and then, ethylacetate/acetone (20/80%vol) to separate products from 
starting material (3). The reaction yield was of 92%mol. The white product was analysed 
by TLC which revealed a strong spot for the product and no other spots from starting 
materials. The product was then examined by mass spectrometry (positive mode, ESI-
TOF) presented in  
Figure 3-10 Mass spectrometry (ESI-TOF, positive mode) of FmocTNO2 
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Figure 3-11 Mass spectrometry (ESI-TOF, positive mode) of FmocTPTX 
 
The analysis by mass spectrometry (Positive mode, ESI-TOF) showed a peak at m/z= 
1549.1414corresponding to the protonated modified tetrapeptide FmocTPTX [M+H]+. 
And at m/z=1567.1709, was observed the [M+NH4]
+
 form of FmocTPTX. 
FmocTPTX did not ionise easily in mass spectrometry, product ratios cannot be 
demonstrated in this analytical method. It was believed that the product purity was 90% 
as the reaction yield was high and TLC was clean. The presence of large phtalate peaks 
at m/z+=279.1823, 391.3130 and 548.4474 coming from plasticisers 
(Diisobutyl phthalate, diisooctyl phthalate and Diisotridecyl phthalate respectively) of tools 
used in labs, represents only traces and show how much this type of analysis is not 
quantitative. 
In the next step, FmocTPTX was deprotected to obtain NH2TPTX (6). Fmoc (9-
fluorenyl-methyloxycarbonyl) amine protecting group is susceptible to be removed by 
weak bases. Usually, primary or secondary amines can be used. A first tentative was 
made using the classical method using a 20%v/v Piperidine/dichloromethane mixture 
where Fmoc is removed by piperidine which in turn scavenges the liberated 
dibenzofulvene to form a fulvene-piperidine adduct (Scheme 3-5).  
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The reaction was first carried out for 20min and revealed a degradation of FmocTPTX in 
several amino acid or combination of amino acid residues. The reaction time was then 
lowered to 10 then 5min but resulted to degradation of compound (5) in all cases.  
Several other methods were experimented, such as the 
diisopropylethylamine/dichloromethane or ethanolamine methods, always varying the 
conditions of time for each one. In all cases, these reactions were too drastic for the 
deprotection of FmocTPTX as fragments of amino acids and paclitaxel were observed in 
mass spectrometry. Although fragmentation may occur in mass spectrometry analysis, in 
this present case, it was thought that the phenomenon was related to a degradation of 
the product as fragmentation by mass spectrometry did not occurred in the previous 
steps. 
An innovative method (for that it is not reported in literature) was trialled using DMAP to 
deprotect FmocTPTX. The synthesis was monitored by mass spectrometry and TLC 
and showed that FmocTPTX primary amine gradually appeared, and the tetrapeptide 
structure was completely preserved since no fragments were measured in mass 
spectrometry: The method was validated.. After 48h, the product was precipitated in cold 
diethylether to yield a off-white product (80%mol) analysed by mass spectrometry (positive 
mode, ESI-TOF) as shown in Figure 3-12. 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 3-12 Mass spectrometry (ESI-TOF, positive mode) of NH2TPTX 
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The analysis by mass spectrometry (Positive mode, ESI-TOF) showed a peak at m/z= 
1368.6470 corresponding to the potassium ionised modified tetrapeptide NH2TPTX. 
The synthesis was successful and the final NH2TPTX was kept for future attachment to 
the polymer carrier. 
High Performance Liquid Chromatography (HPLC) 
HPLC chromatograms of NH2TPTX and free PTX are showed in Figure 3-13. Retention 
time of both compounds obtained by RP-HPLC analysis, performed in identical 
conditions, were fundamentally different one from another. NH2TPTX eluted at 
tR=12.783min while free PTX elution time was observed at tR=7.797min.  This was 
expected as the paclitaxel prodrug was less polar than the free drug due to the 
introduction of hydrophobic amino-acids (Gly, Pro, Nle) in the final structure. RP-HPLC 
demonstrated the high purity of NH2TPTX as well as the absence of free PTX peak. 
 
 
 
 
 
 
 
 
The successful synthesis of the paclitaxel prodrug NH2TPTX allowed to continue on the 
next step, in the creation of the polysaccharide-drug conjugate aimed in this project. The 
next step was the synthesis of the targeting module based on the bisphosphonate 
alendronate. 
1.13.4 Targeting function: Synthesis of NH2-PEG-Alendronate 
 
Several tactics were considered for the synthesis of the alendronate prodrug  
FmocGlyGlyProNleAlendronate including, N,N'-dicyclohexylcarbodiimide (DCC) coupling 
in presence of 4-(dimethylamino)pyridine (DMAP) catalyst, and 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide  (EDC) coupling in presence of DMAP,  solution 
phase O-Benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate / 
Hydroxybenzotriazole  (HBTU/HOBt) coupling, EDC in presence of N-hydroxysuccinimide 
A
U
C
 
Figure 3-13 HPLC chromatograms of NH2TPTX (A) and free PTX (B) 
B 
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(NHS) coupling, 4,5-dihydrothiazole-2-thiol (TT) in presence of DCC coupling, pH were 
varied from 7 to above 11.  These synthesis trials were not successful since they did not 
lead to the desired product
55
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
A new approach was elaborated, which would include a relatively low molecular weight 
poly(ethylene glycol) (PEG) in the alendronate derivative. By attaching the PEG in its 
form tBoc-NH-PEG-NHS to alendronate first, tBoc-NH-PEG-alendronate (tBocPEGALN) 
would be produced and facilitate the attachment of this first compound to the pullulan 
backbone after tBoc deprotection as described in Scheme 3-7. The bone targeting 
function of the final polymer-drug conjugate would be maintained. 
 
 
 
 
 
 
 
 
 
 
The reactive N-hydroxysuccinimide-ended PEG was directly coupled to alendronate 
primary amine to form an amide bond yielding tBocPEGALN, releasing N-
hydroxysuccinimide (NHS) which was easily removed by dialysis. This reaction is strongly 
dependant on the pH conditions so it was chosen to perform the modification at pH 8.5. A 
low pH was not recommended as the alendronate primary amine group would be 
Scheme 3-7 Synthesis of NH2-PEG-Alendronate 
Figure 3-14 Molecules designed for the synthesis of a Cathepsin K sensitive ALN 
prodrug. First strategy S1-ALN (A), second strategy PEG-ALN (B) 
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protonated and the reaction would not take place. On the contrary, a too high pH would 
increase the rate of hydrolysis. 
Dialysis to remove excess, unreacted alendronate and by-products was used. The 
absence of free alendronate was verified by TNBS assay which revealed to be negative.  
The amine protected tBocPEGALN was finally deprotected using a mixture of 
Trifluoroacetic acid (TFA)/dichloromethane (50/50%v/v) to yield NH2PEGALN.  The 
generally accepted mechanism for the cleavage of the Boc group under acidic conditions 
involves the formation of carbon dioxide, and a tert-butyl cation resulting in a carbamic 
acid. Decarboxylation of the carbamic acid leads to the free amine. 
‘H NMR spectroscopy  
 
1
H NMR spectroscopy (prior to dialysis) confirmed the full tBoc removal as its 
characteristic peak disappeared at = 1.23 ppm and shifted to 1.53ppm and the formation 
of a NH2 was shown with its distinctive protons at =4.65ppm. 
 
 
 
 
 
 
 
UV-VIS determination of ALN content 
Figure 3-15 
1
H NMR spectra in DMSO of protected and deprotected PEGylated 
alendronate 
Deprotected 
Protected 
NH2 
Scheme 3-8 General mechanism of deprotection of tBoc protected amine by TFA 
Results 
 
  
Page 103 
 
  
The content of NH2PEGALN conjugate was determined by spectrophotometry by 
formation of a complex between alendronate and ferric ions (Fe(III)) in perchloric acid 
solution. The measure of the complex absorbance was performed by UV at λ=280nm. 
The quantification of alendronate in the conjugate was verified against a calibration curve. 
It was found a maximum alendronate content of 24%mol of alendronate in the conjugate. 
This low value could be explained by the strong competition with hydrolysis due to 
experimental conditions.  
The synthesis could only and strictly be performed in aqueous environment as 
alendronate is only soluble in water. However, in these conditions, the active N-
hydroxysuccinimide was very easily hydrolysable. Optimal conditions could be reached 
by use of anhydrous organic solvents instead of an aqueous environment if the solubility 
of alendronate allowed it. An additional reason for low alendronate content could also be 
due to the pH conditions. Although the reaction pH is optimal at around 8.3-8.5 when 
using NHS esters, it is important to note that this pH is a lot lower than the pKa of the 
alendronate primary amine group which is of 11. This means that at pH 8.5, the amine is 
protonated and the reaction of esterification becomes less favourable. In spite of this low 
alendronate concentration, the PEGylated alendronate was kept for further coupling onto 
the polymer backbone as the bisphosphonate is very potent and  should play its role of 
targeting agent even in a small amount as reported in literature. 
 
1.13.5 Polymer therapeutics: Synthesis of Pullulan-Paclitaxel-Alendronate 
(Pull-PTX-ALN) 
 
Formerly synthesised paclitaxel and alendronate prodrugs were both conjugated to the 
modified pullulan by formation of a carbon-nitrogen double bond (Schiff base) followed by 
a selective  reduction with sodium borohydride as described in Scheme 3.9. 
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In a first step, NH2TPTX (1) was reacted onto oxidised Pullulan Pullox30 in 
dimethylsufoxide (DMSO) to form a Schiff base (2). The unstable bound is part of an 
equilibrium which is unfavourable for the successive reactions. Consequently, compound 
(2) was stabilised using sodium acetoxyborohydride, known selective reducing agent for 
imines
56
: the polysaccharide Schiff bases were reduced to stable secondary amines (3) 
while aldehyde groups remained available for further conjugation. Subsequently, a large 
excess of NH2PEGALN (4) was added to the polymer mixture (3), followed by 
stabilisation with sodium borohydride which reduces the newly formed Schiff bases of 
compound (5) to simultaneously convert the unreacted aldehyde groups into alcohol 
groups and give the final compound (6) named Pull-PTX-ALN. 
GPC 
The gel permeation chromatography analysis of the Pull-PTX-ALN showed a molecular 
weight Mw of 89124Da and a polydispersivity index (PDI) of 1.88 as shown in Figure 
3-16. 
 
Fourier Transform Infrared Spectroscopy (FT-IR)  
The FT-IR spectra of Pull-PTX-ALN showed the disappearance of the strong C=O 
stretching band from the aldehyde (Pullox30 starting material) and the appearance of two 
strong characteristic bands at approximately 1250-1100 cm
-1
 and 1100-900 cm
-1
, due to 
the vibrations (P=O) (1200-1160 cm
-1
), (P-OH) (≈ 1000 cm
-1
 and ≈ 925 cm
-1
) and δ(POH) 
(around 1080 cm
-1
) bands of the bisphosphonate alendronate.  
Stretching bands were observed over the (O-H) band. The (O-H) band also overlapped 
with the very large and weak (PO-H) and δ(POH) bands, with maximum around 2600-
2800 cm
-1
. 
Figure 3-16 GPC traces of Pull-PTX-ALN against Pullulan standards 
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 The amide band (between 1600 and 1700 cm
-1
) was mainly associated with the C=O 
stretching vibration and related to the N-H from the tetrapeptide spacer GlyGlyProNle. 
 
  
 
 
 
 
 
 
 
 
 
 
RP-HPLC characterisation 
Pull-PTX-ALN was characterised by reverse phase chromatography to control its purity. 
As shown in Figure 3-18, the retention time obtained for Pull-PTX-ALN (tR=18.093 min) 
varied from free PTX (tR= 7.840 min) while native Pullulan was not detectable as 
expected. These results indicated a good purification of product and the absence of free 
PTX. 
  
  
  
²  
  
  
  
  
  
Figure 3-18  HPLC chromatograms of native Pullulan (A) free PTX (B) and Pull-
PTX-ALN (B) 
A 
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C 
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Figure 3-17 FT-IR spectra of Pull-PTX*ALN (A) and native Pullulan (B) 
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The success of the synthesis of final polymer-drug conjugate Pull-PTX-ALN allowed to 
make further studies for understanding it physico-chemical properties and its properties 
on cancerous cells. The subsequent sections will investigate Pull-PTX-ALN in details, 
from its composition to its anti-tumour and anti-angiogenic properties without forgetting 
the study of its stability. 
  
1.14 Properties of Pull-PTX-ALN 
1.14.1 Solubility of Pull-PTX-ALN 
 
The solubility of Pull-PTX-ALN was assessed by preparing sequential dilution of a 
polymer-drug suspension of known composition. The picture in Figure 3-19 shows the 
solubility of the free drug paclitaxel and Pull-PTX-ALN in water. The quantity of compound 
was normalised to get an equivalent amount of paclitaxel for both tests. 
 
 
 
 
 
 
 
The final nano-carrier solubility was of about 513µg/ml equivalent paclitaxel which was 
500 times higher solubility than the free drug,  an encouraging result for one of the 
purpose of the project; to increase the solubility of the highly hydrophobic drug 
paclitaxel (free paclitaxel has a low water solubility of approximately 0.3µg/ml)
57
. 
1.14.2 Identification of the polymer-drug conjugate composition 
 
UV-VIS determination of ALN  and PTX content  
As showed in Figure 3-20 and Figure 3-21, Pull-PTX-ALN spectrum () was 
superimposable to free ALN and free PTX spectra indicating that the ALN and PTX 
attachment to the pullulan backbone through a spacer did not compromise the 
physicochemical characteristic of the drug in UV-VIS spectroscopy. 
 Free PTX Pull-PTX-ALN 
Figure 3-19 Solubility of the free drug paclitaxel (left) and PullPTXALN (right) in 
ultrapure water at room temperature 
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Figure 3-20 UV-VIS spectra in perchloric acid of Pull-PTX-ALN () and ALN (---) after 
complexation with Fe
3+ 
 
UV-VIS determination of PTX content 
 
Figure 3-21 UV-VIS spectra in MeOH of Pull-PTX-ALN () and PTX (---)  
 
Results obtained via spectrophotometry after complexation of Pull-PTX-ALN with Fe (III) 
indicated an alendronate weight percentage of 1.6%w/w while the quantity of paclitaxel 
present onto the polymeric carrier was of 7.8%w/w in weight corresponding to our initial 
loading target. The %w/w was also confirmed by another method using RP-HPLC using 
PTX as calibration standards. 
Summary Pull-PTX-ALN composition 
The composition of Pull-PTX-ALN is summarised in Table 3-2. These data were used as 
reference all through the cell studies. 
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Table 3-2 Composition of Pull-PTX-ALN in comparison with non-modified pullulan 
 
Pull-PTX-ALN  
composition 
Native Pullulan 
Mw (DA) SEC 89124 104000 
PDI SEC 1,88 1.92 
%w/w Alendronate 
UV-VIS 
(complexation with 
Fe(III) 
1.6 0 
%w/w Paclitaxel UV-VIS 7.8 0 
 
It is worth noting that higher loading of paclitaxel onto the polymer backbone was 
attempted to identify the maximum conjugation capacity. The NH2TPTX:Pullox30 ratios 
were varied from 2:100, 5:100 10:100 to 20:100. The value of 7.8%w/w of PTX reported 
above was the maximum conjugation obtained. 
1.14.3 Molecular size and surface charge of conjugates 
 
The hydrodynamic diameter and size distribution profile of Pull-PTX-ALN conjugate was 
evaluated using Dynamic Light Scattering (DLS). 
The mean hydrodynamic diameter of the nano-carrier in PBS, pH5.5 was of 163.30± 
18.25nm and the polydispersity index (PDI) was of 0.20±0.02. In water the particle size 
was of 100.2±7.3 nm and the PDI of 0.17±0.03nm. Finally, in PBS, pH7.4 the particle size 
was of 69.88±6.27nm and the PDI of 0.15±0.01 (Figure 3-22).  
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
C 
Figure 3-22 Size analysis by DLS of Pull-PTX-ALN in PBS, pH5.5 (A) at 25°C in water (B) at 
25°C and in PBS, pH 7.4 (C) at 25°C 
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This particle size was in agreement with the recommended size to allow drug delivery to 
the bone, considering the anatomical fenestrations of the bones known to be between 
80nm and 150nm.  
As a control, a solution of native Pullulan in water was analysed in the same conditions  
as for Pull-PTX-ALN and demonstrated that the unconjugated polymer was of about 
10nm; meaning ten times smaller than the conjugated one (Figure 3-23).  
This result suggested the formation of self-assemblies of the polymer-drug conjugate in 
solution. 
Figure 3-23 Comparison of the size by DLS of native pullulan (-) and the Pull-PTX-
ALN (-) conjugate in water at 25°C 
 
Measure of the Zeta potential 
The ζ- potential of the Pull-PTX-ALN conjugate was measured in water to evaluate the 
global charge on the polymer surface at pH 7.4 in HEPES. 
 
 
 
 
 
 
Figure 3-24 ζ- potential of Pull-PTX-ALN in water at 25°C  
 
The analysis indicated that the polymer-drug conjugate had a ζ- potential of -0.33967± 
0.247308 mV which could be considered neutral and was as expected. 
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1.14.4 Stability of polymeric structures in buffer solutions at different pH 
over time 
 
Pull-PTX-ALN conjugate solutions were prepared in water (pH6) and in buffers at different 
pH. The first pH selected was pH5.5 to mimic the acidic bone lacunae at the tumour site 
where the drug should be released, and pH7.4 to simulate the pH value prevalent in 
plasma. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-25 Size-time course profiles of Pull-PTX-ALN at 25°C at pH5.5(), 6.0 
()and 7.4() 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-26 Polydispersity-time course profiles of Pull-PTX-ALN at 25°C at 
pH5.5(), 6.0() and 7.4() 
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The size of self-assemblies and polydispersity index was monitored over time and 
showed that both at acidic and plasma pH, the nanoparticles were completely stable over 
8h. This was expected as, on the assumption that paclitaxel remains on the polymeric 
carrier, the solubility of the overall colloid should not change. Indeed, as the equilibrium 
between hydrophilic and hydrophobic fragment is maintained, the assembly should be 
stable. This stability in time was important as the conjugate was designed to only release 
paclitaxel in the presence of Cathepsin K. after it travels to the target site was reached. 
1.14.5 Stability of polymeric structures in buffer solutions at different T°C 
 
The stability of Pull-PTX-ALN at room temperature (25°C) and physiological temperature 
(37°C) was also examined by monitoring the size of the self-assemblies at these 
temperatures, using DLS. 
 
 
Figure 3-27 Size-temperature of Pull-PTX-ALN at 25°C and 37°C and at pH5.5, 6.0 
and 7.4 
 
The analysis confirmed that the particles were stable at both temperatures, independently 
of the pH of the solution.  
1.14.6 Critical micellar concentration 
 
The Critical Micellar Concentration (CMC) is defined as the definite concentration above 
which polymeric micelles form in aqueous solution.  
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At the CMC, polymers containing a hydrophobic part and a hydrophilic fragment may 
assemble in an ordered manner in order to minimise the contact of the hydrophobic 
fragment with water molecules, leading to a core-shell micellar structure. 
The fluorescent probe pyrene was chosen for the determination of the CMC.  This non-
polar poly-aromatic molecule preferably partitions from a hydrophilic to more hydrophobic 
environment which would be the core of the polymeric micelles, leading to a change in its 
fluorescent properties translated by a red shift in the excitation spectrum
58
 (Figure 3-28).  
 
 
 
 
 
 
 
 
 
 
The CMC of polymeric micelles can be described as the turning point of these 
modifications at the increase of polymer concentration. 
The CMC of Pull-PTX-ALN was determined by way of the fluorescence intensity of 
pyrene as a function of the logarithm of the polymer concentration in PBS (20mM, pH7.4) 
(Figure 3-29).  
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Figure 3-29 critical micellar concentration of the Pull-PTX-ALN  
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Figure 3-28 Determination of CMC using a pyrene probe – Spectra at increasing 
concentration of polymer drug conjugate Pull-PTX-ALN 
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At low polymer concentration, low pyrene intensity was observed. Above a precise 
polymer concentration, a rapid rising in pyrene fluorescence intensity ratio was observed.   
The critical micellar concentration of the final polymer-drug conjugate Pull-PTX-ALN was 
obtained at 73.3µg/ml, considered as low CMC and suitable for drug delivery as to 
consider the dilution into plasma after injection of the drug.  
1.14.7 Transmission electron microscopy (TEM) 
 
A Pull-PTX-ALN solution was prepared in water at a concentration of 1.5mg/ml, above the 
CMC, to confirm the presence of self-assemblies and determine their morphology.  
 
The nanoparticles were visualised by TEM. Spherical structures with a narrow size 
distribution were observed, confirming the organisation of the polymer-drug in micellar 
structure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-30 TEM images of Pull-PTX-ALN micelles in water 
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The average overall size of Pull-PTXALN micelles was approximately 90-135nm, which 
was in good agreement with the molecular size determined by DLS. 
1.15 Pull-PTX-ALN: In-Vitro assays 
1.15.1 Hydroxyapatite binding assay 
 
Hydroxyapatite, main constituent of the bone, is particularly exposed in lysis sites when 
metastases reach bone tissues. Bisphosphonate show a strong affinity for the bone 
mineral as well-acknowledged in the literature. Alendronate, belonging to the 
bisphosphonate family and chosen in this project, has an especially strong affinity 
towards bone tissues. This characteristic is due to the presence of its phosphonate 
groups and hydroxyl groups. 
The binding capacity of Pull-PTX-ALN and Pull-PTX polymer conjugate and free 
alendronate to bone mineral through ALN was assessed at the physiological temperature 
of 37°C. Hydroxyapatite was used as a model mineral simulating bone tissues. 
The conjugates were incubated with the bone mineral HA for 0, 10, 30, 60, 120 and 180 
and 480min. 
Samples were taken at the specified time points and analysed by UV spectrophotometry 
by quantifying separately the alendronate concentration in the supernatant, after 
complexation with Fe(III) ions and paclitaxel by direct reading. Both analyses allowed the 
quantification of the non-bounded polymer in the supernatant. Results from both methods 
were confronted and gave same profiles. Pullulan bound to PTX (Pull-PTX) through the 
same peptidyl and self-immolative linkers as for Pull-PTX-ALN  was synthesised, to use 
as reference for this test and following assays. The quantity of PTX on the polymer 
backbone was equivalent to the quantity used for the synthesis of Pull-PTX-ALN.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-31 Binding kinetics of ALN, ()Pull-PTX-ALN(), Pull-PTX () to the bone 
mineral hydroxyapatite at the temperature of 37°C and pH 7.4 
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Figure 3-32 Binding kinetics of ALN, ()Pull-PTX-ALN(), Pull-PTX () to the bone 
mineral hydroxyapatite at the temperature of 37°C  and pH 5.5  
 
After 5 min of incubation, 80% of free alendronate was bond to HAp to reach a plateau 
between 75 and 80%. The pH of incubation did not affect the binding of free alendronate. 
Pull-PTX-ALN was bond to hydroxyapatite at a different rate and ratio in respect to free 
alendronate. It was also noticed variations in the binding capacity of the polymer 
conjugate, depending on the pH of incubation. Indeed, after 30min at pH7.4, 30% of 
polymer conjugate linked to the bone mineral and reached a plateau of around 40% 
binding. When decreasing the pH to 5.5, pH simulating tumour tissues, approximately 
45% Pull-PTX-ALN was bound to hydroxyapatite after 30min, against 30% at pH 7.4, and 
a plateau was reached after around 65% binding. 
The polymer conjugate Pull-PTX, exempt of alendronate, did not bind at all to 
hydroxyapatite as expected. 
The results indicate that the Pull-PTX-ALN conjugate can accurately and rapidly target 
the bone tissue lysis sites. 
1.15.2 Drug release in-vitro assay 
 
In this project, the polymer-drug conjugate was designed so that it would release the 
unmodified form of the anti-tumour drug paclitaxel at the target site. The enzyme 
triggered release occurs in several consecutive steps (cascade reaction). Primarily, the 
peptide Gly-Gly-Pro-Nle should rearrange in the subsites of the active site of Cathepsin 
K; the amide bond between Gly and Pro would be cleaved. Consecutively, the amide 
bond between norleucine and 4-aminobenzyl alcohol moiety would break apart to finally 
free the unmodified paclitaxel after an 1,6-elimination. 
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The drug release assay was performed at 37°C and pH5.5, mimicking the physiological 
tumour environment. The HPLC traces showed a shift to the left of the polymer-drug 
conjugate from 18min to 15min at a flow rate of 0.7ml.min
-1
, demonstrating an increase of 
hydrophilicity due to the loss of paclitaxel. It was assumed that the paclitaxel peak should 
show at a retention time of 8min, however it was presumed to be in minute quantity at the 
limit of detection by the HPLC UV detector. Additionally, the peak of paclitaxel was 
probably covered by incubation materials and cleavage products. The available enzyme 
amount was not sufficient for increasing scales for the assay. It was decided to follow the 
kinetic of drug release indirectly by measuring the quantity of Pull-PTX-ALN remaining, 
surmising the loss of paclitaxel, i.e. the paclitaxel release. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The % disappearance of Pull-PTX-ALN was plotted against the time of incubation in 
presence of Cathepsin K. A control was performed using identical conditions of 
incubation, excluding Cathepsin K.  
  
Figure 3-33 HPLC traces of the drug release assay using Cathepsin K as trigger for 
the release of paclitaxel 
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The graph showed that after 45min, around 45% of Pull-PTX-ALN disappeared. 
The enzyme degraded the spacer more slowly after that time and reached a plateau at 
approximately 96% disappearance of the polymer-drug conjugate peak after 8h 
incubation. 
Over the same amount of time, results demonstrated that the control did not free PTX as 
the quantity of Pull-PTX-ALN remained equal all along the experiment. 
 
The results from the drug release assay proved that the new Pull-PTX-ALN conjugate 
fulfilled with elementary requirements for efficient anticancer prodrugs by releasing the 
active drug PTX only in the environment mimicking conditions in case of breast cancer 
bone metastasis; i.e., the drug release of PTX was only triggered by the presence of 
Cathepsin K. 
 
1.15.3 Red Blood Cell Lysis Assay 
 
The biocompatibility of Pull-PTX-ALN was assessed using rat red blood cell (RBC) 
haemolysis assay. Rat RBC solution was incubated with serial concentrations of PTX 
(1:1:8 ethanol/Cremophor EL/saline), and Pull-PTX-ALN conjugate at equivalent PTX and 
ALN concentrations. Dextran, and poly(ethylene imine) (PEI) served respectively as 
negative and positive control for haemolysis. 
Results are presented in Figure 3-35 as % of haemoglobin release produced by the 
various compounds 
Figure 3-34 Kinetics of the drug release assay using Cathepsin K as trigger for the 
release of paclitaxel 
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Figure 3-35 Biocompatibility of PTX, Pull-PTX-ALN, Dextran and PEI in RBC.  
 
PTX-PEG-ALN conjugate did not exhibit detectable RBC haemolysis at any 
concentrations up to 5 mg/ml (the expected blood concentration after in vivo 
administrations is about 0.5 mg/ml) as shown in Figure 3-35. PTX vehicle cytotoxicity is 
known on normal non-proliferating cells and certainly, a slight RBC haemolysis of 
approximately 4% was observed in RBC incubated with PTX.  The identified haemolysis 
was also possibly instigated by the Cremophor EL vehicle in which PTX was dissolved. 
1.16 Cell Studies 
1.16.1 Evaluation of the anti-tumour properties of Pull-PTX-ALN 
1.16.1.1 Cytotoxicity of Pull-PTX-ALN on MDA-MB231cells, murine 4T1 cells and 
bone SAOS-2 cells  
 
A further step in this project was to assess whether PTX retained its cytotoxic activity 
when covalently bound to the polymeric carrier pullulan. Consequently, cytotoxicity 
assays were performed on a range of cell lines. Cell toxicity on mammary 
adenocarcinoma cells sourced from bone metastasis MDA-MB231 BM, on murine 
mammary adenocarcinoma 4T1 and bone sarcoma cell lines SAOS-2 was evaluated.  
Pullulan bound to ALN (Pull-ALN) through the same PEG spacer as for Pull-PTX-ALN 
was synthesised, to use as reference for this test and the following assays. The quantity 
of ALN on the polymer backbone was equivalent to the quantity used for the synthesis of 
Pull-PTX-ALN. The range of compounds tested was free PTX, free PTX in combination 
with free ALN, Pullulan, Pull-PTX, Pull-ALN and Pull-PTX-ALN at equivalent 
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concentration of PTX and ALN. Results are shown in Figure 3-38, Figure 3-39, and 
Figure 3-41.  
Figure 3-36 3-37Cell toxicity assay in MDA-MB231 BM mammary adenocarcinoma 
cells were incubated with free PTX, free ALN, Pullulan, Pull-PTX, Pull-ALN and Pull-
PTX-ALN at equivalent concentration of PTX and ALN for 72 h. Data represent the 
mean ±SD (standard deviation). The X-axis is presented as a logarithmic scale 
 
Figure 3-38 Cell toxicity assay in murine 4T1 mammary adenocarcinoma cells. 
Cells were incubated with free PTX, free ALN, Pullulan, Pull-PTX, Pull-ALN and 
Pull-PTX-ALN at equivalent concentration of PTX and ALN for 72 h. Data represent 
the mean ±SD (standard deviation). The X-axis is presented as a logarithmic scale 
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Figure 3-39 Cell toxicity assay in human sarcoma SAOS-2 cells were incubated 
with free PTX, free ALN, Pullulan, Pull-PTX, Pull-ALN and Pull-PTX-ALN at 
equivalent concentration of PTX and ALN for 72 h. Data represent the mean ±SD 
(standard deviation). The X-axis is presented as a logarithmic scale 
 
Cells proliferation was inhibited by both Pull-PTX and Pull-PTX-ALN polymer-drug 
conjugates, exhibiting IC50 about 1-fold and two-fold higher respectively, than the IC50 of 
the free drug paclitaxel (PTX) for the three cell lines MDA-MB231 BM, 4T1 and SAOS-2 
as reported in Table 3-3. 
 
Table 3-3 Cytotoxicity of PTX, Pull-PTX and Pull-PTX-ALN on MDA-MB231 BM, 4T1 
and SAOS-2 cell lines 
 MDA-MB231 BM 4T1 SAOS-2 
IC
50
PTX (nM) 20 30 3 
IC
50
PullPTX (nM) 500 1500 500 
IC
50
PullPTXALN (nM) 90 300 60 
 
For all cell lines verified, Pullulan served as the control and was non-toxic at any of the 
concentrations tested. Alendronate alone was found not to be toxic at any of the 
concentrations tested. 
1.16.1.2 Wound healing assay Pull-PTX-ALN on MDA-MB231 BM cells 
  
Furthermore the influence of Pull-PTX-ALN on the ability of MDA-MB231 BM to migrate 
was assessed, modelling the phenomenon of metastasis in breast cancer. A wound 
healing assay was carried out (Figure 3-40) to check if cells would move in a defined 
direction to close the wound. MDA-MB231 BM cells were incubated with free PTX, free 
ALN, a combination of free ALN and free PTX, Pullulan, Pull-PTX, Pull-ALN and Pull-
PTX-ALN at equivalent concentration of PTX and ALN for 24h. 
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Figure 3-40 Wound healing assay on MDA-MB231 BM cells incubated  with free PTX, free ALN, Pullulan, Pull-PTX, Pull-ALN and Pull-PTX-ALN at 
equivalent concentration of PTX and for 24 h. (scale bar represents 100 μm). 
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Figure 3-41  % migrated cells in a wound healing assay performed on MDA-MB231 
BM cells incubated  with  free PTX, free ALN, a combination of PTX and ALN, 
Pullulan, Pull-PTX, Pull-ALN and Pull-PTX-ALN at equivalent concentration of PTX 
and ALN for 24h- 
 
 
The migration of MDA-MB231 BM incubated with both Pull-PTX and Pull-PTX-ALN was 
inhibited by over 63 and 99% respectively (Figure 3-41). The previous cell proliferation 
assays demonstrated that the presence of ALN onto the polymer backbone might have a 
synergetic anti-tumour effect when in combination with PTX; this hypothesis was 
confirmed with the wound healing assays. Pull-PTX-ALN prevented mammary 
adenocarcinoma cells from migrating in the same fashion as PTX free drug. 
 
1.16.2 Inhibition of angiogenic cascade 
 
The anti-angiogenic properties of Pull-PTX-ALN were assessed by performing endothelial 
cell proliferation assays, capillary-like tube formation assay and migration assay so as to 
evaluate if the polymer-drug conjugate preserved the features of the free drug PTX. 
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1.16.2.1 Cytotoxicity of Pull-PTX-ALN on Human Vein Endothelial Cells (HUVEC) 
 
Primarily, HUVEC were incubated with, Pullulan, Pull-PTX, Pull-ALN and Pull-PTX-ALN 
at equivalent concentration of PTX and ALN. The proliferation of HUVEC was inhibited 
similarly by free PTX and free PTX in combination with free ALN and Pull-PTX-ALN 
exhibiting an IC50 of ~15nM. Pull-PTX inhibited HUVEC with a twofold higher IC50 
(~700nM) than Pull-PTX-ALN. 
 
Figure 3-42 Cell toxicity assay in human umbilical vein endothelial cell (HUVEC). 
HUVEC were incubated with free PTX, free ALN, Pullulan, Pull-PTX, Pull-ALN and 
Pull-PTX-ALN at equivalent concentration of PTX and ALN for 72 h. Data represent 
the mean ±SD (standard deviation). The X-axis is presented at as logarithmic scale 
 
1.16.2.2 Capillary-like tube formation assay on HUVEC 
 
Finally, the anti-angiogenic activity of the polymer-drug conjugate Pull-PTX-ALN was 
evaluated by capillary-like tube formation assay. The test performed on Matrigel. 
 
 
 
 
 
 
 
 
 
0
20
40
60
80
100
120
140
0.00001 0.0001 0.001 0.01 0.1 1 10 100 1000 10000
C
e
ll
 v
ia
b
il
it
y
 (
%
 o
f 
c
o
n
tr
o
l)
 
PTX concentration (nM) (PTX:ALN ratio 1:0.6) 
PTX Pull-PTX Pull-PTX-ALN Pullulan ALN Pull-ALN
Results 
 
  
Page 125 
 
  
 
* 
* 
* 
* 
* 
0
20
40
60
80
100
120
140
C
ap
ill
ar
y 
le
n
gt
h
 (
%
 o
f 
co
n
tr
o
l)
 
Figure 3-43 Capillary like-tube formation assay : representative images of capillary-like 
tube structures of HUVEC seeded on Matrigel following treatment (scale bar represents 
100 μm).  
 
PTX ALN 
PTX + ALN Pullulan 
Pull-PTX 
Pull-PTX-ALN 
Positive control No matrigel Pull-ALN 
100µm 
Figure 3-44 Capillary like-tube formation assay: Quantitative analysis of the mean 
length of the tubes. Data represents mean ± SD. *p<0.05 
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The assay was performed at non-cytotoxic concentration at the indicated incubation time 
and showed that Pull-PTX and Pull-PTX-ALN both demonstrated a significant anti-
angiogenic potential. The conjugates inhibited the formation of tubular structures of 
HUVEC by ~60% as comparable with free PTX and PTX combined with ALN. However, 
the pullulan carrier and the targeting agent ALN did not prevent HUVEC from forming 
capillary-like tubes (Figure 3-44). 
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4. Discussion 
 
The field of selective drug delivery refers to the development of systems in which drugs 
are directly delivered to a specific site of the organism according to particular 
mechanisms and kinetics, in order to optimise the targeting to the diseased tissue and 
improve the drug performance of the therapeutic effect. 
To such purpose, in the past years, various supramolecular systems defined as "polymer 
therapeutics" have been developed. These “nano-medicines" are obtained by chemical 
conjugation or physical assembly of bioactive molecules with polymeric macromolecules 
and/or other functional molecules to endow nano-systems with specific biopharmaceutical 
or physico-chemical features. The polymeric part represents the basic structure, platform, 
on which molecules or chemical functions can be physically or chemically anchored. 
Consequently, the polymer must possess specific characteristics for pharmaceutical 
applications, including biocompatibility, solubility, ability to be eliminated and multi-
functionality. The use of polymer therapeutics for drug delivery has opened new 
perspectives for the development of novel and efficient treatments of several pathologies. 
They are of particular interest in the field of anti-tumour therapy to overcome drawbacks 
related to the employment of chemotherapeutics, which, due to their poor selectivity 
towards tumour cells, often cause serious damage to normal tissues inducing strong side 
effects. They also are usually poorly soluble in water, instable and produce problematic 
pharmacokinetic profiles. 
The structural particularity of the vascular endothelium, the micro-environmental 
characteristics (pH, temperature, redox potential and enzymatic composition) as well as 
the overexpression of specific receptors of tumour tissues can be exploited for the 
development of new passive or active targeting technologies for specific delivery of the 
medicine. For these reasons, polymeric drug delivery systems, bio-conjugates or 
physically assembled systems are becoming more important in the field of anti-tumour 
therapy.  
Polymer-anti-tumour drug conjugates have been investigated for many years as improved 
therapies against cancer, aimed to address the relevant limitations of current therapies 
using low molecular weight drugs; it is well acknowledged that most of the 
chemotherapeutics are potent drugs. However, they generally lack of selectivity to direct 
the cytotoxicity to tumour cells, causing severe and serious side effects to normal healthy 
cells. The coupling of antineoplastic drugs with water-soluble polymers has been 
demonstrated to strongly improve both the safety profile and anti-tumour effectiveness of 
the overall drug conjugate, by playing on several aspects, such as: 
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 Increasing the solubility: many anti-tumour agents are poorly soluble in biological 
fluids, requiring an oil formulation for clinical administration, 
 Improving the biodistribution and consequently reducing the concentration in sites 
of dose-limiting toxicity: conjugates have limited distribution due to their large 
sizes, 
 Providing passive targeting to solid tumours; the enhanced permeability and 
retention (EPR) effect promotes the extravasation of macromolecules into 
tumours due to the abnormally leaky blood vessels in cancers with respect to 
healthy tissues 
 By-passing P-glycoprotein-mediated drug resistance: due to alternative cellular 
entry and trafficking,  
 Preventing drug inactivation and degradation. 
The concept of utilising polymers in drug delivery has been explored in this project for 
improving the therapeutic performance of paclitaxel, an anti-tumoural drug used in the 
treatment of late stage breast cancer and more particularly, at its the metastases stage. 
Metastases are defined as the delocalisation and propagation of tumour cells from the 
primary site to distant tissues or organs.  
Metastases are directly connected to breast cancer-related mortality and occur in 25 to 
50% of patient diagnosed with the disease. Only 25% of patients reach the average of 5 
year survival rate. The actual common treatments are the use of traditional chemotherapy 
with its drawbacks, where anticancer drugs are often combined with other biomolecules. 
Breast cancer metastases develop in bone at an advanced stage. Paclitaxel (PTX) is one 
of the main anticancer drugs currently utilised clinically for the treatment of solid tumours, 
and more particularly in advanced breast cancer. Paclitaxel promotes the stabilisation of 
microtubule assemblies and consequently discontinues mitosis and cellular division. 
Although being a potent anti-neoplastic agent, paclitaxel suffers from serious drawbacks, 
one of them being its poor selectivity towards tumour cells. 
Since breast cancer metastases develop in bone at a final phase bisphosphonates, 
initially indicated for the treatment of osteoporosis or other bone related disease as anti-
resorptive agents, have also been indicated for bone-related breast cancer metastases in 
breast cancer patients, and as they considerably improve breast cancer survival and 
reduce bone resorption induced by bone metastases. Additionally, recent studies 
demonstrated that bisphosphonates may also have direct anticancer activity and synergy 
with cytotoxic chemotherapy.  
Although actual treatments exist, they suffer from serious drawbacks mentioned earlier. 
Therefore, there is a strong need for improving the actual therapeutics for the treatment of 
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breast cancer bone metastases, by developing innovative strategies for solubilising 
paclitaxel and targeting tumour tissues. One of these strategies is to use polymer based 
therapeutics. 
In this framework, the present project was aimed at developing a new colloidal drug 
delivery system for disease site targeting and controlled release of anti-tumour drug and 
anti-resorptive agent. The simultaneous delivery, from a single polymeric carrier, of the 
two therapeutic agents that would act synergistically, would permit the administration of 
each drug at lower concentrations, increasing their combined anti-tumour efficiency and 
decreasing their toxicity. 
Accordingly, a novel Pullulan based nano-system was designed to improve the 
biopharmaceutical and therapeutic properties of the anti-cancer drug paclitaxel, namely to 
increase the paclitaxel solubility in water and to promote its selective accumulation in the 
tumour. The novel polymer-drug conjugate would accomplish both synergistic inhibitory 
anti-tumour effect and dual active and passive targeting effect that would result in a fast 
tumour accumulation in bone-associated neoplasms.  
In order to yield a bioconjugate with selective targeting properties, a few chemical 
approaches have been implemented in the construction of the supramolecular structure. 
Paclitaxel was conjugated to the polymer backbone through an enzyme sensitive peptide 
arm that provides for the drug release by action of enzymes that are overexpressed in the 
tumour tissue. Paclitaxel was associated with alendronate to endow a polymer 
therapeutic with selective recognition properties. Indeed, the bisphosphonate has high 
affinity toward the apatite structure of bone.  
Similarly to other bone diseases, bone tumour causes local inflammation and results in 
the exposure of HAp to blood. These two characteristics can be exploited to deliver high 
drug contents distinctively to diseased tissue. 
Accordingly, the alendronate was grafted to the polysaccharide backbone to provide a 
bioconjugate with enhanced selectivity for the bone metastasises. Therefore, active 
targeting properties conveyed by alendronate combined with selective drug release due 
to specific enzymes, associated with the colloidal properties of the overall construct that 
exploit the micro-environmental features of the bone metastases by the EPR effect, can 
ensure a selective accumulation and release of the anti-tumour drug at the desired site of 
action. Bisphosphonates bind strongly to HAp and retain much of the binding affinity after 
conjugation to other molecules or carriers. 
Pullulan is a linear polysaccharide that presents only primary and secondary alcohol 
groups, which cannot easily exploited for conjugation.  
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Therefore, in a first stage, Pullulan was activated in order to produce a polymer with 
multipoint attachment sites that should be exploited for the multiple conjugations of the 
various modules, namely drug and targeting agent. One characteristic feature of Pullulan, 
is the presence of vicinal hydroxyl groups on its backbone. This advantage was utilised to 
form active aldehyde groups by oxidation. Periodate oxidation was selected as oxidising 
agent to achieve the ring-opening cleavage of the 1,2-diols at C-2 and C-3 of 
polysaccharides very efficiently, and accurately.  Periodate allows the selective oxidation 
of vicinal diol groups of the polysaccharide backbone to form reactive aldehyde functions 
that can be used as anchoring groups. As compared to other activation methods, the 
oxidation offers an easy control of the amount of anchoring groups along the polymer 
chains. Furthermore, the aldehyde groups are stable until functionalization and can be 
derivatised with a variety of moieties. 
The quantification of the formed aldehyde groups was performed by pH titration, 
exploiting the formation of HCl after the reaction of aldehydes with hydroxylamine 
hydrochloride. This quantification method uses a nucleophilic attack of the reagent onto 
the carbonyl carbon, but not all aldehydes are accessible, thus resulting in the detection 
of 2 out of 3 of the aldehydes generated by periodate reaction. A possible explanation of 
such phenomenon is the spontaneous formation of a hemiacetal (with recyclisation) in α-
1,4 of the glycosidic residue (Bruneel D., 1993)
53
. 
Oxidised Pullulan was obtained with different degrees of oxidation using different molar 
ratios oxidant/glycosidic units. More precisely, the polysaccharide was prepared with a 
theoretical degree of oxidation of the glycosidic units of 30% and 95% which should 
correspond to 20% and 60% detectable aldehydes by hydroxylamine method. . The 
kinetic studies of aldehyde formation by periodate oxidation showed that after 30min, 
almost 90% of the maximum oxidation was obtained to reach plateau after 1h.The 
reaction yielded an oxidation degree of 23% and 63% respectively (Hydroxylamine 
titration), which corresponded to 34% and 95% of total aldehydes. These results indicate 
that the oxidation reaction was complete. Slightly higher oxidation values with respect to 
the theoretical values can be attributable to the analytical process that includes some 
inaccuracies.  
As described in the literature, and according to previous studies
22c
, the periodate 
oxidation of Pullulan resulted in the reduction of the polysaccharide molecular weight
53
. 
The two pullulan derivatives presented a molecular weight of about 20kDa and 93kDa in 
the case of the 65% and the 23% oxidized pullulan correspondingly. 
On the basis of these considerations, it was decided to use a 23% oxidised pullulan 
corresponding to a number of aldehyde functions sufficient to attached prodrugs. This 
choice allowed keeping a molecular weight close to native pullulan, which properties are 
well documented in literature; thus, avoiding possible alterations of pullulan properties 
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that might occur in the much lower molecular weight of the 65% oxidised pullulan. This 
option represented a reasonable compromise between degree of oxidation, molecular 
weight of the polymer backbone and preservation of polysaccharide structure. 
Paclitaxel was conjugated to pullulan through an enzyme sensitive spacer in order to 
obtain an efficient and selective drug release and activation exclusively in the tumour site. 
This type of spacer has an advantage over other spacers as it must hydrolyse only in 
presence of specific enzymes at the target site, independently from temperature, pH or 
other environmental factors. Enzyme sensitive spacers are more stable compared to 
other spacers such as carbonates, esters or hydrazones. The use of this type of spacer 
also contributes to the targeting function and constitutes a further motivation of this 
choice.  
The enzyme sensitive spacer chosen for the paclitaxel conjugate was a Cathepsin K 
sensitive tetrapeptide.  
Cathepsin K is an enzyme expressed outside the cell, highly present at osteolytic lesions 
and site of active bone resorption, which makes Cathepsin K specific spacer a distinct 
and suitable choice for selective delivery to bone. 
In order to achieve Cathepsin K selectivity a Gly-Gly-Pro-Nle tetrapeptide was 
synthesised. The oligopeptide sequence predisposed to cleavage by Cathepsin K was 
carefully chosen. This sequence was selected according to the work of Schechter and 
Berger, which showed that Cathepsin K had a distinctive predilection for proline in P2 
position. The basic amino acids, lysine and arginine were preferred in P1 position. 
Nevertheless, it was chosen to use the neutral amino acid norleucine in P1 position to 
warrant the stability of the spacer in blood circulation. The cleavable Gly-Pro oligopeptide, 
in positions P3 and P2 respectively, were selected according to the literature (Rejmanová 
P et al). Finally, glycine was chosen for position P3. The same research group showed 
that the increase of the length of the spacer from three to four amino acid residues 
decreased the steric hindrance in an enzyme-substrate complex for chymotrypsin and 
Cathepsin B. 
The tetrapeptide spacer was obtained by Solid Phase Peptide Synthesis using a 
hydroxymethyl-based Wang resin, which is known to be an unhindered resin, easing the 
formation of the amide linkage between amino acid residues. The resin beads were of 
200-400 mesh in order to ensure a good penetration of the reagents inside the porous 
gel. Fmoc group was used as a protecting group of the amino function because it allows 
the final cleavage of the peptide from the resin under mild conditions, which avoids 
deleterious changes in the structural integrity of the oligopeptide.  
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The selected peptide sequence was built in a linear approach using a CN strategy, from 
the C-terminus to the N-terminus to obtain, after cleavage from the resin, a final 
tetrapeptide bearing a protected amine and a free carboxylic group available for further 
conjugation.  
The coupling of Proline to Norleucine was not complete, as revealed by a colorimetric test 
(Kaiser test) due to the aggregation of the hydrophobic amino acid proline; therefore, a 
double coupling was necessary for this amino acid residue to ensure a complete coupling 
between the two amino acid residues. 
The last amino acid residue glycine was chosen to remain Fmoc protected so that further 
functionalization of the final tetrapeptide could be performed via its carboxylic group, 
exempting any reaction with the primary amine group. The latter was needed in the final 
step of synthesis of the polymer-drug conjugate. 
The subsequent worked focused on the anti-tumour function by creating a paclitaxel 
prodrug to ensure selective release at the tumour site via enzymatic catalysis. 
Two methods to conjugate methods paclitaxel to the tetrapeptide spacer were carried out 
according to two approaches. 
In a first attempt, Fmoc-Gly-Gly-Pro-Nle was conjugated to the hydroxyl bond of paclitaxel 
via direct binding after activation of the oligopeptide carboxylic acid. This simple approach 
would accomplish the function of liberating paclitaxel triggered by Gly-Pro Cathepsin K 
cleavage while Pro-Nle would remain attached to the anti-tumour drug since the enzyme 
hydrolyses the substrate on position P3-P2. The specific activity of paclitaxel-GlyPro  
would necessitate some investigations.  
The first approach was initially chosen for its simplicity in terms of synthesis. Multiple 
coupling agents were used for the paclitaxel conjugation, including, N,N'-
dicyclohexylcarbodiimide (DCC) coupling in presence of 4-(dimethylamino)pyridine 
(DMAP) catalyst, and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide  (EDC) coupling in 
presence of DMAP. Also, numerous conditions were investigated, including the use of 
reagent excesses, solvents and temperature. However, in all cases, the synthesis 
resulted in very poor product yields. This could be explained by the poor accessibility of 
the paclitaxel hydroxyl group and the steric hindrance exerted by the large Fmoc 
protecting group born by the tetrapeptide.  
In order to overcome these steric limitations and improve free drug release, a second 
approach using a 4-aminobenzyl alcohol based, self-immolative spacer was designed to 
create the paclitaxel prodrug. The fundamental process of self-immolation refers to a 
spontaneous and irreversible dissociation of compounds made of various modules into 
their constituent modules, through an intramolecular reaction. The 4-aminobenzyl alcohol 
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used in this synthesis was selected because it undergoes 1,6-elimination that yields the 
cleavage of the benzylic carbonate bond and release free paclitaxel as first reported in 
literature by Katzenellenbogen and co-workers in 1981
59
 and later by Greenwald et al.
54
. 
This method may have another benefit as it would increase the distance between the 
conjugated drug paclitaxel and the active cleavage site. Paclitaxel is in fact a sterically 
bulky molecule and the enzymatic access to the substrate may be problematic and 
prevent the cleavage and release of the anti-tumoural drug. The introduction of the self-
immolative spacer allows circumventing the risks of steric restrictions and favour drug 
release. In such a case free PTX is released, exempt of any amino-acid residues.  
A shortcoming to this second method would be the longer synthesis due to the numerous 
steps necessary to obtain the final prodrug. Katzenellenbogen and co-workers reported 
the 4-aminobenzyl alcohol spacer functionalization with a lysine and conjugation to a 4-
nitroaniline molecule through a carbamate linkage at the benzylic site
59
. Following 
enzymatic cleavage of the amino acid residue, the strongly electron-donating 4-
aminobenzyl group initiates a 1,6-elimination reaction, followed by a spontaneous 
decarboxylation to release the 4-nitroaniline. Similarly, the synthesis of the prodrug 
containing the enzyme sensitive substrate Fmoc-Gly-Gly-Pro-Nle and the benzyl 
carbonate self-immolative spacer was successfully produced through a 5-step synthesis. 
In the final step the amine function of glycine in P4 position was deprotected, allowing for 
further conjugation to the pullulan polymeric carrier. The critical step in this synthesis was 
the second step where p-nitrophenyl chloroformate was introduced to the molecule. The 
reactant was highly unstable in handling conditions and deactivated rapidly by forming 
stable by-products. Increased precautions in handling were taken to ensure best yields to 
move on the subsequent steps. 
With regard to the targeting module, a process similar to the one used for paclitaxel was 
originally designed. The Cathepsin K sensitive peptidyl-alendronate module would have 
fulfilled two functions; the targeting of the polymer-drug conjugate to the bone and the 
action of the bisphosphonate as anti-resorptive agent. Accordingly, alendronate could on 
one side, reduce bone metastases induced pain and bone resorption induced fracture, 
and on the other side, kill the tumour at the selected site. 
Various strategies were considered for the synthesis of the peptidyl-alendronate, 
including, N,N'-dicyclohexylcarbodiimide (DCC) coupling in presence of 4-
(dimethylamino)pyridine (DMAP) catalyst, and 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide  (EDC) coupling in presence of DMAP,  solution phase O-Benzotriazole-
N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate / Hydroxybenzotriazole  
(HBTU/HOBt) coupling, EDC in presence of N-hydroxysuccinimide (NHS) coupling, 4,5-
dihydrothiazole-2-thiol (TT) in presence of DCC coupling, pH were varied from 7 to above 
11. None of the synthesis described above succeeded, probably because of the divergent 
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solubility of reagents. Alendronate is in fact soluble only in aqueous medium while, Fmoc-
Gly-Gly-Pro-Nle was only soluble in organic solvents. Additionally, the pKa of the 
alendronate amino group is 11.4. At pH above this pKa the peptidyl spacer degraded, as 
observed by the mass spectra obtained with the reaction mixture. As reported in the 
literature by Uludag et al 
55
 , below this pKa, coupling was not favoured. Indeed, very low 
coupling was obtained. Therefore, a new approach, which replaces the tetrapeptide with 
a relatively low molecular weight poly(ethylene glycol) (PEG) was designed. This second 
approach does not allow for the alendronate release. Therefore, alendronate retains only 
the targeting function while the anti-resorptive function that requires the bisphosphonate 
release is probably lost. The 3kDa PEG plays the role of spacer between Pullulan 
conveying flexibility and free movement of the targeting agent to reach its target; 
hydroxyapatite. In order to produce a conjugate with a free amino group for Pullulan 
conjugation, tBoc-NH-PEG-NHS was first covalently bond to alendronate through its NHS 
activated carboxylic acid and then deprotected by TFA to free the primary amine.   
In order to optimise the rate of conjugation of ALN to PEG, several attempts were 
performed at pH ranging from 7 to 11.4. As reported above, as the pH increases the 
alendronate reactivity increases. Nevertheless, the inactivation of t-Boc-PEG-NHS by 
NHS hydrolysis also increases thus, competing with conjugation process. The results 
obtained in the pH range of 7-9, well acknowledged pH range for optimum NHS reactivity, 
showed that all conditions generated equivalent results of approximately 24%mol 
conjugation of ALN, while at higher pH the conjugation was negligible. Moreover, NHS is 
a hydrolysis sensitive molecule and conjugations completed in water would necessarily 
compete with the rate of hydrolysis, hence the low binding rate attained.  
Other conditions adopted to enhance the reaction yield included the use of a mixture of 
solvents DMSO/H20 at different ratios. Nonetheless, also in such a case no 
improvements were obtained. 
Even the re-activation of PEG by NHS/DCC, prior to coupling with alendronate, did not 
resulted in an improvement of the reaction yield.  
In conclusion the maximal alendronate conjugation yield was 24%mol. The final product 
was a mixture of tBoc-PEG-ALN and tBoc-PEG-COOH, formed by hydrolysis of NHS by 
water. The two species were not separated since tBoc-PEG-COOH could have two 
advantages; allowing binding of a fluorophore for later investigations and improving the 
overall solubility of the final bio-conjugate. This deprotected product obtained by 
treatment with trifluoroacetic acid was used for conjugation to the oxidized pullulan. 
The preparation of the final bioconjugate pullulan derivatised with NH2-
GlyGlyProNlepaclitaxel and NH2-PEG-alendronate Pull-PTX-ALN was performed 
according to a multi-step protocol in order to obtain a suitable composition of all modules. 
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Aimed at obtaining the maximal drug payload, NH2-GlyGlyProNle--PTX was first 
conjugated to the aldehyde-pullulan under reductive amination followed by the 
conjugation of NH2-PEG-Alendroonate. This sequence was followed to prevent the steric 
hindrance of PEG-Alendronate that could limit the conjugation of the drug. The reduction 
process was set up in order to selectively stabilize the Schiff base formed by NH2-
GlyGlyProNle-PTX or NH2-PEG-alendronate conjugation to the aldehydes of pullulan. 
within the first step, when NH2-GlyGlyProNlePTX was conjugated, triacetoxyborohydride 
was used as selectively allowed the reduction of the Schiff bases to secondary amino 
groups in organic solvent without reducing the unreacted free aldehydes remaining that 
are then used for the NH2-PEG-alendronate conjugation.. In the last step, when NH2-
PEG-alendronate was added, sodium borohydride was used. This less selective reductive 
agent was employed to ensure the complete reduction of Schiff bases and likewise, the 
reduction of unreacted aldehydes to alcohol functions. The complete reduction of the 
aldehyde groups was necessary to obtain a safe product for pharmaceutical use; indeed 
several studies show that molecules bearing aldehyde functional groups have a distinct 
cellular toxicity. 
To evaluate the drug payload in the bioconjugate, the NH2-GlyGlyProNlePTX 
conjugation was carried out by using a range of NH2-GlyGlyProNlePTX: oxidised 
Pullulan weight ratios (2:100, 5:100, 10:100 and 20:100). The results obtained by 
spectroscopic analysis of the bioconjugates showed that even using high NH2-
GlyGlyProNlePTX: oxidised Pullulan ratios, maximal 7.8% drug loading was obtained It 
should be noted that the synthesis was performed in DMSO where all reagents are freely 
soluble.. Possible explanations to this behaviour are the hindrance of the reagents as 
both of them have high molecular weight, or to the change of the polymer structure when 
the NH2-GlyGlyProNlePTX derivatives are conjugated, preventing further conjugation 
The conjugation of 7.8% w/w of paclitaxel was in line with the drug loading reported with 
similar polymer therapeutics
60
 and can be considered suitable for pharmaceutical 
purposes. Moreover, the solubility of the conjugate in physiological solution is strictly 
affected by the paclitaxel content that is a poorly soluble molecule. PTX is a drug poorly 
soluble in water (water solubility of 0.3µg/ml and is used clinically, solubilised in a 
substantial amount of Cremophor EL in Taxol® formulation (Bristol–Myers Squibb). It is 
therefore expected that too high paclitaxel payloads would result in products with low 
solubility that have no biopharmaceutical prerequisites for in vivo applications. 
In the case of alendronate the conjugation was found to be 1.2%w/w; value compatible 
with literature to ensure bone targeting and anti-tumour activity. In order to perform these 
in-vitro studies, Pull-PTX and Pull-ALN were synthesised at equivalent amounts of ALN 
and PTX as for Pull-PTX-ALN. 
Discussion 
 
 
  
Page 138 
 
  
The polymer-drug conjugate Pull-PTX-ALN, was fully soluble at a concentration of 
513µg/ml paclitaxel equivalent whereas the equivalent amount of paclitaxel in its free 
form was completely insoluble; this result demonstrated a first advantage in binding PTX 
to the polysaccharide carrier pullulan. 
 The dimensions of Pull-PTX-ALN in solution were assessed by both Gel permeation 
chromatography and Dynamic Light Scattering that allowed for determination of apparent 
molecular size and colloidal size, respectively. The molecular weight of the final product 
was of 89kDa and the polydispersivity index (PDI) was 1.88. These values indicate that 
the final product has a size above the threshold value of estimated glomerular filtration, 
which is commonly accepted to be 68kDa for proteins (albumin molecular weight) and 
30k to 50Da for polymers Therefore, the system is expected to circulate for prolonged 
time in the bloodstream thus displaying high systemic bioavailability. On the other hand, 
the size of the bioconjugate can allow for passive deposition in the tumours according to 
the EPR effect. It is in fact reported in the literature that EPR effect takes place in case of 
macromolecules with size over the threshold value of 50kDa. 
The Dynamic Light Scattering analysis showed that Pull-PTX-ALN  has a mean average 
hydrodynamic diameter of 163.30±18.25nm, 100.20±7.3nm and 69.88±6027nm at  
pH5.5, 6.0 (water) and, pH7.4 respectively whereas native Pullulan alone had a particle 
size of around 10nm at all pH. The higher size of the bioconjugates as compared to 
native pullulan is ascribable to supramolecular physical associations due to the presence 
of hydrophobic segments of PTX along the polysaccharide backbone. On the other hand, 
the different size at the various pH indicates the pH sensitivity of this derivative. This may 
be due to the presence of carboxyl groups deriving from PEG-COOH and the phosphate 
group of alendronate along the polymer backbone. As the pH decreases, the percentage 
of unionized groups increases. The reduction of negative charge repulsion and the 
increase of unionised hydrophobic groups can result in increased interchain associations.  
The Critical micellar concentration (CMC) of the Pull-PTX-ALN was 73.3µg/ml which 
confirmed the self-assembling attitude of the bioconjugate already described above. The 
CMC; this value was compatible with requirement for drug delivery applications. Indeed, a 
low CMC was necessary to ensure that the nano-assembly would retain its structure upon 
intravenous injection Micelles must stay intact upon injection to prevent the premature 
release the anti-tumoural drug paclitaxel from the polymeric vehicle before reaching the 
target cells.  
The micellar shape of Pull-PTX-ALN was confirmed by Transmission electron microscopy 
(TEM), which showed that above the CMC the bioconjugate formed circular shape nano-
assemblies of approximately 100nm, size.  
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According to the structural data obtained by DLS and TEM it was hypothesised that the 
bioconjugate forms structures where the paclitaxel mainly inside the supramolecular 
assembly is engaged into hydrophobic bonds that stabilize the colloidal system while the 
alendronate is externally exposed on the colloidal surface where is available for the target 
recognition. 
Interestingly, the DLS analysis showed a single colloidal population at all pH over more 
than 8h either at room or physiological temperature, demonstrating that the bioconjugate 
was pretty stable as no aggregates were formed during storage. Finally, the size of the 
polymer-drug conjugate in solution was much below the threshold of 600nm for 
accumulating in tumour masses; Pull-PTX-ALN was a good candidate to benefit from the 
passive accumulation in tumours by EPR effect. 
In order to confirm the stability of the polymer-drug conjugate in solution, release studies 
of PTX and ALN were conducted in buffers at pH 7.4 and pH 5.5 at 37°C, which simulate 
osteoclast lysosomal and physiological pH, respectively. The results showed that over 
24h no drug release was observed indicating that in the absence of Cathepsin K the 
bioconjugate is chemically stable and no drug is released.  
In vitro studies showed that the polymer-drug conjugate displayed a pronounced affinity 
for the bone mineral model hydroxyapatite employed to simulate bone tissues. After 
60min incubation at pH 7.4 and 5.5, which simulate the physiological and Howship’s 
lacunae pH, respectively, 40% and 65% of Pull-PTX-ALN were bound to hydroxyapatite. 
The difference of binding observed between the two pH tested cannot be easily 
explained. Probably, the different conformation of the supramolecular association, 
together with the different size and the altered overall charge have role in the interaction 
of the bioconjugate with the substrate of the bioconjugate. Indeed, as reported above, as 
the pH decreases, the polymer hydrodynamic diameter increases. . 
The paclitaxel release in the presence of Cathepsin K showed that the novel bioconjugate 
has suitable biopharmaceutical properties for in vivo application.  
While in the absence of Cathepsin K no drug release was observed, in the presence of 
the enzyme, a fast release of the anti-neoplastic agent PTX (96% of control) from the 
polymer-drug conjugate was obtained within 8h at 37°C. The study was carried out under 
conditions simulating lysosomes of target cells, i.e. conditions of pH and enzyme present 
in the osteoclast lacunae. This indicated that Pull-PTX-ALN was a good substrate for the 
enzyme and steric hindrance did not appear to be an issue for the drug release. 
According to the bioconjugate structure, the release mechanism includes a two-step 
cleavage: the cleavage of the amide bond between norleucine residue and the 4-
aminobenzyl alcohol would occur first, followed by the quasi-spontaneous 1,6-elimination 
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of the self-immolative spacer and final release of free paclitaxel, exempt of any amino 
acid residues (Scheme 4 1).  
 
Scheme 4-1 Proposed mechanism for Cathepsin K triggered drug release 
 
In conclusion, the controlled release of paclitaxel triggered by Cathepsin K was 
successfully achieved. 
Another essential aspect in nano-systems used for therapeutic applications is to ensure 
that they will not cause toxicity to blood elements after injection into a patient. 
The presence of haemolytic substances in contact with blood may cause loss of, or 
damage to, red blood cells. Consequently, an increased level of free plasma haemoglobin 
may be produced, inducing toxic effects or other effects which could strain the kidneys or 
other organs. Haemolysis (i.e., damage to red blood cells) can lead to life-threatening 
disorders such as anaemia, hypertension, arrhythmia, and renal failure.  
Haemolytic properties were evaluated and showed that Pull-PTX-ALN was non-toxic 
therefore blood compatible, as revealed by the in vitro RBC lysis assay, whereas the 
commercial vehicle for PTX that contains Cremophor EL has significant haemolytic 
activity. 
The toxicity and biological activity of Pull-PTX-ALN was assessed by in vitro in cell 
cultures, namely. Human mammary adenocarcinoma cells sourced from bone metastasis 
MDA-MB231 BM, murine mammary adenocarcinoma 4T1 and bone sarcoma cell lines 
SAOS-2 were used as model. 
The MDA-MB231 BM cell line was chosen to simulate the early invasive phase of breast 
cancer that forms bone metastases. The 4T1 cell line was selected as it mimics a stage 
IV human breast cancer with similar kinetics to human breast cancer metastatisation; 
when injected in mice these breast cancer cells spontaneously disseminate tumour cells 
from the primary tumour to the bone thus making them a good model in breast cancer 
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bone metastasis targeting. The SAOS-2 cell line was elected as being an appropriate cell 
model of the bone tissue. 
The studies performed by using the MTT and Coulter counter assays  showed that 
Pullulan used as control  and alendronate were non-cytotoxic at any of the concentrations 
tested the while the cells proliferation was inhibited by both Pull-PTX and Pull-PTX-ALN 
polymer-drug conjugates, as well as by PTX free drug. The tumour cell killing efficacy or 
IC50 of Pull-PTX-ALN and Pull-PTX were approximately one fold and two-fold higher than 
for PTX alone respectively, at equivalent drug concentration. The different IC50 of Pull-
PTX-ALN and free PTX is due to a combination of effect: different free drug availability 
and different cell up-take-systems The difference of IC50 of Pull-PTX-ALN and Pull-PTX 
suggested a synergism between PTX and ALN in inhibiting the tumour cell proliferation 
Indeed, according with the literature, the efficacy of the polymer-drug conjugate bearing 
alendronate was higher as compared to the alendronate free counterpart.   
It is worth to note that the lower biological efficacy obtained with the bioconjugate as 
compared to the free drug can be compensated in vivo, by a favourable pharmacokinetic 
profile of the former as compared to the latter. The combination of EPR effect for passive 
accumulation in the tumour and active targeting by the use of the bisphosphonate 
alendronate can increase the drug deposition in the tumour. 
A wound healing assay performed using MDA-MB231 BM cells allowed to evaluate of the 
bioconjugate on cell migration. This assay was intended to simulate the process of 
tumour cell invasion and metastasis; indeed, tumour dissemination is usually assumed as 
the migration of single cells that disconnect from the primary tumour, enter lymphatic 
vessels or the blood circulation, and seed in distant organs. 
The migration of MDA-MB231 BM incubated with both Pull-PTX and Pull-PTX-ALN was 
inhibited by over 63% and 99%, respectively. These results suggest once again that the 
presence of ALN onto the polymer backbone has a synergetic anti-tumoural effect with 
PTX.  
Finally, the anti-angiogenic activity of Pull-PTX-ALN was assessed. 
Angiogenesis can be defined as the creation of new blood vessels from an existing 
vasculature.  This expansion involves endothelial cells which reorganise to form a three-
dimensional vessel structure. Angiogenesis is a fundamental process in the development 
of cancerous tumours and dissemination of malignant tumour or metastasis; therefore, it 
was an important parameter to investigate for the purpose of this project.  
Anti-angiogenic properties of Pull-PTX-ALN were appraised by two different assays 
completed on Human Vein Endothelial Cells (HUVEC), namely a cell proliferation assay 
and a capillary-like tube assay. 
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The results from these investigations indicated that Pull-PTX-ALN retained anti-
angiogenic properties by inhibiting cell proliferation and was analogous to free PTX. In 
comparison, Pull-PTX showed a two-fold higher IC50, confirming the synergistic effect of 
ALN in inhibiting cell proliferation. 
Angiogenesis can be defined as the creation of new blood vessels from an existing 
vasculature.  This expansion involves endothelial cells which reorganise to form a three-
dimensional vessel structure. Angiogenesis is a fundamental process in the development 
of cancerous tumours and dissemination of malignant tumour or metastasis; therefore, it 
was an important parameter to investigate for the purpose of this project.  
The ability of HUVEC to form capillaries, simulating the angiogenesis, showed that Pull-
PTX-ALN and Pull-PTX are as potent as the combination of free ALN plus PTX at 
equivalent concentrations, impeding the formation of the network. On the other hand, 
Pullulan alone and Pull-ALN did not significantly reduce the tube formation, 
demonstrating the essential presence of PTX for inhibiting tube formation. 
Therefore, the overall results on cells suggest that Pull-PTX-ALN is has a double role by 
preventing angiogenesis and causing tumour cell death. 
 
 
 
 
 
  
  
 
 
 
CONCLUSION 
 
Conclusion 
 
  
Page 144 
 
  
 
 
Conclusion 
 
  
Page 145 
 
  
5. Conclusion 
The development of new carriers for the delivery of anti-tumour drugs represents an 
important step in the creation of new efficient and selective therapeutic systems. These 
systems allow to improve the chemico-physical and pharmacological characteristics of 
this class of molecules by increasing their solubility and stability, and conferring new 
biopharmaceutical properties of biodegradability and biocompatibility.  
This study was aimed at creating a new drug-delivery system for the treatment of breast 
cancer bone metastases, system based on a natural polysaccharide, Pullulan. 
Pullulan has proven to be a versatile scaffold for the creation of promising polymer 
therapeutics for bioconjugation chemistry of the drug to obtain a supra-molecular 
structure. Pullulan was efficiently able of organising in self-assembly of adequate size for 
parenteral administration. The backbone of pullulan has proven to be well suited for the 
attachment of polymeric prodrugs for the controlled release of active molecules. 
Paclitaxel was conjugated to the polymer via a Cathepsin K sensitive spacer, which 
ensured adequate stability in plasma (pH 7.4 ), while allowing a drug release exclusively 
in the Howship’s lacunae in osteoclasts, as a result of hydrolysis of the spacer in the 
osteoclast’s pit where Cathepsin K is located (pH 5.5 ),followed by instantaneous self-
immolation of a second short spacer.  The conjugation of the alendronate, through a PEG 
flexible spacer, allowed to obtain an active targeting, using a process of high affinity of 
the bisphosphonate for the mineral bone hydroxyapatite, particularly exposed around 
bone metastases. The molecular weight and hydrodynamic volume determined are 
appropriate in order to take advantage of the EPR effect and reduce the renal clearance 
of the drug. Polymer-paclitaxel conjugates are presumed to prolong their plasma half-life 
and to have superior tumour accumulation as a result of their slow excretion from kidney 
and the enhanced permeation and retention effects, correspondingly. 
Pull-PTX-ALN was found as a promising bone targeted drug delivery system able to act 
as anti-tumour and anti-angiogenic agent in-vitro. The overall results of this thesis work 
are promising and showed the polymer-paclitaxel conjugate is suitable in-vitro; therefore, 
the area of future research would go towards in-vivo investigations.  
The studies discussed above supported that there is an added benefit by the inclusion of 
the alendronate to the polymeric carrier, contributing to the ability of the bisphosphonate 
to reduce tumour growth in bone as strongly demonstrated an increased anti-tumour 
effects when  combined with paclitaxel, result of a synergism between the two drugs. 
The reduce cytotoxicity of the polymer-paclitaxel conjugates might be a strategic property 
to improve their paclitaxel-equivalent dose, while preserving a reasonable toxicity profile 
for in-vivo animal models and clinical developments of chemotherapy, versus the 
Cremophor  EL formulation of paclitaxel.  
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